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 SUMMARY 
 
Telomerase confers an unlimited lifespan, and is reactivated in most tumor cells. The 
catalytic subunit of telomerase, hTERT, is defined as the limiting factor for telomerase 
activity. Between activators and repressors that bind to the hTERT 5’ regulatory region, and 
the role of CpG methylation and histone acetylation, an abundance of regulatory models have 
been suggested. None of these models can explain the silence of telomerase in most somatic 
cells and its reactivation in tumor cells. Moreover, the contradictory observations of the low 
level of hTERT mRNA in telomerase-positive cells and the high transcriptional activity of the 
hTERT promoter in transfection experiments remain unresolved. 
In this study, we demonstrated that the proximal exonic region of the hTERT gene (exon 
1 and 2) is involved in the inhibition of its promoter. We identified the protein CTCF as the 
inhibitor of the hTERT promoter, through its binding to the first exon. The methylation of the 
first exon region, which is often observed in cancer cells but not in normal cells, represses 
CTCF binding. Study of hTERT promoter methylation shows a partial demethylation 
sufficient to activate the transcription of the hTERT gene. Therefore, we demonstrated that the 
particular methylation profile of the hTERT regulatory sequences inhibits the binding of 
CTCF, while it allows a low transcription of the gene. Nevertheless, in some tumor cells, the 
promoter and the proximal exonic region of hTERT are unmethylated. In testicular and 
ovarian cancer cell lines, CTCF inhibition is counteracted by its BORIS paralogue that also 
binds the hTERT first exon but allows the promoter activation. The study of BORIS gene 
regulation showed that this factor is exclusively expressed in normal tissue of testis and ovary 
of young woman, as well as in almost all tumors with different levels. Two promoters were 
found to induce its transcription. The proximal promoter was regulated by methylation. 
Moreover, a major alternative transcript, deleted of the exon 6, is detected when this promoter 
is active. 
All these results lead to a model for hTERT regulation that takes into account the 
epigenetic profile of the gene and provides an explanation for the low transcriptional level 
observed in vivo. BORIS expression in cancers and its implication in hTERT activation might 
also permit the understanding of epigenetic deregulation and immortalization phenomena that 
occur during tumorigenesis. 
RESUME 
 
La télomérase confère une durée de vie illimitée et est réactivée dans la plupart des 
cellules tumorales. Sa sous-unité catalytique hTERT est définie comme le facteur limitant 
pour son activation. De l’identification de facteurs liant la région régulatrice d’hTERT, au rôle 
de la méthylation de l’ADN et de la modification des histones, de nombreux modèles de 
régulation ont été suggérés. Cependant, aucun de ces modèles n’a pu expliquer l’inactivation 
de la télomérase dans la plupart des cellules somatiques et sa réactivation dans la majorité des 
cellules tumorales. De plus, les observations contradictoires entre le faible niveau 
d’expression d’ARN messager d’hTERT dans les cellules télomérase-positives et la très forte 
activité transcriptionnelle du promoteur d’hTERT en transfection restent incomprises. 
Dans cette étude, nous avons montré que la région proximale du gène hTERT (exon 1 et 
2) était impliquée dans la répression de l’activité de son promoteur. Nous avons identifié le 
facteur CTCF comme étant un inhibiteur du promoteur d’hTERT, en se liant au niveau de son 
premier exon. La méthylation de l’exon 1 du gène hTERT, couramment observée dans les 
tumeurs mais pas dans les cellules normales, empêcherait la liaison de CTCF. L’étude du 
profil de méthylation du promoteur d’hTERT indique qu’une partie du promoteur reste 
déméthylée et qu’elle semble suffisante pour permettre une faible activité transcriptionnelle 
du gène hTERT. Ainsi, la méthylation particulière des régions régulatrices d’hTERT inhibe la 
liaison de CTCF tout en permettant une faible transcription du gène. Cependant, dans 
certaines cellules tumorales, le promoteur et la région proximale du gène hTERT ne sont pas 
méthylés. Dans les lignées cellulaires tumorales de tesitcules et d’ovaires, l’inhibition de 
CTCF est contrée par son paralogue BORIS, qui se lie aussi au niveau de l’exon 1 d’hTERT, 
mais permet ainsi l’activation du promoteur. L’étude de l’expression du gène BORIS montre 
qu’il est exclusivement exprimé dans les tissus normaux de testicules et d’ovaires jeunes, 
ainsi qu’à différents niveaux dans la plupart des tumeurs. Sa transcription est sous le contrôle 
de deux promoteurs. Le promoteur proximal est régulé par méthylation et un transcrit 
alternatif majoritaire, délété de l’exon 6, est trouvé lorsque ce promoteur est actif. 
Tous ces résultats conduisent à un modèle de régulation du gène hTERT qui tient 
compte du profil épigénétique du gène et qui permet d’expliquer le faible taux de transcription 
observé in vivo. De plus, l’expression de BORIS dans les cancers et son implication dans 
l’activation du gène hTERT pourrait permettre de comprendre les phénomènes de dérégulation 
épigénétique et d’immortalisation qui ont lieu durant la tumorigenèse. 
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The balance between life and death of cells in tissues of multicellular organisms is 
possible since each cell has a limited lifespan. As cells divide, most of them gradually lose 
terminal DNA sequences of the chromosomes, which are capped with specialized DNA-
protein structures called telomeres. These specific structures are eroded at each replication 
round until the cell death is induced. The telomeres are crucial for protecting chromosomes 
from fusing through DNA strand break repair processes, and so telomeres are essential for 
maintaining the integrity and stability of the genome. As telomere erosion is not balanced 
by elongation, telomeres will progressively shorten. Therefore, stem and germ cells require 
a mechanism to counteract telomere attrition. These cells possess telomerase, a highly 
regulated specific enzyme that maintains telomere length. This enzyme is not expressed in 
adult tissues but is reactivated in about 85% of cancers. 
Nowadays, the inhibition of telomerase in cancer cells became an important point of 
interest in the anti-cancer strategies. In particular, regulation of its catalytic subunit hTERT 
was the hot spot of numerous investigations. This study focuses on the hTERT gene 
regulation in normal and cancer cells. For better understanding the importance of telomere 
and telomerase in the protection of the genome integrity, a general introduction is first 
reviewed. Then, we summarized the principale advances in telomerase regulation. As 
methylation plays an important role in the hTERT regulation, we described how this 
phenomenon occurres in normal and pathological situations. The last part is a general 
overview on CTCF and BORIS factors that might be two potential proteins involved in the 
hTERT regulation. 
 
 
 
1. Telomeres and the maintenance of the genome integrity 
 
Telomeres cap the termini of the chromosomes in order to stabilize them. This 
structure is essential for the conservation of genetic information and maintenance of 
genome stability (Blackburn, 1997; Greider, 1996). In addition, telomeres anchor the 
chromosomal ends to the nuclear matrix and aid in alignment and segregation during 
meiosis (De Lange, 1992; Kirk et al., 1997; Smilenov et al., 1999; Smith and De Lange, 
1997). Telomeres enable cells to distinguish chromosome ends from intrachromosomal 
INTRODUCTION 
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double stranded breaks (DSBs). Dysfunctional or uncapped chromosome ends are a great 
risk for degradation, recombination, and/or fusion by cellular repair systems such as 
homologous recombination (HR) and non-homologous DNA end-joining (NHEJ) (Chan 
and Blackburn, 2002; Lundblad, 2000). Without functional telomeres, genetic information 
can get lost, rearranged or unstable. Depending on the cell type, genetic background and 
extent of telomeric damage, cells can die (generally by apoptosis), undergo a permanent 
cell cycle arrest (senescence), or acquire structural chromosomal abnormalities (Shay and 
Wright, 2001; Yaswen and Stampfer, 2002). These genomic changes can drive both cancer 
and aging phenotypes (Klapper et al., 2001; Pandita, 2002). 
 
1.1. Telomere structure 
 
Although the importance of telomeres was recognized 67 years ago (Muller, 1938 ; 
McClintock, 1938), the telomeric sequences were characterized for the first time in 
Tetrahymena thermophila in 1978 (Blackburn and Gall, 1978). Subsequently, these GT-
rich sequences were shown to be well conserved in eukaryotes (Muniyappa and Kironmai, 
1998). Nevertheless, telomeric sequences are specific to an organism (Kirk et al., 1997). 
Telomere length varies according to chromosomes and species. In man, telomeres are 
compared of an average of 5 to 15 kilo-base-pairs (kb) of (TTAGGG)n repeats and 
telomere-binding proteins. In man and mouse, the unusual chromatin structure of telomeres 
suggests that telomeres have dense nucleosome spacing, a characteristic of 
heterochromatin (Tommerup et al., 1994). Telomeres are dynamically organized and 
remodelled during cell cycle and are subject to epigenetic regulation. That is also believed 
to be responsible for the telomere position effect (TPE), the transcriptional silencing of 
genes near the telomeres (Baur et al., 2001; Garcia-Cao et al., 2004; Koering et al., 2002). 
Recently, the telomere structure has been identified in mammals. The current model 
involves a lasso structure, with a three-stranded DNA displacement loop (called D-loop) 
and a RNA-like displacement loop (called t-loop) (Griffith et al., 1999; Munoz-Jordan and 
Cross, 2001; Nikitina and Woodcock, 2004) (Figure 1). Specialized telomere-associated 
proteins are crucial for forming and maintaining the protective telomeric structure, or cap, 
in vivo. 
In mammals, three telomere-associated proteins have been identified that bind 
directly and specifically to telomeric DNA. These proteins are TRF1, TRF2 (Telomere 
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Repeat Factor) and POT1 (Protection of Telomere) (Kim et al., 2002). TRF1 and TRF2 
each form homodimers that bind the double stranded TTAGGG repeat sequence (Broccoli 
et al., 1997). TRF2 may have a more direct role than TRF1 in modulating telomere 
structure because it has been shown to be crucial for the formation of the t-loop structure, 
at least in vitro (Stansel et al., 2001). POT1, by contrast, binds the single-stranded 
TTAGGG overhang (Baumann and Cech, 2001) (Figure 1). These proteins appear to be 
essential regulators of telomere structure, capping and length control, as is revealed by 
proteins, which have both telomeric and non-telomeric functions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some telomere-associated proteins, including TRF1, TRF2 and POT1, act primarily 
to modulate telomere structure, function and length. TIN2 appears to bring together TRF1 
and POT1 by binding the bridge protein PTOP/PIP1 (Kim et al., 2003; Liu et al., 2004a; 
Ye et al., 2004). The structure formed by the TRF1-TIN2-PTOP/PIP1 complex is thought 
to negatively regulate telomere length by indirectly limiting the accessibility of telomerase 
(Blackburn, 1992). TRF1 also interacts with the telomere length-control protein PINX1. 
This protein may modulate the influence of TRF1 on telomere structure, but it also has a 
direct effect on telomere length as it also binds TERT, the telomerase catalytic subunit 
Figure 1: Core telomeric structure: telomeric DNA repeats are associated with the direct 
telomeric DNA binding proteins TRF1, TRF2 and POT1 to form a core telomeric structure. 
(Rodier et al., 2005) 
t-loop 
D-loop 
INTRODUCTION 
 9
(hTERT in human) (see 2.1.2.). Recently, TIN2 was found to bind TRF2 (Kim et al., 
2004). The TIN2-TRF2 interaction is very likely crucial for both TRF2 and TRF1 
functions in vivo. In addition, TRF2 also binds RAP1 (Li et al., 2000). Perturbations to 
either TRF1 and TRF2, or their associated proteins POT1, RAP1 or TIN2, influence both 
telomere length and capping (Baumann and Cech, 2001; Colgin et al., 2003; Iwano et al., 
2004; Loayza and De Lange, 2003; Van Steensel and De Lange, 1997) (Figure 2). 
Other telomere-associated proteins, which bind the telomere indirectly through TRF1 
and TRF2, have different functions, in addition to their presumed functions at the 
telomeres. TRF1 binds two highly related poly-ADP ribosylases (PARPs), TANK1 and 
TANK2 (Kaminker et al., 2001; Smith et al., 1998) (Figure 2). TANK-mediated ADP-
ribosylation causes TRF1 to dissociate from telomeric DNA in vitro (Smith et al., 1998). 
PARP-2 is also involved in the maintenance of telomere integrity by physically binding to 
TRF2 (Dantzer et al., 2004). Both TRF1 and TRF2 also interact with several DNA repair 
proteins (Figure 2). They interact with Ku (Hsu et al., 1999; Song et al., 2000), the DNA 
end-binding protein that is crucial for NHEJ (Critchlow and Jackson, 1998). In addition, 
TRF2 interacts with several proteins that participate in DNA damage sensing and repair, 
including the RMN complex (Zhu et al., 2000), which is crucial for homologous 
recombinational repair (HR) and may also participate in NHEJ (D'Amours and Jackson, 
2002). TRF2 also interacts with the DNA damage sensing protein ATM, and is thought to 
inhibit ATM activity specifically at telomeres (Karlseder et al., 2004), and WRN (Opresko 
et al., 2002), the protein that appears to participate in both the NHEJ and the HR DNA 
repair pathways (Cheng et al., 1990; Li and Comai, 2000; Oshima et al., 2002; Prince et 
al., 2001; Yannone et al., 2001). One possible role for DNA repair proteins at the telomere 
is storage: here these proteins might be helpt, from which they can be readily mobilized 
upon damage to the genome, as demonstrated in yeast (Martin et al., 1999; Mills et al., 
1999). Nevertheless, a recent study shows that the formation of Nucleotide Excision Repair 
(NER) complexes needs the recruitment of proteins that freely diffuse in the nucleus, 
before beginning the repair. This mechanism could be valid also for other protein 
complexes implicated in major nuclear processes, such as excision repair, DNA 
replication, transcription initiation by RNA polymerase I and II and DNA double strand 
break repair (Mone et al., 2004). 
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1.2. Mechanisms of telomere erosion 
 
The most common mechanism of telomere disruption is shortening due to the end-
replication problem (Figure 3). This problem predicts the progressive loss of chromosomal 
DNA at the 3’ end over multiple cycles of replication. As the replication fork proceeds 
from the left to the right, DNA synthesis leads leading and the lagging strand synthesis. 
During the synthesis of the leading strand, the DNA polymerase proceeds continuously to 
replicate one strand of the original DNA, from an RNA primer until the end. In contrast, on 
the lagging strand, DNA synthesis proceeds away from the replication fork and relies on 
the ligation of small newly synthesised DNA fragments named Okasaki fragments. Most 
RNA primers are replaced with DNA from an upstream Okasaki fragment, but the terminal 
RNA primer is never replaced with DNA (Dhaene et al., 2000) (Figure 3). 
 
Figure 2: Telomeric capping structure. The core telomeric structure recruits other essential 
organizers that do not interact directly with telomeric DNA but are important for telomeric 
capping (TIN2, RAP1, PINX1; PTOP/PIP1). The telomeric capping structure recruits myriads of 
other proteins, such as TANKs and DNA repair proteins that also have specific functions 
elsewhere in the cell. (Rodier et al., 2005) 
INTRODUCTION 
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Linger et al. (Lingner et al., 1995) proposed that if eukaryotic chromosomes are to 
maintain a 3’-terminal extension, their replication problem would appear to be the inability 
of leading strand DNA synthesis to produce the 3’ overhang, not a problem with the 
lagging strand or with the gap left by removal of an RNA primer. Consequently, each 
round of replication produces daughter chromosomes, that lack the sequences 
corresponding to the original 3’ ends (Counter et al., 1992; Harley et al., 1990). Telomeres 
then become shortened by 50-100 bp (base-pairs) at each round of replication and this acts 
as a mitosis counter that determines the maximum number of cell divisions and thus limits 
the proliferative capacity of any cell type.  
Telomeres can also malfunction as a consequence of direct damage, especially 
telomeres are susceptible to oxidative DNA damage (Rubio et al., 2004), which may be the 
major source of DNA damage in mammalian organisms (Finkel and Holbrook, 2000). 
3’ 
5’ 
Lagging strand 
Leading strand 
RNA 
prime
Okazaki 
fragmen
Ligase 
3’ 
5’ 
A 
3’ 
5’ 
Leading strand 
Lagging strand 
5’ 
3’ 
gap 
gap 
B 
Figure 3: The « end-replication problem ». A: As the replication fork opens, lagging strand 
synthesis proceeds from 3’ to 5’ as the overall result of removal of RNA primers and ligation of the 
individual 5’ to 3’ synthesised Okazaki fragments. B: After removal of the terminal RNA primers, 
gaps remain at the 5’ end of the lagging and leading strand which can not be filled. (Dhaene et al., 
2000). 
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Finally, mutations that alter the expression or function of any of the telomere-associated 
proteins can also cause telomeres to malfunction. 
 
1.3. Consequences of telomere erosion 
 
Normal cells in tissues have a limited lifespan and undergo a process called 
replicative senescence, in which cells cease to proliferate (Harley et al., 1990; Harley, 
1997; Wright et al., 1996a). Senescent cells are large and flat, become polyploid, show β-
galactosidase activity and increased autofluorescence (Dimri et al., 1995; Sedivy, 1998). 
Senescence occurs when cells contain at least some critically short telomeres and is 
believed to be recognized by a DNA damage repair signaling program, releasing 
transcriptional factors from sequestration and relaxing heterochromatin (Campisi, 1997; 
Sedivy, 1998). Short telomeres elicit the cellular tumor suppressor mechanisms of 
apoptosis or senescence (Smogorzewska and De Lange, 2002). Apoptosis, or programmed 
cell death, literally eliminates cells at risk for neoplastic transformation. Senescence, by 
contrast, permanently arrests their growth.  
Telomere length in most senescent cells has been reported to be 5-10 kb (Allsopp 
and Harley, 1995; Harley et al., 1990). These telomeres are still capable to form t-loop 
structures, and the length as such does not induce the senescent phenotype (Karlseder et 
al., 2002; Ouellette et al., 2000; Zhu et al., 1999). On the other hand, when telomeres 
become extremely short, in vitro cultured cells that lose critical cycle checkpoint functions 
escape this initial growth arrest and divide until they enter crisis, in which telomeres 
drastically shorten, chromosome end fusions and apoptosis occur (Hande et al., 1999; Shay 
et al., 1991; Wright and Shay, 1992). Furthermore, it has been shown that the shortest 
telomere is critical for cell viability and genomic stability (Hemann et al., 2001; Liu et al., 
2002). The p53 tumour suppressor protein is a transcriptional regulator that targets genes 
involved in DNA repair, transient cell cycle arrest, permanent cell cycle arrest (senescence) 
or cell death (apoptosis) in normal cells (Amundson et al., 1998; Bringold and Serrano, 
2000; Hickman et al., 2002; Itahana et al., 2001). This factor is crucial for mediating the 
cellular response to telomere dysfunction. In cells in which only p53 and pRb have been 
knocked-out, tumour-suppressor pathways are inactivated, leading to the absence of 
senescence or apoptosis. Moreover, a recent study shows that the transformation of 
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multiple strains of human fibroblasts requires the constitutive expression of c-myc, H-RAS 
and hTERT, together with loss of function of the p53, RB and PTEN tumor suppressor 
genes (Boehm et al., 2005). Rare immortalized cells emerge from crisis when telomerase 
or a telomerase-independant mechanism, termed alternative lengthening of telomeres 
(ALT) (described below), are activated (Bryan et al., 1997; Duncan and Reddel, 1997; 
Murnane et al., 1994; Wright et al., 1989). The figure 4 summarized these findings 
showing a model of cancer development proposed by Brunori et al. (Brunori et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4. Telomere maintenance 
 
Unicellular organisms and viruses have developed mechanisms to circumvent the 
limited life-span. In these organisms, the chromosomes are circular. This phenomenon has 
been identified in yeast (K. lactis, (McEachern and Iyer, 2001), in yeast mitochondria 
(Tomaska et al., 2000), and, to some extent, also in human tumors and human 
immortalised cell lines (Regev et al., 1998). 
« Too much » 
proliferation 
P53 
P16/RB 
Telomeric 
instability 
INITIATION 
Telomerase/ALT 
PROGRESSION 
« Too much » 
instability 
Crisis 
Telomeric signal 
Senescence 
Apoptosis 
REGRESSION 
Figure 4: A model of cancer development. Absence of telomerase in dividing cells results in 
telomere erosion that lead to either apoptosis or senescence. Cells that lack antiproliferative 
response proteins (p53, p16, RB) continue to divide and develop telomeric instability. Although 
long-term proliferation of these cells requires telomere maintenance by telomerase or ALT, cells 
sustaining prolonged telomeric instability are not compatible with cell viability and massive cell 
death occurs (crisis). Cells can escape crisis by reactivation of telomerase or ALT. It is conceivable 
that tumor cells have overcome both the p53-telomere barrier and the crisis (Brunori et al., 2005). 
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Other mechanisms are likely to exist in human cells. They are tentatively named 
Alternative Lengthening of Telomeres (ALT). ALT is particulary common in certain 
sarcomas, including osteosarcomas, and in glioblastoma multiform (Hakin-Smith et al., 
2003; Montgomery et al., 2004; Ulaner et al., 2003). The ALT mechanism is not fully 
understood, but seems to involve telomere recombination and is characterized by telomeres 
of heterogenous length that have size distributions that extend from <2 to >20 to 80 kb 
(Bryan and Reddel, 1997; Reddel, 2003). ALT cells are also characterized by ALT-
associated Promyelocytic leukaemia Bodies (APBs), which are nuclear structures 
containing promyelocytic leukaemia (PML) protein, telomeric DNA, telomeric proteins 
TRF1 and TRF2, as well as proteins involved in DNA recombination such as RAD51 and 
RAD52 (Henson et al., 2002). Several groups have proposed that ALT cells may use other 
telomeres or themselves following the formation of telomeric loop structure, as a copy 
template (Griffith et al., 1999; Reddel et al., 1997). It has been shown that APB cells 
present very long telomeres, developed through homologous recombination and copy 
switching from telomere to telomere (Dunham et al., 2000). Recent studies have shown 
that APBs are not always essential for ALT-mediated telomere maintenance (Fasching et 
al., 2005). Similar to ALT cells, these cells show evidence of telomere recombination, but 
unlike standard ALT cells, they lack ALT-associated PML bodies and their telomeric DNA 
is transcribed (Marciniak et al., 2005). 
However, the mechanism mostly used by human tumour cells as well as several 
normal cells involves a specialized complex capable of elongating telomere sequences. 
This complex is referred to as telomerase. 
 
 
2. Human telomerase 
 
The most versatile and widely used mechanism of telomere maintenance is based on 
telomerase. Telomerase is expressed in embryonic cells, in adult germline cells (Kim et al., 
1994a; Wright et al., 1996b), and in most human tumors (Avilion et al., 1996; Kim et al., 
1994a; Shay and Gazdar, 1997), but is undetectable in normal somatic tissues except for 
proliferative cells of renewing tissues including haemopoietic stem cells (Broccoli et al., 
1995; Chiu et al., 1996; Hiyama et al., 1995). Telomerase has been shown to preferentially 
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elongate critically short telomeres, stabilize telomere length, prevent overhang loss, and 
permit continued cell division (Bodnar et al., 1998; Ouellette et al., 2000; Steinert et al., 
2000; Stewart et al., 2003). It also protects telomeres from NHEJ (Chan and Blackburn, 
2003; Zhu et al., 1999). Furthermore, telomerase may have possible protective capping, 
anti-apoptotic and survival functions (Cao et al., 2002; Forsythe et al., 2002; Fu et al., 
2000; Smith et al., 2003). 
 
2.1. Telomerase components 
 
Telomerase is a very large complex, with a mass over 1000 kDa (Schnapp et al., 
1998). In vitro, two components are absolutely essential for the telomerase activity: the 
highly conserved reverse transcriptase, TERT (Telomerase reverse transcriptase), and an 
associated template RNA, TERC (Telomerase RNA component) (also referred to as TR or 
TER) (Feng et al., 1995; Greider and Blackburn, 1989; Lingner et al., 1997; Nakamura et 
al., 1997). However, many others proteins are present in the telomerase complex. 
 
2.1.1. hTERC : human TElomerase RNA Component 
 
hTERC RNA is one of the 2 components essential for obtaining telomerase activity 
in vitro (Weinrich et al., 1997). In 1998, the hTERC gene was cloned and localized on 
human chromosome 3q26.3 (Soder et al., 1997; Zhao et al., 1998). This single-copy gene 
does not contain any intron. 
RT-PCR showed that hTERC RNA is widely expressed in both tumour and non-
tumour tissues (Feng et al., 1995; Yi et al., 2001b). Thus, it was concluded that hTERC 
was not essential to telomerase activation. Moreover, observations on hTERC-deficient 
mice indicate that this enzyme is not required for the development and normal life span of 
laboratory mice in early generations (Blasco et al., 1997). Nevertheless, propagation of 
mTERC -/- mice for three or more generations leads to extensive telomere shortening and 
affects development and function of multiple tissues (Lee et al., 1998). In later generations 
loss of telomere function and fusions occurred preferentially on chromosomes with 
critically short telomeres (Hemann et al., 2001). In addition, in situ hybridisation 
experiments showed that hTERC expression is significantly up-regulated in tumor tissues 
CHAPTER I 
 16 
(Heine et al., 1998; Soder et al., 1998). Moreover, RT-PCR analyses on colon cancer RNA 
digested with DNase I showed that the hTERC mRNA expression is correlated with 
telomerase activity (Yan et al., 2001). These data indicate that this gene might be involved 
in telomerase-reactivation. 
In man, the mature hTERC transcript is 451 nucleotides long and lacks polyA. The 
RNA contains a template region of 11 nucleotides 5’-CUAACCCUAAC-3’ located in the 
5’ extremity. Although hTERC RNA sequences are phylogenetically divergent, their 
secondary structures have been found to be similar from ciliates to vertebrates (Chen et al., 
2000). Studies reported the presence of a classical small nucleolar RNA (snoRNA) 
structure called the H/ACA box (Mitchell et al., 1999a). This motif consists of a hairpin-
Hinge-hairpin-ACA-tail; The H/ACA structure is essential for accumulation of hTERC 
RNA in vivo (Mitchell and Collins, 2000). Several proteins, such as dyskerin or snoRNP 
recognise this sequence and may be involved in RNA stability. Moreover, the H/ACA 
motif is also crucial for telomerase activity in vivo, a role that cannot be replaced by a 
heterologous domain. Furthermore, 2 other elements in the H/ACA 5’ neighbour hairpin 
(HS1 also called CR4-CR5) are also required for the hTERT-hTR interaction in vivo 
(Bachand and Autexier, 2001; Bachand et al., 2001; Chen et al., 2002; Mitchell and 
Collins, 2000). Finally, a pseudoknot has been also found to play a role in hTERC RNA 
stability (Gilley and Blackburn, 1999). 
 
2.1.2. hTERT : human TElomerase Reverse Transcriptase 
 
hTERT is the catalytic subunit of telomerase and harbours the reverse transcriptase 
activity. The expression of hTERT is closely correlated with telomerase activity in vitro 
and in vivo (Meyerson et al., 1997; Nakamura et al., 1997). The hTERT cDNA was isolated 
in 1997 (Kilian et al., 1997; Meyerson et al., 1997). However, the genomic sequence and 
the gene organisation were only described in 1999 by several groups (Cong et al., 1999; 
Horikawa et al., 1999; Takakura et al., 1999; Wick et al., 1999). The single-copy hTERT 
gene is composed of 16 exons and 15 introns spanning more than 40 kb. Using FISH 
(Fluorescence In Situ Hybridisation), it was localised on human chromosome 5p15.33, 
very close to the telomere (Bryce et al., 2000; Meyerson et al., 1997). The hTERT promoter 
lacks traditional TATA and CAAT boxes. A consensus transcription start site is as yet 
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undefined, but the various identified start sites are all located around the –80 and the –100 
bp upstream of the traductional start site of the gene (ATG, referred to as +1). 
The hTERT gene encodes a 127 kDa protein of 1132 amino acids (Meyerson et al., 
1997). This protein is almost exclusively localised in the nucleus (Harrington et al., 
1997b). hTERT protein presents a telomerase-specific motif (T), followed by 7 conserved 
RT (Reverse Transcriptase) motifs (1 and 2, A-E) , forming a finger-palm-thumb structure 
(Lingner et al., 1997; Nakamura et al., 1997). Phylogenetic studies have shown that the 
reverse transcriptase subunit is very well conserved from protozoa to man, including 
plants. RT motifs are very important for the reverse transcriptase activity as mutations in 
amino acids in these motifs prevent telomerase activity (Harrington et al., 1997a; 
Nakayama et al., 1998; Weinrich et al., 1997). Through these motifs, hTERT protein 
recognises the RNA template and reverse transcribes the telomeric motif, which leads to 
telomere elongation. The region containing the RT motifs has also been shown to bind 
hTP1 protein, independent of the hTERC binding (Beattie et al., 2000). 
In man, two regions of the hTERT protein (amino acid 301-538 and amino acid 914-
1132) may be involved in homomere formation (Arai et al., 2002). This oligomerization 
seems not to be linked with hTERC RNA as region 301-358 has been shown to overlap the 
hTERC binding site (Armbruster et al., 2001; Beattie et al., 2001). Arai et al. suggested 
that the homomeric interaction might occur in a “head to tail” manner (Arai et al., 2002). 
Another new domain called DAT (Domain essential for Another cellular function of 
Telomerase) was found to be essential for the reverse transcriptase activation in vivo, as 
mutations in this region led to cell death (Armbruster et al., 2001). However, this domain 
was not found implicated in the nuclear location of hTERT protein, in the hTERT 
oligomerization nor in the recruitment of telomerase onto the telomeres. Thus, DAT is 
thought to be involved in telomere elongation.  
 
2.1.3. Auxiliary proteins 
 
Numerous proteins or protein complexes bind to the telomerase complex and 
contribute to its activation or its stabilization. 
The hTP1 protein was shown to bind hTERC, hTERT protein and to be associated 
with telomerase activity (Beattie et al., 2000; Harrington et al., 1997a). However, TP1 gene 
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expression is widespread in human tissues, indicating that this component is unlikely to be 
linked with telomerase activation. 
The Hsp90 chaperone complex, composed of at least hsp90 (heat shock protein 90), 
p23, hsp70, HOP (hsp Organising Protein) and hsp40 (Dittmar et al., 1998), has been 
found to associate with the telomerase complex. Hsp90 and p23 were found to bind 
hTERT protein, to promote assembly of the telomerase complex and to be involved in the 
in vivo activity of the telomerase complex (Holt et al., 1999). Hsp40 and hsp70 favour the 
correct assembly of hTERT protein and hTERC, into telomerase, by providing energy to 
the hsp90/p23 complex (Forsythe et al., 2001). HOP is the unique co-chaperone that has 
the ability to interact with hsp70 and hsp90 chaperones, thus providing a physical link into 
the chaperone machinery (Chen and Smith, 1998; Dittmar et al., 1996). 
The L22 and the hStau proteins are RNA-binding proteins associated with hTERC 
and hTERT protein (Le et al., 2000). These two proteins do not interact and it was 
suggested that they might be implicated in hTERC transport, location, processing and 
telomerase assembly (Le et al., 2000). 
Heterogenous nuclear ribonucleoproteins (hnRNPs) were also found to interact with 
telomerase complex. HnRNP A1 may help to position telomerase at the telomere extremity 
in order to elongate the 3’ strand. Deficiency of hnRNP A1 led to telomere shortening, 
whereas its restoration allows telomere elongation (LaBranche et al., 1998). The complex 
hnRNP C1/C2 was reported to directly bind to hTERC RNA (Ford et al., 2000). This 
association was found to be essential for telomerase activity. Moreover, this complex can 
also co-localise with telomeric proteins TRF1 and TRF2, suggesting a role for these 
proteins in telomere elongation by telomerase. HnRNP D might interact with telomerase 
(Eversole and Maizels, 2000) and could destabilise intramolecular G-G base pairs in order 
to enhance telomere extension by telomerase. Finally other hnRNPs, such as hnRNP E or 
the hnRNP A2/B1 complex also participate in the telomerase complex. 
Other accessory factors have been found for human telomerase. The EST1A and B 
were recently shown to encode telomerase associated-proteins. In S. Cerevisiae, Est1 and 
Est3 orthologs are not required for in vitro telomerase acitvity (Cohn and Blackburn, 1995; 
Lingner et al., 1997) but mutations of these genes lead to progressive telomere shortening 
(Lendvay et al., 1996). These data suggest a conserved role for Est1 in telomerase 
regulation (Lundblad, 2003). 
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Human telomerase interacts with another RNA binding protein, Dyskerin. This 
protein has been proposed to play a role in ribosomal processing because it binds to many 
small nucleolar RNAs (snoRNA) (Luzzatto and Karadimitris, 1998).Like snoRNA, hTERC 
contains a H/ACA motif that constitutes a dyskerin binding site (Mitchell et al., 1999b). 
Evidence in favour of the functional significance of the binding of dyskerin to hTERC 
comes from the genetics of a rare human disease, dyskeratosis congenita (DKC) (Dokal, 
2000). Dyskerin mutations induce reduction of telomerase activity, and this is correlated 
with shorter telomeres and chromosome end fusions, which are pathognomonic for 
telomere dysfunction (Dokal et al., 1992; Mitchell et al., 1999b). 
 
2.2. Telomere maintenance by telomerase 
 
The assembly of active telomerase is an energy-requiring process that involves the 
stabilization and transcriptional upregulation of hTERC and its functional association with 
hTERT. H/ACA proteins such as Dyskerin stabilize hTERC (Mitchell et al., 1999a; 
Mitchell et al., 1999b; Vulliamy et al., 2001). These proteins may serve to stabilize hTERC 
only until it forms a stable complex with hTERT. However, it seems more likely that they 
remain stably associated as part of the telomerase holoenzyme, as both Dyskerin and 
hnRNP C1/C2 are associated with active telomerase (Ford et al., 2000; Mitchell et al., 
1999b). Furthermore, p23 and hsp90 mediate assembly of telomerase which is the 
predominant mechanism of holoenzyme folding in cells (Forsythe et al., 2001; Holt et al., 
1999). 
The consistent observations by many groups that even overexpressed hTERT 
localizes predominantly in the nucleus and that the vast majority of hTERC is nuclear, 
supports the hypothesis that telomerase assembly occurs in the nucleus (Hiyama et al., 
2001). The 14-3-3 protein, found to hold the hTERT protein in the nucleus, adds another 
level of complexity in the compartimentalization of telomerase, but contributes evidence in 
favour of this hypothesis (Seimiya et al., 2000). 
Telomerase is likely to function as a dimer of hTERT proteins, hTERC RNA or both 
(Beattie et al., 2001; Wenz et al., 2001). A model for the mammalian telomerase complex 
assembly has been proposed by Collins (Collins, 2000), in which 3 steps are required 
before obtaining a functional telomerase (Figure 5). 
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Several potential roles for hTERT/hTERC multimerization have been proposed: 
- enhancer of telomerase processivity (perhaps using a template switching 
mechanism), 
- allosteric regulation of one hTERT molecule by another hTERT molecule, 
- formation of a binding interface that can recognize telomeric DNA, 
- alteration of the avidity of hTERT for telomeric DNA, 
- asymetric multimerization to generate new binding interfaces, thereby allowing for 
nuclease activity. 
 
After correct assembly, telomerase is ready to act. The telomerase complex locates at 
the 3’ extremity of the leading strand. HTERC is correctly positioned through its sequences 
adjacent to the template region. Elongation is then performed by the catalytic subunit 
hTERT, until the end of the template region. Following this step, the complex is 
translocated and repositioned on the newly synthesised DNA, in order to continue telomere 
elongation. Finally, the lagging strand is elongated by the DNA polymerase complex 
(Figure 6). 
 
Figure 5: A model for mammalian telomerase assembly. A step-wise RiboNucleoProtein (RNP) 
assembly pathway first associates H/ACA proteins with the telomerase TERC RNA H/ACA motif. 
Processing of the telomerase RNA precursor to form a mature TERC RNA 3’ end could occur before 
or after this initial RNP assembly reaction. Subsequent assembly of telomerase-specific proteins such 
as TERT and additional shared proteins including molecular chaperones would complete the 
telomerase RNP assembly process (Collins, 2000). 
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Based on the telomere elongation property, a very sensitive assay has been 
developed (Kim et al., 1994a). This technique, called TRAP (Telomeric Repeats 
Amplification Protocol), allows the detection of as few as 1-10 positive cells and about 
0.01% positive cells in a mixed population (Wright et al., 1995). However, the sample 
quality (hTERC RNA and hTERT protein preservation), as well as PCR inhibitors, might 
produce false-negative results (Yan et al., 1998). 
 
3. Regulation of telomerase 
 
Human cells that retain readily detectable telomerase activity include germ cells and 
other self-renewing tissues, such as basal epidermal cells, lymphocytes and other 
hematopoetic cells (Forsyth et al., 2002; Mason, 2003). By contrast, telomerase is inactive 
in most somatic cells. A recent study shows that hTERT inhibits differentiation of bovine 
lens epithelial cells by suppression of the RAS/RAF/MERK/ERK signaling pathway. This 
Figure 6: Mechanism of telomere elongation by telomerase.  Step 1: 3’ end of chromosomal DNA 
binds to the part of template region in telomerase RNA. Step 2: Telomerase RNA provides the 
template for elongating the 3’ end of the chromosome (newly synthesized sequence in red and 
italics). Step 3: The chromosome is translocated and repositioned to repeat the polymerisation step.  
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could explain how hTERT regulates cell differentiation (Wang et al., 2005). In contrast, 70 
% of immortalized human somatic cell lines and 85 % of human cancers express high 
levels of telomerase and have stable telomere length as compared to the cells from which 
they originate. This suggests an active telomere length maintenance mechanism necessary 
for tumorigenesis or immortalisation (Bryan and Reddel, 1997; Saldanha et al., 2003; Shay 
and Gazdar, 1997). 
In this context, regulation of the expression of its components and of the activation of 
the complex are important. This could take place at the level of the recruitment to the 
telomere terminus, at the initiation of elongation, or at the rate and processivity of the 
elongation cycles (Smogorzewska and De Lange, 2004). 
Telomerase can also be regulated at the level of accumulation of telomerase 
components and catalytic activation via assembly of the telomerase complex. 
Accumulation involves transcription, translation and stabilization of telomerase 
components. Most cells that lack telomerase activity also lack hTERT expression and, to 
some extent, hTERC expression, whereas the auxiliary components appear to be widely 
expressed. In vitro reconstitution experiments revealed that hTERC and hTERT are 
sufficient to reconstitute telomerase activity (Weinrich et al., 1997). Therefore, the main 
element involved in telomerase activation is expression of both hTERT and hTERC. 
However, other regulatory principles are likely to be involved. First, in order to form an 
active ribonucleoprotein complex, all components must be recruited and assembled in an 
active conformation. Second, telomerase complex should be directed to the telomere end. 
Finally, access to the telomere sequences might also be a regulatory point (see 3.1.) (Evans 
and Lundblad, 2000). 
 
3.1. Regulation of telomerase at the telomere terminus 
 
Telomerase is regulated in cis by proteins that bind telomeric DNA. This regulation 
can take place at the telomere terminus, involving single-stranded DNA-binding proteins 
(POT1 in humans and Cdc13 in budding yeast), which have been proposed to contribute to 
the recruitment of telomerase and may also regulate the extent or frequency of elongation. 
Two models for POT1-mediated telomere length control have been proposed. POT1 has a 
preference for binding to its recognition site at a 3’ end (Figure 7A) (Baumann and Cech, 
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2001; Lei et al., 2002; Loayza et al., 2004). Its physical presence may simply preclude 
telomerase from accessing the telomere ends. A second model is based on an unusual 
architecture of telomeres (Figure 7B). Mammalian telomeres have been observed in an 
altered conformation, called the t-loop (Griffith et al., 1999). The telomere terminus is 
unlikely to be accessible to telomerase when telomeres are in t-loops. Based on its 
biochemical features, POT1 should have the ability to bind to the displaced TTAGGG 
repeats at the base of the t-loop (the D-loop) (Loayza et al., 2004). Potentially the binding 
of POT1 to the D-loop could stabilize the t-loops and thereby block telomerase from 
gaining access to the 3’ telomere terminus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Proposed role for POT1 in telomere length regulation by TRF1 complex. 
(Smogorzewska et De Lange, 2004) 
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In addition, proteins that bind along the length of the telomere 
(TRF1/TIN2/tankyrase in humans and Rap1/Rif1/Rif2 in budding yeast) are part of a 
negative feedback loop that regulates telomere length. TRF1 can limit telomere elongation 
in cis (Ancelin et al., 2002). A long telomere recruits a large number of TRF1 molecules, 
which block telomerase from adding more repeats. Conversely, a telomere that is short 
contains less TRF1 and has a greater chance of being elongated. As a consequence, all 
telomeres in a given cell line will eventually converge to a similar median telomere length 
setting. The binding of TRF1 to telomeres can be inhibited by two related enzymes, 
TANK1 and 2 (Cook et al., 2002; Kaminker et al., 2001; Smith and De Lange, 2000). 
Overexpression of TANK1 leads to telomere elongation, the phenotype seen upon TRF1 
inhibition. A second interacting partner of TRF1, TIN2, can also affect telomere length. 
The presence of TIN2 appears to stabilize the TRF1-TANK interaction. Conversely, 
TANK promotes the interaction between TRF1 and TIN2. PINX1, that interacts also with 
TRF1, has been proposed to affect telomere length control (Zhou and Lu, 2001). PINX1 
can inhibit telomerase in vitro, and it has been suggested that PINX1 affects telomere 
length by altering the telomerase activity throughout the nucleus. Indeed PINX1 is 
concentrated in the nucleolus (Zhou and Lu, 2001), the site of both rRNA and, possibly, 
telomerase maturation. Recently, a novel gene, MCRS2, has been found to interact with 
PINX1, and its overexpression results in a gradual and progressive shortening of telomeres 
(Song et al., 2004). 
 
3.2. Regulation of the telomerase component: hTERC 
 
Experiments introducing antisense hTERC transcript into cells in vitro led to 
telomerase inhibition and cell crisis (Feng et al., 1995), indicating that hTERC is an 
essential element of the telomerase complex. HTERC expression might be regulated 
through several mechanisms. The promoter sequences of hTERC contain several putative 
transcription factor binding sites that have been shown to be bound by activators and 
repressors (Zhao et al., 1998). The CAAT box is likely to be recognised by the NF-Y 
transcriptional complex. Activation of hTERC might occur thought binding of SP1 and 
pRB, whereas SP3 may act as a repressor (Zhao et al., 2000). Recently, mdm2 was found 
to inhibit transcriptional activity of the hTERC promoter. Mdm2 may directly repress 
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activation by pRB, SP1 or NF-Y. Furthermore, the ability of mdm2 to interact and interfere 
with components of the general transcription machinery might also explain its general 
repressive effect (Zhao et al., 2005). The presence of a CpG island has suggested the 
possibility of hTERC regulation by DNA methylation. Hoare et al. suggested that 
inhibition of hTERC expression through methylation might take place in some telomerase-
negative cell lines, but normal and most tumour tissues did not show any methylated 
patterns (Hoare et al., 2001). Recently, it has been demonstrated that the hypomethylation 
of the hTERC promoter region is not likely to be the main mechanism regulating hTERC 
expression (Nakamura et al., 2004). In colorectal cancer, it has been shown that hTERC 
expression correlates with telomerase activity (Yan et al., 2001). Nevertheless, hTERC 
expression was also detected in telomerase-negative samples (Feng et al., 1995; Yan et al., 
2001). All these results are in keeping with the concept that hTERC does not have a major 
role in the telomerase regulation. 
 
3.3. Regulation of the catalytic subunit of the telomerase: hTERT 
 
hTERT expression is fundamental for telomerase activity (Liu et al., 2000; Meyerson 
et al., 1997; Ramakrishnan et al., 1998). Exogenous expression of hTERT in primary 
human fibroblasts is sufficient to reconstitute telomerase activity and to couteract telomere 
erosion (Bodnar et al., 1998; Ramirez et al., 2001; Vaziri and Benchimol, 1998). Genomic 
organization and promoter characterization of the hTERT gene have been described by 
several groups (Cong et al., 1999; Horikawa et al., 1999; Takakura et al., 1999; Wick et al., 
1999). These investigations demonstrated that the so called core promoter region, 
encompassing the proximal 283 bp region upstream of the initiation ATG codon, is 
essential for transcriptional activation. Several groups have found specific sites involved in 
transcriptional activation and repression in the hTERT promoter sequence (Ducrest et al., 
2002; Poole et al., 2001; Mauro and Foster, 2002; Wu et al., 1999; Misiti et al., 2000b; Li 
et al., 1999; Xu et al., 2000b; Gunes et al., 2000; Xu et al., 2001). In addition, the presence 
of abundant CpG sites in the hTERT promoter region has triggered an increasing interest in 
examining the possible role of DNA methylation in regulation of hTERT transcription in 
normal and cancer cells.  
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hTERT gene regulation can occur at the epigenetic, the genetic, and the post-
transcriptional level. 
 
3.3.1. Regulation at the epigenetic level 
 
 
The DNA methylation 
 
Several groups have debated whether there is a correlation between hTERT promoter 
methylation and hTERT activity. Hypomethylation of the hTERT promoter is seen in 
undifferentiated and untransformed cells which are hTERT-negative, suggesting that these 
cells have a mechanism to strongly repress hTERT transcription independent of promoter 
methylation (Dessain et al., 2000; Devereux et al., 1999; Lopatina et al., 2003; Shin et al., 
2003). Methylation of the hTERT promoter is also observed in differentiated and senescent 
cells that do not express hTERT (Lopatina et al., 2003; Shin et al., 2003). Moreover, 
hypermethylation of the hTERT promoter correlated with repression of telomerase activity 
in B-cell lymphocytic leukemia (Bechter et al., 2002) and normal human oral cells (Shin et 
al., 2003). In ovarian and cervical cancers no correlation was found between the 
hypermethylation of hTERT and hTERT mRNA expression (Widschwendter et al., 2004). 
In some transformed and neoplastic cells, hTERT is reactivated and transcribed regardless 
of a methylated promoter (Guilleret et al., 2002; Nomoto et al., 2002). Moreover, in cancer 
cell lines with a hypermethylated hTERT promoter, treatment with the demethylating agent 
5-aza-2’-deoxycytidine led to hTERT promoter demethylation up to 95%, which strongly 
decreased hTERT mRNA, suggesting a role of hTERT promoter hypermethylation in 
regulation of telomerase activity (Guilleret and Benhattar, 2003). Methylation of most gene 
promoters inhibits transcription. Recently, a DNA methylation map was established on the 
5' part of the hTERT gene. A central region, localized from –500 to +180 according to the 
ATG translation start, was surrounded by 2 border areas, framed by 2 heterogeneous 
hypermethylated regions in all samples tested (tumour and normal tissues and cells). These 
hypermethylated regions did not exclude transcriptional activity of the hTERT promoter 
(Guilleret and Benhattar, 2004). Partial demethylation of the hTERT promoter was 
observed in immortalized fibroblasts and correlated with telomerase activity (Kumakura et 
al., 2005).Various transcription factors interacting with the hTERT promoter might 
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participate in promoter activation. The activity of the hTERT promoter depends on the final 
balance between all the involved factors. It has been proposed that the establishment of a 
nucleation site methylation at the hTERT promoter may also be influenced by a particular 
transcription factor which recruits the DNMTs (DNA MethylTransferase) to the hTERT 
promoter in a cell-type-specific manner (Casillas et al., 2003). 
Although DNA methylation participated in hTERT regulation, mechanisms and 
factors involved in this context remain to be identified. 
 
 
The DNA packaging 
 
The chromatin structure of the native hTERT locus, linked to the histone 
deacetylation, was also examinated. It is likely that histone deacetylation, leading to 
chromatin condensation is implicated in hTERT repression in telomerase-negative normal 
cells (Cong and Bacchetti, 2000; Hou et al., 2002; Nakamura et al., 2001; Takakura et al., 
2001; Wang and Zhu, 2003). Recent findings suggeste the possibility that human tumors 
may be able to reversibly interconvert their telomere maintenance phenotypes by 
chromatin structure-mediated regulation of hTERT expression (Kumakura et al., 2005). 
Recently, Wang and Zhu showed that the entire hTERT gene is embedded in a 
chromatin domain resistant to DNase I. hTERT transcription was associated with the 
appearance of a major DNase I-hypersensitive site positioned around the hTERT 
transcriptional start site and several minor hypersensitive sites. In telomerase-negative 
cells, the inhibition of histone deacetylase by Trichostatine A led to opening up of this 
chromatin domain, accompanied by transcription from the hTERT gene (Wang and Zhu, 
2003). In undifferentiated embryonic human teratocarcinoma (HT) cells, histone 
deacetylation is found to be involved in early hTERT gene down-regulation (Lopatina et 
al., 2003). Moreover, Won et al. suggested that dynamic assembly of E2F-pocket protein-
histone deacetylase complex plays a central role in the regulation of hTERT in a variety of 
proliferative conditions, such as normal cycling, senescence and immortalization (Won et 
al., 2004). Interestingly, telomere length in mice was recently reported to be directly 
regulated by histone methylation (see 4.1) (Garcia-Cao et al., 2004). 
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The Telomere Position Effect (TPE) 
 
The TPE is dependent of a specific higher-order organization of the telomeric 
chromatin (Koering et al., 2002) and might play a role in telomerase regulation. TPEs on 
gene expression have now been shown to occur in mammalian cells and the extent of this 
effect is proportional to telomere length (Baur et al., 2001). Moreover, the observation that 
hTERT is the most distally located gene on 5p opens the door to speculation that 
telomerase action on telomeres may regulate hTERT levels via TPEs, thus forming an 
autoregulatory feedback loop (Bryce et al., 2000; Shay and Wright, 2000). 
 
 
3.3.2. Regulation at the genetic level 
 
 
Since the identification of the promoter region of the hTERT gene, much effort has 
been focused on the identification of transcriptional factors involved in the control of 
hTERT transcription in normal and cancer cells (Figure 8). In addition, in normal cells, 
inhibitors might repress hTERT expression, and their action might be blocked in tumour 
cells resulting in telomerase activation (Ducrest et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
The presence of sites for multiple activators and repressors suggests a complex 
system of regulation. 
 
ER81 sites, 
E-box : c-Myc/Mad1 sites and USF1/2 sites, 
SP1 sites, 
WT1 sites. 
HIF1 sites, c-Ets-2 sites,  
Figure 8: Regulatory sequences in the hTERT minimal promoter and the exonic proximal 
region.  
+1 
Exon Exon
+200 +300 +100 -100 -200 -300 
E2F-1 sites, 
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Factors downregulating hTERT transcription 
 
Studies showed that the downregulation of hTERT transcription is partial and cell-
type specific. Therefore, Mad1 does not seem capable of completely switching off the 
expression of hTERT (Poole et al., 2001; Ducrest et al., 2002). And, in oral cancer cells, 
other factors such as USF1 and USF2 inhibit hTERT expression through direct binding at 
the E-box site (Chang et al., 2005). The WT1 factor downregulates hTERT transcription, 
only in Wilm’s tumor cells (Oh et al., 1999). Likewise, the presence of MZF-2 
significantly downregulates hTERT transcription (Fujimoto et al., 2000), but it is assumed 
to play a minor role in hTERT regulation. 
Moreover, hTERT repressors are preferentially expressed in telomerase-positive 
cells, but not in the telomerase-negative ones. Recently, it has been shown that Mad1 has a 
regulatory effect on hTERT transcription in hTERT-positive cells, but not in telomerase-
negative normal cells (Zou et al., 2005b). Although, overexpression of p53 can trigger a 
rapid downregulation of hTERT mRNA expression (Xu et al., 2000a; Kanaya et al., 2000), 
inhibition of its activity failed to reactivate hTERT expression (Lin and Elledge, 2003). 
Saito et al., demonstrated that p16, as well as p53, suppress telomerase activity through 
transcriptional regulation of hTERT in malignant glioma (Saito et al., 2004). A recent study 
showed that p53-mediated downregulation of hTERT is critical for efficient p53-dependent 
apoptosis (Rahman et al., 2005). COUP-TIFII is a transcription factor belonging to the 
nuclear hormone receptor superfamily, which plays a major role in development and 
cellular differentiation (Tsai and Tsai, 1997; Jonk et al., 1994; Laudet et al., 1999). This 
factor was shown to inhibit telomerase activity through reducing hTERT transcription by 
E-box binding in telomerase-positive cells (Wang et al., 2004). Thus, the partial inhibition 
of hTERT transcription cannot explain the downregulation of the hTERT expression in 
telomerase-negative cells. 
Moreover, the repression of hTERT transcription is not always due to a direct effect 
of inhibitors. A recent study suggests that the inactivation of distinct telomerase repressor 
genes occurs in different types of human cancers and may have implications for the tissue-
specific regulation of telomerase during human development and carcinogenesis (Tanaka 
et al., 2005). Shats et al. suggest that repression of hTERT by endogenous p53 is mediated 
by p21 and E2F (Shats et al., 2004). Menin can bind directly to the hTERT promoter, 
whereas TGF-β acts through Smad-interacting protein-1 (SIP-1, (Lin and Elledge, 2003). 
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TNF-α (Tumor necrosis factor alpha) was also found to indirectly inhibite the hTERT 
transcription in human myeloid normal and leukemic cells (Beyne-Rauzy et al., 2005). 
 
Moreover, a recent study demonstrated that the transriptional regulation of 
telomerase is influenced by given genetic alteration that currently occurred in esophageal 
cancer (Quante et al., 2005), showing an additional level in the complexity of the hTERT 
regulation. 
 
Factors activating the hTERT transcription 
 
Numerous factors able to activate hTERT transcription were identified, including c-
Myc, Sp1, estrogen and progesterone. In particular, the c-Myc network is thought to be an 
important activator acting through binding the two E-boxes located in the hTERT promoter 
(Ducrest et al., 2002). Recently, c-Myc was shown to have positive effects on the hTERT 
promoter in a dose-dependent manner, while its role in regulating a mutant hTERT 
promoter (double-mutated in the E-box) was inverse (Zou et al., 2005b). C-myc and Sp1 
could also be indirectly activated by Survivin, a member of the inhibitor-of-apoptosis 
family, inducing up-regulation of telomerase through hTERT activation (Endoh et al., 
2005). Hormones and growth factors are also crucially involved in regulating telomerase 
activity and gene expression of hTERT (Bayne and Liu, 2005). 
Other factors have been identified to bind the hTERT promoter region and have an 
effect on its transcription. Nevertheless, the activation of hTERT by these factors seems to 
be either indirect, or dependent of specific conditions. A novel factor hALP (human N-
acetyltransferase-like protein) influences the activity of histone acetylation and could up-
regulate telomerase activity through transactivation of hTERT promoter (Lv et al., 2003). 
Three oncoproteins, HER2/Neu, Ras and Raf stimulate hTERT promoter activity via the 
ETS transcription factor ER81 and ERK mitogen-activated protein (MAP) kinases (Goueli 
and Janknecht, 2004). Bmi-1 overexpression induced the escape from cellular growth 
control mechanisms such as the p53 and the pRB pathways (Pardal et al., 2003; Valk-
Lingbeek et al., 2004), and leads to telomerase activation through the activation of hTERT 
gene transcription (Dimri et al., 2002). Recently, a novel human gene telomerase 
transcriptional elements-interacting factor (TEIF) was isolated from HeLa cells and might 
be a transcriptional activator of hTERT (Tang et al., 2004). The binding of USF1/2 
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heterodimers to the E-boxes in the hTERT promoter occurs in both hTERT-positive and 
hTERT-negative cells, but USF1/2 activates the hTERT promoter exclusively in hTERT-
positive cells. USF1/2 contributes to the acquisition and maintenance of immortality 
(Goueli and Janknecht, 2003). The hTERT promoter is activated by HIF-1 during hypoxia 
in cervical cancer cells (Yatabe et al., 2004) and in trophoblast (Nishi et al., 2004). 
Interestingly, introduction of chromosome 3 in tumor cell lines led to hTERT 
expression inhibition. However, the interpretation of such experiments is difficult and 
conclusions are confusing (Ducrest et al., 2001; Ducrest et al., 2002; Cuthbert et al., 1999). 
 
Apparently complex mechanisms involving regulatory elements distant from the 5' 
flanking region of the hTERT promoter are also implicated in the regulation of hTERT 
expression. Tollefsbol and Andrews propose that the collective effect of binding of all 
these different factors, which may be under methylation control, is the mechanism 
regulating reversible hTERT gene expression in aging cells and tumorigenesis. Moreover, 
the region of cumulative control extends beyond the core promoter region of hTERT and 
includes several kilobases of the 5’ gene regulatory region (Tollefsbol and Andrews, 
2001). 
 
Many factors are involved in the hTERT transcriptional regulation (see recapitulative 
table), but how exactly hTERT is activated in telomerase-positive cells and repressed in 
telomerase-negative ones, is not yet clear. Moreover, the endogenous-hTERT mRNA levels 
detected in telomerase-positive cell lines are very low (0.2 to 6 copies per cell) (Ducrest et 
al., 2001;Yi et al., 2001b). This is in stark contrast with the high level of transcriptional 
activity obtained in transient transfection of the hTERT core promoter in telomerase-
positive cell lines, similar to that induced by the SV40 early promoter (Cong et al., 1999). 
Actually, no statistical association existed between hTERT gene copy number and hTERT 
RNA expression or telomerase activity. Nevertheless, a recent study indicated that the 
increased of copy number of the hTERT gene in colorectal carcinoma was a result of 
genomic instability with no obvious consequence for telomerase activity levels (Palmqvist 
et al., 2005). 
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Recapitulative table of the transcription factors that bind the hTERT 5’-regulatory region. 
Transcription 
factors 
Role Number of binding 
site in the 5’-
regulatory region 
Number of binding 
site in the core 
promoter (-283 to +1) 
Reference 
p53/p21WAF Repressor 2 0 (Xu et al., 2000a;Kanaya et 
al., 2000) 
Mad1 Repressor 2 2 (Oh et al., 2000) 
MZF-2 Repressor 4 0 (Fujimoto et al., 2000) 
WT1 Repressor 1 0 (Oh et al., 1999) 
TGFβ/SIP-1 Repressor - - (Yang et al., 2001a) 
Menin/JunD/NF-κB Repressor 2 - (Lin and Elledge, 2003) 
COUP-TIFII Repressor 3 2 (Wang et al., 2004) 
E2F-1 Repressor 
in cancer 
cells 
2 2 (Crowe et al., 2001) 
USF1/2 Repressor 2 2 (Chang et al., 2005) 
E2F-1 Activator 
in normal 
cells 
2 2 (Won et al., 2004) 
Estrogen Activator 2 0 (Kyo et al., 1999;Misiti et al., 
2000a) 
Sp1 Activator 14 9 (+ 1 in the exonic 
region) 
(Kyo et al., 2000) 
c-Myc Activator 2 2 (Kyo et al., 2000;Wu et al., 
1999;Zou et al., 2005b) 
Bmi-1 Activator   (Dimri et al., 2002;Pardal et 
al., 2003;Valk-Lingbeek et al., 
2004) 
USF1/2 Activator 2 2 (Goueli and Janknecht, 2003) 
hALP Activator Potential binding to +90 to -120 (Lv et al., 2003) 
ER81 Activator 2 0 (+ 2 in the exonic 
region) 
(Goueli and Janknecht, 2004) 
HIF-1 Activator 2 2 (Nishi et al., 2004;Yatabe et 
al., 2004) 
TEIF Activator Potential binding to +90 to -120 (Tang et al., 2004) 
AP2 Activator 17 9 (+ 5 in the exonic 
region) 
(Cong et al., 1999;Horikawa et 
al., 1999;Takakura et al., 
1999;Wick et al., 1999) 
AP4 Activator 9 3 (+ 1 in the exonic 
region) 
(Cong et al., 1999) 
CCAC Activator 1 0 (Wick et al., 1999) 
c-Ets-2 Activator 2 2 (Horikawa et al., 1999) 
c-Myb Activator 2 0 (Horikawa et al., 
1999;Takakura et al., 
1999;Wick et al., 1999) 
CREB/ATF Activator 1 0 (Cong et al., 1999) 
NFκB/T3Rα Activator 1 0 (Cong et al., 1999) 
 
 
All these findings suggest a complex system of transcriptional regulation of the 
telomerase catalytic subunit hTERT. Moreover, the hTERT mRNA and protein are still 
submitted to higher regulation increasing the complexity of its activation. 
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3.3.3. Regulation at the post-transcriptional and post-translational level 
 
Studies of RNA processing revealed complex splicing patterns in different cell types 
(Kilian et al., 1997) and a potential regulation of hTERT expression by alternative splicing 
(Ulaner et al., 1998). At least 7 alternatively spliced mRNA variants (4 insertions and 3 
deletions [α, β and α/β]) can co-exist. Presence of these alternative forms is regulated 
during human development and depends on the tissue type (Ulaner et al., 1998; Ulaner et 
al., 2000; Wick et al., 1999). However, only full length mRNA permits translation into a 
protein with catalytic activity (Collins and Mitchell, 2002; Kilian et al., 1997). 
Interestingly, the full-length hTERT mRNA is significantly less abundant than the β-
spliced variant. Expression of the α-spliced variant leads to telomerase inhibition and, to 
some extent, to cell death (Colgin et al., 2000; Yi et al., 2000). As this splice variant still 
contains the hTERC binding site, it would compete with full length mRNA and thus could 
lead to a weak concentration of active telomerase complex (Lai et al., 2001). Recently, it 
was been shown that alternative splicing of hTERT mRNA does not contribute to the 
suppression of telomerase activity during ATRA (All Trans Retinoic acid)-induced HL-60 
leukemia cell differentiation (Liu et al., 2004b). Nevertheless, the presence of alternative 
splicing of hTERT in osteosarcoma cell lines has been correlated with the lack of 
telomerase activity (Fujiwara-Akita et al., 2005). In most lung carcinoids, which are 
telomerase-negative, hTERT transcription and alternative splicing play a negative 
regulatory role (Zaffaroni et al., 2005). Moreover, alternatively spliced hTERT mRNA 
tends to be less abundant in tissues with high telomerase activity (Ohyashiki et al., 2005). 
These results support a role for hTERT spliced-variants in the regulation of telomerase 
activity. 
 
Finally, post-translational processing of the hTERT protein might also regulate its 
three-dimentional conformation. For example, phosphorylation of hTERT by protein 
kinase Cα,  by PP2A (protein phosphatase 2A) or by c-Abl tyrosine kinase are involved in 
modulation of telomerase activity (Kharbanda et al., 2000; Li et al., 1998). It has been 
suggested that PKC (Protein Kinase C) is required for post-transcriptional or post-
translational modification of hTERT (Fishman et al., 1998; Kim et al., 2001b). A recent 
study indicates that PKC acts as a transient post-translational activator of telomerase 
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during megakaryocytic differentiation (Nakatake et al., 2004). Aisner et al. proposed that 
hTERT is present in the cytoplasm in an inactive, unphosphorylated state in unstimulated 
cells but upon stimulation, phosphorylation permits nuclear localization of hTERT thereby 
allowing for assembly of active telomerase and function on telomeres (Aisner et al., 2002). 
 
The understanding of hTERT regulation should also take into account the genomic 
dynamics of the hTERT gene, including epigenetic modifications. Additional investigations 
of the interactions between transcriptional factors and these epigenetic modulators are 
necessary for further understanding of the chromatin structure-mediated regulation of 
hTERT transcription. Moreover, transport of the hTERT protein to the nucleus, assembly 
of the telomerase holoenzyme, recruitment of telomerase to the telomere and the role of 
post-translational modifications of hTERT protein may also play a role in the telomerase 
activation. 
 
3.4. Telomerase and cancer 
 
Like primary cells, tumour cells require a telomere maintenance system for long-
term proliferation, and in the majority of cases, this is provided by upregulation of hTERT 
(Kim et al., 1994a). Telomerase activity per se does not induce transformation (Morales et 
al., 1999), and although telomerase is necessary for immortalisation, hTERT is not an 
oncogene (Hahn et al., 1999; Hahn, 2002). hTERT-immortalized keratinocytes are 
nontumorigenic and still fairly normal with regard to growth control (Farwell et al., 2000). 
Nevertheless, telomerase activation can allow a growth advantage to hTERT-transfected 
epithelial cells so that they sustain stable epigenetic or genetic alterations to become 
immortal (Farwell et al., 2000). Conversely, oncogenic transformation does not require 
telomerase activity, and cells with very long telomeres can be fully transformed into a 
tumorigenic phenotype in vitro without a telomere maintenance system (Seger et al., 
2002). Similarly, certain childhood tumours that originate in juvenile cells with long 
telomeres can be cancerous and metastatic even though they lack telomerase. However, the 
extensive proliferation of cells during the prolonged multistep tumorigenesis pathway that 
leads to most adult human cancers is predicted to exhaust the telomere reserve, 
necessitating telomerase activation (Hiyama et al., 1995). 
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Whether telomerase activation and subsequent immortalization might eventually lead 
to malignancy remains a point of controversy. Moreover, the maintenance of genetic 
stability by telomerase activation may be an important defense against cancer and 
degenerative diseases. Patients carrying mutations in gene that alter telomeric functions 
(ATM, DKC, WRN) show an increase in tumor susceptibility (Brunori et al., 2005; 
Brunori and Gilson, 2005). A recent study showed that the combination of hTERT and 
bmi-1 or E6 or E7, induced prolongation of the life span of bone marrow stromal cells 
from an elderly donor. Moreover these cells with extended life span differentiated into 
neuronal progenitors (Mori et al., 2005). 
Nevertheless, telomerase reactivation remains an important characteristic of human 
cancer cells. It is clear that telomerase is required for continuous tumor cell proliferation 
and malignant progression, but it is not yet clear whether telomerase exists as a 
consequence of selection of preexisting telomerase-positive cells during carcinogenesis or 
through induction of hTERT expression in cells that lack telomerase activity. Relatively 
low levels of telomerase activity have been detected in the proliferative cells of self-
renewing tissues (Forsyth et al., 2002; Masutomi et al., 2003). Therefore, these few cells 
could be the cancer precursor cells, which fit with a cancer stem cell hypothesis. 
 
The expression of hTERT decreases to undetectable levels in most differentiated 
adult somatic cells but increases in highly proliferative somatic cells such as endometrium 
and mitogen-stimulated lymphocytes. High levels of hTERT are present in most 
immortalized and cancer cells, while a lack of detectable hTERT expression in most normal 
somatic cells results in telomeric attrition, ultimately leading to cellular senescence. In the 
absence of telomerase, normal human cells in culture have a finite life span and undergo 
cellular senescence normally after 40 to 70 population doublings. This stage of the life 
cycle of the cell has become known as the Haflick limit. In the presence of a transforming 
event, such as the expression of an oncogenic virus (human papillomavirus type 16 [HPV 
16] E6 and E7 or SV40 large T antigen), some cells may escape from senescence to a 
condition of further cell division referred to as pre-crisis. Still telomerase-negative, these 
cells may continue dividing until chromosomal termini are essentially constituted of very 
short telomeres. This state of crisis is characterized by massive cell death. Alternatively, 
the up-regulation of hTERT expression, telomerase activation and the subsequent extension 
of telomeric ends at this stage enable escape from crisis and in cases of prolonged hTERT 
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expression, cellular immortalization (Counter et al., 1992). The process of immortalisation 
almost always requires the reactivation of telomerase to preserve genomic stability by 
maintaining structural integrity at the ends of the chromosomes (Kim et al., 1994a) (figure 
9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5. Anti-telomerase strategies 
 
Because of the link between cell proliferation and telomerase activity, inactivation of 
telomerase is a potentially important target for the treatment of human cancer. Recent 
studies have shown that tamoxifen induced suppression of telomerase activity in a human 
hepatoblastoma cell line (Brandt et al., 2005). In ovarian cancer, apoptosis is induced by 
1,25-dihydroxyvitamin D3 through down-regulation of telomerase (Jiang et al., 2004). 
Moreover, ATRA inhibits ovarian cancer cell growth by suppressing telomerase activity, 
thereby pushing cells to proliferative crisis (Purev et al., 2004). 
As hTERT and hTERC are both important for telomerase activation, anti-cancer 
strategies include antisense- or ribozyme-targeting of telomerase (Herbert et al., 1999; 
Kondo et al., 1998; Saretzki et al., 2001) and using dominant-negative TERT (Hahn et al., 
1999) or mutant hTERC (Kim et al., 2001a). Another study suggests that an si-RNA-based 
strategy can be applied to the development of novel telomerase inhibitors, the antitumor 
Figure 9: Expression of hTERT in various cell types over the time course of differentation, 
aging, stimulation and immortalization. Poole et al., 2001. 
INTRODUCTION 
 37
effects of which may be enhanced in combination with ionizing radiation and 
chemotherapy (Nakamura et al., 2005). 
In studies using ribozymes to target various components of the telomerase complex, 
effects on tumor cell proliferation were only measured in vitro (Folini et al., 2000; Saretzki 
et al., 2001; Yokoyama et al., 1998). Recently, plasmid-based ribozymes specifically 
targeting TERC have been shown to reduce both telomerase activity and metastatic 
progression in tumor-bearing hosts (Nosrati et al., 2004). Overexpression of mutant-
template human telomerase RNA (MT-hTer) to add mutant DNA to telomeres in cancer 
cells, induced apoptosis in telomerase-positive precancerous or cancer cells (Li et al., 
2004). Moreover, expression of a hairpin short-interfering RNA that specifically targeted 
the endogeneous wild-type hTERC template region, also caused cell growth inhibition and 
apoptosis, and when coexpressed with MT-hTer, synergistically killed cancer cells (Li et 
al., 2004). Direct inhibition of the hTERT mRNA was also investigated. In laryngeal 
squamous cell carcinoma, short-term antisense treatment targeting the mRNA of hTERT 
results in apoptotic cell death (Tao et al., 2005). The anti-proliferative effects of small 
hairpin interfering RNA (shRNA)-targeted hTERT gene demonstrated a potent inhibitor 
effect in bladder cancer cells (Zou et al., 2005a). 
The use of a modified-adenoviral vector containing the TRAIL (TNF-related 
apoptosis-inducing ligand) gene or interferon-β gene under the control of the hTERT 
promoter has also been advocated (Dudognon et al., 2004; Jacob et al., 2004; Wang and 
El-Deiry, 2003). Treatment with these adenovectors induces apoptosis in tumour cells and 
may open new possibilities for targeted gene therapy of a variety of cancers. Recently, 
telomerase-dependent conditionnally replicative adenoviral vectors (CRADs) have been 
developed that combine the specificity of hTERT promoter based expression systems with 
the lytic efficacy of replicative viruses (Wirth et al., 2005). All these strategies, in 
particular MT-Ter and anti-hTERC-siRNA expression, represent promising novel 
anticancer strategies (Natarajan et al., 2004). 
A recent meeting report reviews novel preclinical and clinical findings in the 
telomerase field (Shay, 2005). GRN163L, a potent telomerase antagonist and fully 
complementary to the hTERC template region, is promised to become the first telomerase 
inhibitor for the treatment of cancer and has potential as a universal anticancer agent with 
an acceptable safety profile. Vaccination of metastatic breast cancer-, prostate cancer- and 
pancreatic cancer-patients against hTERT are encouraging. Development of a telomerase-
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based universal cancer vaccine is a promising approch for cancer treatment. In addition to 
direct enzyme inhibition and telomerase immunotherapy for cancer treatment, approches to 
kill telomerase-positive cancer cells include the oncolytic virus CG5757. This virus was 
generated by replacing the endogenous promoters with promoters derived from the human 
E2F-1 and the hTERT genes. It destroys tumor cells 100 to 10,000 times more efficiently 
than normal cells. Other small molecules, as BRACO-19, were reported to exhibit potent 
(nanomolar) inhibitory activity against telomerase (Shay, 2005). 
In summary, the progress made in the last 2 years has been impressive and there is 
general consensus that telomerase-targeting therapies are likely to provide a promising and 
novel approach to cancer therapeutics. Nevertheless, the existence of ALT raises the 
possibility that telomerase-positive tumors undergoing anti-telomerase therapies may 
escape by activating the ALT pathway. For these reasons a detailed understanding of the 
ALT pathway is critical to the future design of anti-neoplastic therapies (Stewart, 2005). 
 
 
4. Epigenetic regulation 
 
Major epigenetic mechanisms include methylation modification of DNA and 
packaging of DNA by histone proteins into chromatin structure. These mechanisms result 
in silencing of genes without changing the coding region of the gene, and they are 
potentially reversible. The importance of epigenetic changes in human cancer is only now 
being recognized in the medical community. Therefore the potential reversibility of these 
epigenetic events open up opportunities for therapeutic intervention. Current knowledge 
suggests that agents that intervene in this process by “turning back on” silenced genes may 
represent a significant advancement in treating many forms of cancer (Jones, 2005). 
 
4.1. Packaging of DNA 
 
During DNA packaging, modifications of histone proteins by methylation or 
acetylation can remodel the conformation of the chromatin DNA, affecting the 
accessibility of a gene to transcription factors. Histone modification is an universal 
epigenetic mechanism employed by eukaryotes for gene regulation (Jenuwein and Allis, 
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2001). Adding an acetyl group to the lysine residue located in the N-terminus of histones 
changes the charge status of the histone tails, which decreases the attraction between DNA 
and histone tails. This confers an open conformation to the chromatin DNA, allowing 
transcription factors to bind (Krajewski, 2002). Histone acetyltransferase (HAT) and 
histone deacetylase (HDAC) are two antagonists involved in acetylation and deacetylation 
of the chromatin. 
Methylation modification of the histone lysine residues (H3-Lys9 or H3 K9) may 
exist in three different forms. It has been demonstrated that mono- and dimethylation are 
associated with inactive genes in silent euchromatin domains, wherease trimetylation is 
enriched at pericentric heterochromatin (Rice et al., 2003). The reasons of the different 
distribution of methylated histones within the genome are not yet understood. One 
possibility may be that these different forms of methylation modification occur in situ by 
target-specific histone methyltransferase (HMTase) activities after the incorporation of 
nonmethylated histones into the chromatin (Rice et al., 2003). 
Interestingly, histone methylation is a mechanism involved in the regulation of 
telomere length in mice (Garcia-Cao et al., 2004). Telomeres are normally enriched in the 
trimethylated Lysine 9 residue of the histone H3. In embryonic stem cells and embryonic 
fibroblasts, derived from HTMase null mice, telomeres appear to have less trimethylated 
than monomethylated H3-Lys9. In addition, HTMase null mice seem to have abnormally 
long telomeres relative to wild-type mice. Surprisingly, there is no change in telomerase 
activity in HTMase-mutant cells that harbor such an abnormal telomere elongation. A 
possible contributing factor may be an increased recruitment of the telomerase to telomeres 
(Garcia-Cao et al., 2004). 
 
4.2. DNA methylation and epigenetic gene silencing 
 
4.2.1. DNA methylation 
 
DNA methylation is a covalent chemical modification, resulting in the addition of a 
methyl (-CH3) group at the carbon 5 position of the cytosine ring (figure 10). Even though 
most cytosine methylation occurs in the sequence 5’-CG-3’ (also called the CpG 
dinucleotide), some involves CpA and CpT dinucleotides (Ramsahoye et al., 2000). 
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Theoretically, the CpG dinucleotide should occur with a frequency of approximately 
6%. During evolution, this dinucleotide has been progressively depleted from the genome 
of higher eukaryotes by spontaneous deamination of methylated cytosines and 
transformation into thymine (Antequera and Bird, 1993; Bird et al., 1995). As a 
consequence, the actual occurrence of CpG sites is only 5% to 10% of its predicted 
frequency. 
The human genome is not methylated uniformly and contains regions of 
unmethylated segments interspersed by methylated regions (Bird, 1986). These regions 
could facilitate the formation of bulk chromatin containing acetylated histones and 
nucleosomes (Cross and Bird, 1995; Tazi and Bird, 1990). In contrast to the rest of the 
genome, smaller regions of DNA, called CpG islands, ranging from 0.5 to 5 kb and 
occuring on average every 100 kb, have distinctive properties. These regions are generally 
unmethylated, GC rich (60 to 70%), have a ratio of CpG to GpC of at least 0.6, and thus do 
not show any suppression of the frequency of the dinucleotide CpG (Antequera and Bird, 
1993; Cross and Bird, 1995). Approximately half of all the genes in man have CpG islands 
Figure 10: Schematic representation of the biochemical pathways for cytosine (C) methylation, 
demethylation, and mutagenesis of cytosine and 5-methylCytosine (mC). (Singal and Ginder, 
1999) 
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(Antequera and Bird, 1993), and these are present on both housekeeping genes and genes 
with tissue-specific patterns of expression. A recent review summarizes the hypothetic 
mechanisms by wich CpG islands might be protected from methylation and how they 
might be methylated during tumorigenesis, as they are unmethylated in normal cells 
(Caiafa and Zampieri, 2005). One of these mechanism involved boundary caused by Sp1 
sites, which isolates the islands from a general state of methylation. However, this cannot 
be considered universal as Sp1 consensus site are not always present in promoter regions 
of houskeeping genes. The controlled expression of DNMT1 protein during cell cycle and 
the uncondensed structure of CpG islands could also be implicated in the unmethylated 
status of this particular region. At present, more information is required to allow the 
elaboration of a definitive model to explain how CpG islands are protected from 
methylation in normal cells, and how this is disturbed during tumorigenesis (Caiafa and 
Zampieri, 2005). 
DNA methylation is brought about by the DNA methyltransferases (DNMT). The 
DNMTs known to date are DNMT1, DNMT1b, DNMT1o, DNMT1p, DNMT2, DNMT3A, 
DNMT3b with its isoforms, and DNMT3L (Robertson, 2002). Methylation can be de novo 
(when CpGs are unmethylated on both DNA strands) or maintenance (when CpGs are 
methylated on one DNA strand). DNMT1 has de novo as well as maintenance 
methyltransferase activity, and DNMT3A and DNMT3b are powerful de novo 
methyltransferases. The importance of these enzymes has been shown in DNMT-deficient 
mice that die early in development or immediately after birth (Robertson, 2002). In 
addition to the DNMTs, the machinery of methylation includes demethylases (5-
methylacytosine glycosylase, MBD2b [methyl-CpG binding domain 2]), methylation 
centers triggering DNA methylation, and methylation protection centers (Costello and 
Plass, 2001; Szyf, 2003). DNA methylation patterns are established early in embryogenesis 
and are very finely controlled during development. Telomerase activity is required for 
stabilizing DNMT1 activity in normal human fibroblast (Young et al., 2003), which 
contributes to the maintenance of young state of the cells. Recently, the PARP-1 
(Poly(ADP-ribose)polymerase-1) was found to operate as a negative regulator of DNA 
methylation (Reale et al., 2005). Following activation, PARP-1 forms multiple polymers of 
ADP-ribose that become covalently attached to the enzyme itself. With the help of its long 
polymer arms, PARP-1 recruits DNMT1 into a complex and blocks its catalytic activity. 
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Thus, PARP-1 becomes a positive regulator of epigenetic stability by protecting CpG 
islands from aberrant hypermethylation (Althaus, 2005). 
 
4.2.2. DNA methylation and gene regulation 
 
Increased methylation in the promoter region of a gene usually results in strongly 
reduced expression, whereas methylation in the transcribed region has a variable effect on 
gene expression (Jones, 1999; Singal et al., 2002). Several mechanisms have been reported 
to be involved in transcriptional repression by DNA methylation. 
The first mechanism involves direct interference with the binding of specific factors 
to their recognition sites in their respective promoters. Several transcription factors, 
including AP-2, c-Myc, the cyclin AMP-dependant activator CREB, E2F and NFκB, 
recognize sequences that contain CpG residues, and their binding has been shown to be 
inhibited by DNA methylation (Singal and Ginder, 1999; Tate and Bird, 1993). 
The second mode of repression involves direct binding of specific transcriptional 
repressors to methylated DNA. Such factors bind to methylated DNA through a domain 
called Methylated Binding Domain (MBD), and repress transcription using another domain 
named Transcriptional Repression Domain (TRD) (Wade, 2001). Several proteins have 
been identified : MeCP1 (Methyl CpG Binding Protein 1), MeCP2, MBD1, MBD2, MBD4 
and Kaiso (Prokhortchouk and Hendrich, 2002). All bind to 5mCpG through the MBD 
motif, except for Kaiso that binds through a zinc-finger motif (Prokhortchouk et al., 2001). 
MBD4 is associated with DNA repair (Prokhortchouk and Hendrich, 2002), whereas 
MBD1, MBD2, MeCP2 and Kaiso have been shown to repress transcription by interacting 
with histone deacetylase complexes (Prokhortchouk and Hendrich, 2002). 
DNA methylation can also affect histone modification and chromatin structure, 
which, in turn, can alter gene expression. MeCP2 can associate Sin3 histone deacetylase 
complex, thus leading to an inactive configuration of chromatin (Jones et al., 1998). 
MeCP1 complex includes MBD2, the histone deacetylase HDAC1 and HDAC2, and the 
retinoblastoma protein-binding proteins RbAp46 and RbAp48 (Wade, 2001). Finally, the 
complex Mi-2 or NuRD (Nucleosome Remodelling histone Deacetylase complex) contains 
the MBD3, HDAC1, HDAC2, RbAp46, RbAp48, Mi-2b (a protein involved in chromatin 
remodelling), and MTA2 (Metastasis-Associated protein 2, a protein modulating the 
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effects of the core deacetylase complex). Recent studies revealed that histone modification 
can on its own commence the process of DNA methylation (Tamaru and Selker, 2001). 
 
4.2.3. DNA methylation and cancer 
 
DNA methylation can modify gene activity without changing gene sequence and has 
been implicated in tumorigenesis. Therefore, DNA methylation in cancer has become a 
subject of intense investigation. In comparison with normal cells, malignant cells show 
major alterations in their DNA methylation patterns. Hypomethylation usually involves 
repetitive DNA sequences, such as long interspersed nuclear elements, whereas 
hypermethylation involves CpG islands. 
 
DNA hypermethylation and cancer 
 
There are several protective mechanisms that prevent hypermethylation of the CpG 
islands. These include active transcription, active demethylation, replication timing, and 
local chromatin structure (Clark and Melki, 2002). To date, numerous genes have been 
found to undergo hypermethylation in cancer. These genes are involved in cell cycle 
regulation (p16INK4a, p15INK4a, Rb, p14ARF), DNA repair (BRCA1, MGMT), apoptosis 
(DAPK, TMS1), drug resistance, detoxification, differentiation, angiogenesis and 
metastasis (Das and Singal, 2004). Although certain genes are commonly methylated in a 
variety of cancers, other genes are methylated in specific cancers. The mechanism involved 
in targeting of methylation to specific genes in cancer remains to be determined. In one 
report, the leukemia-promoting PML-RAR fusion protein induced gene hypermethylation 
and silencing by recruiting DNA methyltransferases to target promoters (Di et al., 2002). 
Interestingly, retinoic acid treatment induced promoter demethylation, gene re-expression 
and reversion of the transformed phenotype. Many tumours show some kind of 
hypermethylation of one or more genes. For example, hypermethylation results in loss of 
expression of a variety of genes critical in the development of breast cancer. These include 
steroid receptor genes, cell adhesion genes and inhibitors of matrix metalloproteinases 
(Yang et al., 2001b). Hypermethylation is also associated with leukemias and other 
hematologic diseases. Several lines of evidence point to a direct causal role for DNA 
methylation in tumorigenesis. Indeed, reduction of DNA methylation supresses the 
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formation of intestinal polyps in Apc Min mice (Laird et al., 1995) and resultes in re-
expression of hMLH1 and restoration of MMR (Mismatch repair gene) ability in colon 
cancer cell lines containing a hypermethylated hMLH1 gene (Herman et al., 1998). 
Moreover, CpG sites have been shown to act as hotspots for mutations. The 
increased mutability of 5-methylcytosine versus cytosine is thought to be influenced by 
three factors: differential repair efficiency, rate of spontaneous deamination, and rate of 
cell division. The methylation machinery itself may contribute to the increased mutability 
of 5-methylcytosine. Thus, 5-methylcytosine could be considered as an endogeneous 
mutagen that contributes to the cancerogenesis (Robertson and Jones, 2000). 
 
DNA hypomethylation and cancer 
 
Hypomethylation is the second kind of methylation defect that is observed in a wide 
variety of malignancies (Feinberg and Vogelstein, 1983; Kim et al., 1994b). It is common 
in solid tumours such as hepatocellular cancer (Lin et al., 2001), cervical cancer (Kim et 
al., 1994b), prostate cancer (Bedford and van Helden, 1987) and also hematologic 
malignancies such as B-cell chronic lymphocytic leukemia (Ehrlich, 2002). 
Hypomethylation has been hypothesized to contribute to oncogenesis through activation of 
latent retrotransposons (Alves et al., 1996; Singer et al., 1993) or through chromosome 
instability (Tuck-Muller et al., 2000). Long interspersed nuclear elements are the most 
plentiful mobile DNAs or transposons in the human genome. Hypomethylation of these 
mobile DNAs causes transcriptional activation and had been found in many types of 
cancer. Hypomethylation of the mobile DNA can also cause disruption of expression of the 
adjacent gene. 
 
 
4.2.4. DNA methylation: a marker for tumor diagnosis and prognosis, 
and a target for novel therapies 
 
An early diagnosis is important for the successful treatment of cancer. The traditional 
methods of diagnosis (such as cytology, histopathology, immunohistochemistry, serology) 
are still the bases for tumor diagnosis, but molecular markers can further subclassify 
tumors. The methylation profile can distinguish tumour types and subtypes and perhaps the 
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response to chemotherapeutic agents and survival. The sensitivity and specificity of DNA 
methylation markers in cancer diagnosis depends on several factors, including the type of 
cancer and the gene to be studied, the type of body fluid to be used and the technique 
involved. 
Recently many studies have shown several methylated genes to be closely related to 
prognosis. For example, the p16 promoter was found hypermethylated in colorectal and 
lung cancer and hypermethylation correlated with high grade tumours and poor prognosis 
(Maeda et al., 2003; Ng et al., 2002; Tomizawa et al., 2002; Yi et al., 2001a). The 
methylation profile may also help in predicting response to a chemotherapeutic agent. For 
example, methylation of the promoter region of the DNA repair gene MGMT was 
predictive for the sensitivity of gliomas to alkylating agents (Hegi et al., 2005; Kondo et 
al., 2000). In another study, it was found that methylation of the hMLH1 gene in colorectal 
cancer cell lines was associated with increased resistance to the drug fluorouracil (Arnold 
et al., 2003). 
 
Unlike genetic modifications, epigenetic changes are potentially reversible, making 
them a therapeutic target. Experiments using cultured cells, have shown that demethylating 
agents can reverse silencing of genes resulting from methylation (Arnold et al., 2003; 
Plumb et al., 2000; Strathdee et al., 1999). Several clinical trials are presently underway 
using derivatives of deoxycytidine (azacytidine, decitabine, fazarabine, dihydro-5-
azacytidine), histone deacetylase inhibitors and phenylbutyrates to reactivate the silenced 
genes in hematologic and solid tumours (Lubbert, 2000; Strathdee and Brown, 2002). 
Among the novel agents of demethylation that are potentialy useful are DNMT1 antisense 
(MG98) and siRNA. All the tested agents have shown a positive effect in preclinical and 
clinical studies. Nevertheless, we have to keep in mind that widespread use of 
demethylating drugs can have serious side effects and even promote malignant 
transformation of genes. For example, the used of a methyl transferase inhibitor can 
stimulate the metastatic potential of pancreatic cancer through activation of invasion-
promoting genes (Sato et al., 2003). 
The strategies of combining multiple anticancer therapies may ultimately offer the 
most successful approach. How to combine the demethylating agents and histone 
deasetylase inhibitors with conventional chemotherapy to achieve the best outcome 
remains to be determined. 
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5. CTCF and BORIS gene family 
 
CTCF is an ubiquitous multivalent transcription factor, highly conserved nuclear 
protein (Lobanenkov et al., 1990), involved in gene regulation, imprinting and chromatin 
structure. Its characteristics allow to think that it might be involved in the downregulation 
of hTERT transcription. 
 
5.1. The CTCF factor (CCCTC binding factor) 
 
This 727 amino acid protein contains an 11 zinc finger DNA binding domain that is 
flanked by 150 amino acids on the C-terminal side and 267 amino acids on the N-terminal 
side (Vostrov et al., 2002) (Figure 11). Full length CTCF has a molecular mass of 82 kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Structural features of CTCF, and schematic illustration of the molecular basis for 
‘multivalent’ DNA-sequence specificity mediated by different sets of ZFs. For three color-
coded different DNA target sites, particular groups of ZFs which cannot be deleted from the 11 ZF 
domain without loosing binding to a given site, are shown by a ‘rainbow’ above the schematically 
drawn ZFs. Specific examples of such DNA targets and of the corresponding ZF usage mode, are 
given in Ohlsson et al. (ohlsson et al, 2001, trends genet). The complete aa sequence of the wild-
type human CTCF protein is schematically drawn to show the DNA binding domain composed of 
10 C2H2-class and 1 C2HC-class Zn fingers. Functionally significant sites for CKII 
phosphorylation,,and a putative SH3-binding motif are also included in the cartoon. (Klenova et 
al., 2002). 
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However, because of sequences in the N- and C- terminus it migrates at 
approximately 130 kDa on SDS-PAGE gels (Klenova et al., 1997).This protein has been 
implicated in tumour suppression and appears to be involved in several aspects of gene 
regulation including activation, repression, imprinting of genetic information and insulator 
function (Bell et al., 1999; Filippova et al., 1996; Hark et al., 2000; Vostrov and Quitschke, 
1997; Vostrov et al., 2002). Participation in various aspects of gene regulation is achieved 
through binding highly divergent DNA sequences. CTCF appears to prefer DNA 
sequences with high GC content. It targets sequences, located between the Igf2 and H19 
genes and in the coding region of the human and mouse c-Myc genes, that are GC rich 
(Bell and Felsenfeld, 2000; Burcin et al., 1997; Hark et al., 2000; Kanduri et al., 2000). In 
contrast, the CTCF binding site in the second module of the chicken lysozyme silencer 
does not contain a CCCTC motif and is AT rich (Burcin et al., 1997). Actually, no single 
concensus sequence can accurately encompass all CTCF binding sites. 
 
CTCF binds sites within promoters, silencers and insulators through the use of 
different combinations of zinc fingers (Bell et al., 1999; Burcin et al., 1997; Filippova et 
al., 1996; Vostrov and Quitschke, 1997; Vostrov et al., 2002). For example, binding to the 
human c-myc P2 promoter requires zinc fingers 4 through 11 (Filippova et al., 1996), while 
at the F1 element of the chicken lysozyme silencer two different combinations are used, 
either 1 to 8 or 5 to 11 (Burcin et al., 1997). DNA binding may be controlled by post-
translational modification of CTCF. In vivo phosphorylation in the DNA binding domain 
has been found to potentially alter DNA binding specificity (Klenova et al., 2001). CTCF 
is post-translationally modified through poly(ADP-ribosyl)ation, which imparts chromatin 
insulator properties to CTCF at both imprinted or nonimprinted loci with implications for 
the regulation of expression domains and their demise in pathological lesions (Yu et al., 
2004). 
In vitro studies have identified repression domains in CTCF (Filippova et al., 1996; 
Lutz et al., 2000b). The zinc finger domain and the C-terminal portion of CTCF, but not 
the N-terminus, were able to repress transcription of a reporter gene in monkey kidney 
cells (COS-1 and CV-1), although in chicken erythroblasts all the three regions induced 
reporter repression (Lutz et al., 2000b). The association of CTCF with histone deacetylase 
activity suggests that transcriptional repression might occur through chromatin 
condensation (Lutz et al., 2000b). It was shown that CTCF interacts with the Sin3A 
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corepressor protein complex through the zinc finger domain, which could alter the DNA 
binding specificity of CTCF (Lutz et al., 2000b). Dunn et al. failed to show an association 
between HDAC1 and HDAC2 complexes and CTCF, indicating that CTCF does not 
interact with the sin3A HDAC complex (Dunn et al., 2003). They suggest that CTCF 
recruits other corepressors that may have HDAC activity, e.g. the N-CoR/SMRT complex 
that contains HDAC3 (Fischle et al., 2002; Yoon et al., 2003). 
 
5.2. Activation and repression of transcription by CTCF 
 
CTCF has been implicated in the transcriptional activation of amyloid β-protein 
precursor (APP) (Vostrov and Quitschke, 1997) involved in the Alzheimer’s disease and 
Down’s syndrome (Glenner and Wong, 1984; Mann et al., 1990; Masters et al., 1985). 
CTCF has been identified as the nuclear factor binding APBβ, and may mediate 
upregulation of the APP gene in response to TGFβ (Burton et al., 2002; Vostrov and 
Quitschke, 1997). Binding of CTCF to APBβ domain is necessary to reach optimal 
transcriptional activity (Vostrov and Quitschke, 1997) and relies on 248 amino acids in the 
amino-terminus of CTCF. 
CTCF is also known to participate in transcriptional repression, through the binding 
of the second module (F1) of the chicken lysozyme silencer gene and the P2 promoter of 
the chicken and human c-myc genes (Baniahmad et al., 1990; Filippova et al., 1996; Kohne 
et al., 1993; Lobanenkov et al., 1990). CTCF is found to be constitutively bound at the 
insulator and at the promoter region independent of the transcriptional status of c-myc, 
indicating an higher-order nuclear organization of the c-myc locus provided by matrix 
attachment regions (MARs) (Gombert et al., 2003). Moreover, the loss of 4 phosphorylated 
serine residues in the C-terminal region of CTCF increases the repression of the c-myc 
gene, but did not affect the nuclear localization and the DNA binding. (Klenova et al., 
2001). In addition, CTCF binding sites are found in close proximity to thyroid hormone 
response elements (TREs) in the chicken lysozyme silencer and the c-myc genes (Lutz et 
al., 2003). The CTCF-thyroid receptor (TR) binding sites act as enhancer blockers. In these 
cases both CTCF and TR may contribute to HDAC recruitment (Lutz et al., 2000a). The 
thyroid hormone (T3) abrogated the enhancer blocking by these elements without 
interfering with the binding of CTCF to chromatin. Therefore the abrogation of enhancer-
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blocking activity is not due to a simple loss of CTCF (Lutz et al., 2003). This result 
suggests that CTCF may be constitutively present at this site and is not recruited during 
repression. 
CTCF is also responsible for enhancer-blocking activity in the insulator at the 5’ and 
3’ chromatin boundaries of the chicken β-globin locus (Lobanenkov et al., 1990; Vostrov 
et al., 2002). Recently, conserved CTCF sites were also found at 5’HS5 and 3’HS1 of the 
mouse and human β-globin loci (Farrell et al., 2002; Tanimoto et al., 2003). 
In mammals, X-inactivation silences one of two female X chromosomes. Silencing 
depends on the noncoding gene, Xist (inactive X-specific transcript). CTCF was identified 
as a candidate trans-acting factor for X-chromosome selection (Chao et al., 2002). 
Recently it has been demonstrated that mouse and human Xist/XIST promoters contain one 
homologous CTCF-binding sequence. CTCF interacts with the XIST/Xist active promoter 
in female human and mouse cells. These observations suggest that CTCF bound to the 
XIST promoter, and creats a higher order of chromatin conformation that determines the 
choise of the X-chromosome inactivation (Pugacheva et al., 2005). 
 
5.3. CTCF and insulator function 
 
Insulators are DNA elements that prevent the activation of promoters by an 
inappropriate enhancer and/or stop the spreading of condensed chromatin. CTCF is so far 
the only protein known to mediate the enhancer-blocking activity of vertebrate insulators 
and it has been shown to interact with all of the vertebrate insulators tested so far (Bell et 
al., 1999). 
In vertebrates, enhancer blocking may occur through several different mechanisms. 
It has been proposed that insulators function by forming a protein complex that blocks a 
signal traveling along the DNA from enhancer to promoter (Bell and Felsenfeld, 1999). 
This hypothesis assumes that communication between enhancer and promoter occurs 
through the DNA strand. Another explanation for the insulator activity involves the 
formation of chromatin loops. Insulators may interact with one another to form 
independently functioning domains, each containing one gene or several genes that are 
regulated in the same manner (Bell et al., 1999). The formation of independent chromatin 
domains could also occur through interaction of insulators with the nuclear matrix (Bonifer 
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et al., 1991). This is the case for CTCF as it was found to be a nuclear MAR-binding 
protein in human breast cancer cells (Dunn et al., 2003). Recently, it has been suggested 
that CTCF bound to insulators is localized within the nucleus through association with the 
specific nuclear protein nucleophosmin. This localized binding may serve to prevent 
activation by enhancer, either by establishing a barrier to the passage of upstream 
enhancer-bound factors to the promoter or by directly blocking enhancer-promoter 
interaction (Yusufzai et al., 2004). In addition, CTCF shows a dynamic cell cycle-
dependent distribution: in interphase CTCF is a nuclear protein, during mitosis it is 
associated with the centrosome and at telophase, CTCF is localized to the midbody and the 
newly formed nuclei (Zhang et al., 2004). 
The positioning of CTCF target sequences in regions of transition in the chromatin 
structure suggests that chromatin modifying enzymes may be involved in the mechanism 
by which CTCF mediates insulator activity. Histones adjacent to the chicken HS4 β-globin 
insulator are acetylated in cells that do or do not express the β-globin (Litt et al., 2001b). 
This suggests that histone acetyltransferase is recruited to the insulator rather than to 
regulatory elements in the surrounding chromatin. MBD3 and Mi2, two subunits of the 
Mi2/NuRD complex, were observed to bind silenced, noninsulated transgenes but not 
insulated ones. It has also been observed that specific patterns of histones H3 and H4 
hyperacetylation across an insulated transgene are absent in noninsulated transgenes 
(Mutskov et al., 2002). Acetylation of H3 and H4 as well as methylation of the lysine 4 
residue of H3 (H3 K4) are associated with transcriptional activation (Litt et al., 2001b; Litt 
et al., 2001a). In contrast, methylation of lysine 9 of H3 (H3 K9) occurs in a pattern 
inverse to that of methylation of H3 K4 and acetylation of H3 K9 (Litt et al., 2001a). The 
region of condensed chromatin adjacent to the HS4 insulator displays high levels of 
methylated H3 K9. As a high level of acetylated H3 K9 prevents methylation of this site, 
Litt et al. proposed that the HS4 insulator acts as a centre of H3 K9 acetylation and thereby 
prevents the spread of K9 methylation (Litt et al., 2001a). New evidence, indicating that 
recruitment of CTCF leads to the formation of an euchromatic domain surrounding the 
DNA element to which CTCF was recruited, supports this hypothesis (Ishii and Laemmli, 
2003). 
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5.4. CTCF and genomic imprinting 
 
Genomic imprinting is a mode of inheritance whereby only one parental allele is 
expressed, while the other is silenced. During embryogenesis, maternal and paternal alleles 
are imprinted with different levels of DNA methylation resulting in differential expression 
of genes throughout embryogenesis (Tilghman, 1999). 
An approximately 2.4 kb imprinting control region (ICR) regulates somatic 
monoallelic expression of the Igf2 and H19 genes. In man and mice, these two genes are 
reciprocally imprinted such that Igf2 is expressed from the paternal allele and H19 from the 
maternal allele. Transcription of these genes is controlled by a set of shared enhancers 
downstream of the H19 gene and a differentially methylated domain (DMD) upstream of 
H19. This DMD contains binding sites for the protein CTCF, which acts as a chromatin 
insulator. On the maternal chromosome, CTCF binds to the unmethylated DMD, creating a 
chromatin insulator that prevents the Igf2 promoter from gaining access to the downstream 
enhancers. On the paternal allele, the DMD is methylated, blocking CTCF binding and 
inactivating the function of the insulator. Thus, the promoter of the Igf2 may interact with 
downstream enhancers (Bell and Felsenfeld, 2000; Hark et al., 2000) (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Regulated insulator activity 
in the Igf2-H19 locus. (a) The Igf2 and 
H19 genes are indicated on the 90 kb 
locus, with the hooked arrows indicating 
the start site and the direction of 
transcription of each gene. The relative 
postitions of the insulator and the 
enhancer are shown. (b) In maternal 
unmethylated loci, CTCF can bind to the 
insulator and prevent the 3’ enhancer 
from activating the Igf2 promoter. (c) In 
the paternal allele, the insulator is lost 
because of the methylation that prevents 
the CTCF binding. In addition, 
methylation of the H19 promoter 
represses its transcription directly and the 
enhancer activates the Igf2 promoter. 
(Wolffe, 2000) 
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The binding of CTCF to the DMD is necessary to maintain the unmethylated status 
of the maternal allele in somatic cells (Pant et al., 2003; Schoenherr et al., 2003). Recently, 
it was confirmed that CTCF binding sites protect themselves and adjacent sequences 
against methylation (Rand et al., 2004). A recent study based on RNA interference 
(RNAi), indicates that CTCF is required for establishment and maintenance of differential 
methylation and imprinting of H19. Moreover, CTCF-deficient oocytes have decreased 
developmental competence, suggesting that CTCF is important for normal preimplantation 
development (Fedoriw et al., 2004). Another study found that when the CTCF binding sites 
in the H19 DMD were mutated, methylation at the DMD remained unchanged in oocytes 
and early blastocysts (Schoenherr et al., 2003). These contrasting findings imply that 
CTCF regulates H19 DMD methylation by different mechanisms in germline and somatic 
lineages. A mutant ICR (containing mutated CTCF binding sites) remained 
hypomethylated in the female and hypermethylated in the male germ lines, showing that 
the CTCF binding sites are dispensable for establishment of imprinting. After fertilization, 
the maternal mutant ICR acquires methylation, that could be explained by loss of 
methylation inhibition, which normally is provided by CTCF binding. Adjacent regions in 
cis of the H19 promoter and gene also acquire methylation, accompanied by 
downregulation of H19 (Szabo et al., 2004b). Nevertheless, the mechanism by which 
differential methylation is established and maintained is not yet clear. A recent study 
suggests that nuclear hormone receptor complexes participate in the establishment of 
differential ICR methylation imprinting in the germ line (Szabo et al., 2004a). The p53 
protein may be required for the maintenance of DNA methylation patterns in vivo. Indeed, 
two CTCF binding sites in the 5’ ICR of the Igf2-H19 loci tended to be hypomethylated in 
the thymus of p53(-/-) mice, but not in the liver (Park et al., 2005). 
It has now been demonstrated that CTCF is responsible for the long-range interaction 
between the H19 ICR and DMR1, which are separated by more than 80 kb, on the maternal 
chromosome (Murrell et al., 2004). A general model of the maternal Igf2-H19 region 
shows an example of a higher-order chromatin structure where CTCF binds at one or more 
sites but can protect against methylation elsewhere. This structure may be associated with 
the nuclear matrix and involved proteins in addition to CTCF. Tissue-specific variation in 
higher-order structure could be due to different CTCF dependent cis elements forming the 
base of the loop or different proteins acting in trans (Cerrato et al., 2003; Weber et al., 
2003) (figure 13). 
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This higher-order chromatin structure at the Igf2-H19 locus is supported by the 
finding of an association between CTCF and PARP-1 (poly(ADP-ribose) polymerase-1) 
(Yu et al., 2004; Yusufzai et al., 2004). Indeed, PARlation of CTCF could stabilize the 
long-range interactions leading to insulation at the Igf2 (Klenova and Ohlsson, 2005). 
 
5.5. The BORIS factor (Brother Of the Regulator of Imprinting Sites) 
 
Alternatively, CTCF may positively or negatively regulate other factors directly 
involved in the protection from or targeting of methylation to the DMD. One such factor 
might be the CTCF parologue known as ‘Brother of the Regulator of Imprinted sites’ 
(BORIS). BORIS recognizes the same DNA binding sites as CTCF, but in normal cells it 
is expressed exclusively in the testis (Loukinov et al., 2002). This suggests a model in 
which BORIS, rather than CTCF, binds to the H19 DMD in the paternal germline, 
allowing methylation of this region. 
The BORIS protein shares the 11 zinc finger DNA binding domain of CTCF but 
contains distinct N- and C-termini (Klenova et al., 2002; Loukinov et al., 2002). The 
nucleoprotein complexes generated by BORIS and CTCF bound to the same DNA sites are 
likely to have distinct functions. BORIS is only present in primary spermatocytes, and 
expressed in a mutually exclusive manner with CTCF during male germ cell development 
(Figure 14). Switching to BORIS may allow these cells to perform specific functions that 
Figure 13: Regulation of imprinting by CTCF, involving a higher-order chromatin structure. 
(Lewis and Murrell, 2004) 
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otherwise are inhibited in the presence of CTCF. It is interesting to note that demethylation 
of the entire genome occurs during the time that BORIS is expressed as the erasure of 
methylation marks during male-germ line development is associated with dramatic up-
regulation of BORIS and down-regulation of CTCF expression. 
It is also possible that BORIS-CTCF switching is intimately linked with initiating (or 
regional targeting) de novo DNA methylation. In this case, reactivation of CTCF would 
serve to target de novo methylation to the paternal imprinting marks. 
 
The human BORIS gene is mapped to the 20q13.2. It has been shown that this 
chromosomal region is amplified in many cancers and may contain dominant 
immortalizing or transforming genes (Cuthill et al., 1999; Tanner et al., 1994). 
The characterization of BORIS genes in human and mouse may provide a new means 
to understand the molecular mechanisms involved in epigenetic reprogramming both in 
normal development and in tumorigenesis (Klenova et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6. CTCF, BORIS and cancer 
 
The gene encoding CTCF has been localized to chromosome segment 16q22, in a 
region that is often deleted in breast, prostate and Wilms’ tumors (Filippova et al., 1998; 
Yeh et al., 2002). These findings led to the hypothesis that CTCF is a tumour suppressor 
Figure 14: Schematic 
representation of the 
overlapping patterns 
for BORIS-CTCF 
expression switch and 
for resetting of 
genome-wide DNA 
methylation during 
spermatogenesis. 
(Loukinov et al., 2002) 
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gene (Filippova et al., 1998). Subsequent studies have identified several CTCF mutations 
common in breast, prostate and Wilms’ tumors (Filippova et al., 2002). These mutations 
caused a selective loss of DNA-binding ability in the mutant CTCF (Filippova et al., 
2002). An important reduction in CTCF binding was observed in genes involved in 
regulating cellular proliferation, including myc and Igf2 (Filippova et al., 2002). However 
there was no significant decrease in binding of the mutant CTCF to other loci including the 
APP promoter, β-globin insulator and lysozyme silencer (Filippova et al., 2002). These 
observations suggest that mutations of CTCF leading to an altered function may contribute 
to the development of human malignacies (Filippova et al., 2002). Both members of the 
BORIS-CTCF protein family recruit chromatin remodeling enzymes (Loukinov et al., 
2002; Lutz et al., 2000b). Studies have indicated that the modulation of chromatin structure 
by chromatin modifying enzymes plays a key role in the genesis of cancer (Alland et al., 
1997; DePinho, 1998). Any alteration of this structure, perhaps due to a decrease in the 
recruitment of chromatin modifying enzymes, could lead to aberrant gene expression and 
malignant transformation. Furthermore, association of CTCF with the nuclear matrix 
suggests that CTCF plays a fundamental role in the organisation of nuclear DNA into loop 
domains (Dunn and Davie, 2003). 
The human chromosome 20q13.2 region that encompasses the BORIS gene is 
commonly amplified or exhibits moderate gains of material in many human cancers. The 
localization of human BORIS to this locus, as well as frequent LOI (Loss Of Imprinting) in 
cancer involving abnormal methylation of CTCF target sites and possibly other 
mechanisms (Klenova et al., 2002) raises the possibility that aberrant activation of BORIS 
expression in tissues other than testis could be associated with tumour development. 
BORIS transcription is indeed abnormally activated in varying proportions of a wide 
variety of cancers (Klenova et al., 2002). In addition, BORIS is defined as a novel member 
of the cancer testis (CT) gene family. An interplay of DNA-methylation and CTCF 
silencing in BORIS-positive cells that express other CT genes may indicate a common 
mechanism for transcriptional regulation of both BORIS and CT genes (Klenova et al., 
2002). Therefore, CTCF and BORIS may act successively to govern epigenetic states in 
normal male germ cell development, while the rivalry caused by aberrant activation of 
BORIS in soma is associated with cancer (Figure 15). 
Deregulation of BORIS/CTCF regulatory pathways observed in many cancers is 
associated with two events on two different chromosomes: a copy-gain/amplification at 
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20q13 linked with activation of BORIS, and LOH at 16q22 linked with a decrease in 
CTCF dosage. These two events converge in deregulating the same pathway that involved 
CTCF targets recognized by the same 11 ZF domain shared by CTCF and BORIS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, the telomerase is an enzyme reactivated in a majority of cancer and 
conferes the immortality of the tumor cells. Transcriptional regulation of its catalytic 
subunit hTERT is described as the limiting factor for its activation in normal cells. Several 
studies have investigated for potential inhibitors that downregulate the hTERT transcription 
in normal, but not in tumor cells. This factor must be present independently of the type of 
the cell. In this regard, the ubiquitous factor CTCF could be a good candidate. Indeed, 
Figure 15: A model for CTCF-BORIS functions in normal cells and in cancer. The sibling 
rivalry occasioned by aberrant expression of BORIS in cancer may interfere with normal 
functions of CTCF including growth suppression and contribute to epigenetic dysregulation, 
which is a common feature in human cancer. (Klenova et al., 2002) 
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CTCF is involved in different aspect of genes regulation and it preferentially binds GC rich 
sequence (such as hTERT promoter sequences). Its paralogue BORIS, sharing the same 
DNA binding domain, might also be involved in the hTERT regulation. The identification 
of the hTERT repressor is an important step in the understanding of the activation 
mechanism of telomerase in tumors. 
 
 
6. Outline of the present investigation 
 
Given the complexity of the questions surrounding the transcriptional regulation of 
the hTERT gene, we undertook to elucidate the mechanisms by which hTERT is reactivated 
in cancer cells. The following questions were adressed:  
1) Which regions of the hTERT promoter are involved in the repression of its activity 
in normal cells? 
2) Which factor is involved in this repression? 
3) How could DNA methylation contribute to the hTERT transcription in telomerase-
positive cells? 
4) What’happened in telomerase-positive cells that have unmethylated hTERT 
promoter? Is a specific factor involved in the hTERT activation in these cells? 
To answer these questions several experimental approaches were used and are 
described in the following chapter. 
 
In chapter II, a series of luciferase vectors containing the hTERT promoter and gene 
regions were transiently transfected into HeLa cells. This approach allowed the 
identification of the region involved in the repression of hTERT. 
In chapter III, the inhibitory region of hTERT transcription was further 
characterized. We investigated the inhibitory effect of this region on different types of 
promoter (CMV and CDKN2A) and in different types of cells. The DNA sequence analysis 
of this region allowed the identification of a potential inhibitor, CTCF, and its effect was 
investigated in vivo in telomerase-positive cells and the telomerase-negative ones. 
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As a positive correlation was found between telomerase activation and the hTERT 
promoter hypermethylation, we explored, in chapter IV, the role of DNA methylation in 
the hTERT gene regulation and its link with the hTERT inhibitor identified in chapter III. 
Nevertheless, the hypermethylation of the hTERT promoter was not found in all 
tumor cell type, such as ovary and cervical adenocarcinoma. In chapter V, we investigated 
the regulation of hTERT in testicular and ovarian cancer cells. As these cells expressed the 
CTCF paralogue, BORIS, this factor might be the factor involved in the hTERT regulation.  
The conclusions of these two later chapters lead to a hypothetic model of the hTERT 
regulation valiable in telomerase-negative and in almost telomerase-positive cells. 
In chapter VI, we investigated the regulation of BORIS, as well as its expression 
level depending of the cell types. 
 
In the Chapter VII, all findings are discussed and future perspectives are addressed. 
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ABSTRACT 
 
The expression of the catalytic subunit (hTERT) represents the limiting factor for 
telomerase activity. In transfection studies, high level of activity of hTERT promoter is 
found, whereas low copy numbers of hTERT mRNA are detected in vivo. To explain this 
discrepancy, a series of vectors containing the hTERT promoter and gene were transiently 
transfected into HeLa cells. Four important regions were identified. Firstly, the core 
promoter has bidirectional activity. Secondly, the distal upstream region (-1821 to -811 bp) 
involved in the splicing of the first intron and could be a key of splicing specificity. 
Thirdly, the intermediate promoter region (-800 to -300 bp) could play an important role in 
silencing the reverse promoter activity. Fourthly, the structural gene (up to +1077) strongly 
reduced hTERT promoter activity. These results provide the first evidence that the first two 
exons play a major role in the down-regulation of the hTERT promoter in telomerase-
positive cells. 
 
Keywords: Telomerase, hTERT, transient transfection, promoter, splicing, repressor 
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INTRODUCTION 
 
Telomerase is a ribonucleoprotein responsible for maintaining the ends of 
chromosomes, named telomeres, composed of tandem repeats of the sequence TTAGGG 
[1]. Possible functions of this non-coding DNA include prevention of chromosome 
degradation, end-to-end fusions, rearrangements, and chromosome loss [2]. Since DNA 
polymerase cannot completely replicate chromosome ends, telomerase is needed to add 
telomeric repeats to the chromosomes, thereby preventing the loss of telomeric DNA. 
Indeed, in normal cells, lacking telomerase activity, each division is associated with 
telomere shortening [3]. Telomerase activity is detectable during embryogenesis in a 
variety of fetal tissues [4]. In adults, telomerase activity is not detectable in most human 
somatic cells[5]. On the contrary, highly proliferative cells such as germ cells and stem 
cells express telomerase, as well as 85-95% of cancer cells [6].  
Studies of the human telomerase complex reveal the presence of two major 
subunits: a RNA component (hTERC) that serves as template for the polymerase activity 
and a catalytic subunit with reverse transcriptase activity (hTERT) [7,8]. The presence of 
both is sufficient to reconstitute telomerase activity in vitro [9], but other telomerase-
associated proteins have been identified in vivo [10,11]. The hTERT gene seems to be 
highly regulated and its expression correlates with telomerase activity [12,13]. Many 
studies have demonstrated that ectopic expression of hTERT was sufficient to restore 
telomerase activity in telomerase negative cells [14-16]. 
Many studies suggested that expression of hTERT represents the limiting factor for 
telomerase activity, and that the regulation of hTERT should mainly occur at the 
transcriptional level. Genomic organization and promoter characterization of the hTERT 
gene have been described by several groups [17-19]. These investigations demonstrate that 
a region named core promoter, encompassing the proximal 283 bp region upstream of the 
initiation ATG codon, is essential for transcriptional activation. Several groups have found 
specific sites for activators and inhibitors of the transcription in the hTERT promoter 
sequence [20-28]. Apparently complex mechanisms involving regulatory elements distant 
from the 5' flanking region of the hTERT promoter are also implicated in the regulation of 
hTERT expression [29]. Moreover, studies of RNA processing revealed complex splicing 
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patterns in different cell types [12] and a potential regulation of hTERT expression by 
alternative splicing [30].  
The hTERT promoter induced very high expression, similar to that of the SV40 
early promoter, in transiently transfected telomerase-positive cell lines [31]. This is in stark 
contrast with the low hTERT mRNA levels detected in telomerase-positive cell lines which 
was found to be as low as 0.2 to 6 copies per cell [29]. These findings suggest a complex 
regulation of the expression of the hTERT gene. 
In this study, we explore the implication of the structural gene itself, in the 
transcriptional regulation of the hTERT gene. A series of luciferase reporter constructs 
driven by the hTERT minimal promoter and distant sequences (from -1821 to + 1071 bp) 
were constructed and transiently transfected into HeLa cells. These constructs allowed the 
identification of three additional regions involved in the hTERT regulation. 
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MATERIALS AND METHODS 
 
Cell culture. HeLa cells were grown in Dulbecco's modified Eagle's medium supplemented 
with 5% heat-inactivated Fetal Bovin Serum (HI-FBS) and an antibiotics mixture (250 000 
U Penicillin, 25 mg Streptomycine and 2.5 µg Fungizone) at 37°C in a 5% CO2 humidified 
incubator (all products from Invitrogen, Basel, Switzerland). 
  
Plasmid construction. The structure of the different constructions is shown in figure 1. 
Various lengths of DNA fragments upstream and downstream of the initiating ATG codon 
of the hTERT gene were amplified by PCR and inserted into a Firefly luciferase reporter 
vector, pGL3-basic (Promega, Madison, WI), a promoterless and enhancerless vector. 
Plasmids were purified with Midiprep and Miniprep kits (Qiagen, Hilden, Germany). 
Constructs containing only a fragment of the hTERT promoter were named pTERT-1821 (-
1821 to -23), pTERT-811 (-811 to -23), pTERT-499 (-499 to -23) and pTERT-297 (-297 to 
-23). When constructs contained the 357 bp downstream of the ATG initiation codon, 
"ex1" was added to the name of each construction. These 357 bp downstream of the ATG 
correspond to exon1, intron1 and the first 36 bp of exon2 of the hTERT gene. Constructs 
containing the 1071 bp downstream of the ATG initiation codon have the same name with 
addition of "ex2". This 1071 bp downstream of the ATG include exon1, intron1 and a large 
part of exon2 of the hTERT gene (Fig. 1A). The figure 2A shows three types of reporter 
plasmids derived from the “ex1” constructs. These constructs were generated by PCR 
using primers containing one or two additional nucleotides than the standard primer. These 
constructs allowed the evaluation of the translation of the three open reading frames. Each 
construct was confirmed by sequencing (Genome express, Grenoble, France). As shown in 
figure 3, for the three reverse constructs, the plasmids have the same name as their 
homologs with "rev" at the end of the name. pTERT-811/ex1-rev contains, in reverse 
orientation, the 297 bp core promoter, the 357 bp sequence downstream of the core 
promoter and 515 bp upstream of the core promoter corresponding to the sequence -297 to 
-811 bp of the hTERT promoter. pTERT-499/ex1-rev contains the same sequence as 
pTERT-811/ex1-rev except the sequence upstream of the core promoter which contains 
only 203 bp of the hTERT promoter (-297 to -499 bp of the hTERT promoter). The 
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pTERT-297/ex1-rev construct contains only the core promoter and the reverse 357 bp 
sequence in reverse orientation. 
 
Transient transfection and luciferase assay. Cells were seeded at a concentration of 
100’000 cells / 3.8 cm2 and cultured overnight. Transient transfection of luciferase reporter 
plasmids was carried out in triplicate using lipofectin Plus Reagent (Invitrogen, Basel, 
Switzerland) according to the protocol recommended by the manufacturer. All experiments 
were performed at least three times. The Renilla luciferase reporter vector (Promega, 
Madison, WI) was co-transfected as an internal control for transfection efficiency. Briefly, 
cells were exposed to a transfection mixture containing 0.6 µg of luciferase reporter 
plasmids and 0.5 µg of internal control vector for 3h at 37°C. Then, 1 ml of growth media 
supplemented with 15 % HI-FBS was added to the cells. The cells were harvested 48h 
after the transfection. Luciferase assays were performed using the Dual-Luciferase 
Reporter Assay System (Promega, Madison, WI). To compare the results the mean values 
of relative luciferase activity was used. The levels of the different constructs were 
compared to the level of the pGL3-control vector containing the firefly luciferase gene 
under the control of the SV40 early promoter and to the level of the pGL3-basic vector, a 
promoterless and enhancerless luciferase vector. 
 
RT-PCR assay. Three wells of transfected cells were pooled together. Two third of the 
cells were used for RNA extraction and 1/3 was used for the luciferase assay to compare 
the protein level with the RNA level and to normalize the experiments. Total RNA of 
transfected cells was extracted using Trizol-LS (Invitrogen, Basel, Switzerland) according 
to the manufacturer's protocol. A DNase I treatment was performed before the RT-PCR. 
Both cDNA synthesis and PCR were performed in a single tube using the 
SUPERSCRIPTTM One-Step RT-PCR with Platinum® Taq kit (Invitrogen, Basel, 
Switzerland). Sense and antisense oligonuleotide primers amplified a region of 468 bp of 
the firefly luciferase cDNA (5'-AACCGCTGGAGAGCAACTGCATAAG-3' and 5'-
AAACCGGGAGGTAGATGAGATGTGA-3'). The reverse transcriptase step was 
performed at 55°C during 30 min followed by 2 min at 94°C to release the Taq 
polymerase. Then 25 cycles of PCR were performed, including denaturation at 94°C for 2 
min, annealing at 56°C for 45 sec and extension at 72°C for 50 sec. 
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The RT-PCR products were denaturated at 100°C for 10 minutes followed by 5 
minutes on ice. Then 2 µl of each sample were loaded on a nylon membrane and fixed with 
U.V. for 5 min. The DIG-labeled probe was synthesized by PCR on the pGL3-basic vector 
with the same primer set used for the RT-PCR. Hybridization was performed at 42°C for 2 
hours with 30 ng of probe per ml of hybridization buffer. After washing and detection with 
CDP-star (Roche, Rotkreuz, Switzerland), the membrane was exposed on a X-Omat 
sensitive film (Eastman Kodak Company, NY) for 30 min. Blots are quantified by 
comparing its intensity to a reference range dilution of RNA extracted from pGL3-control 
transfected in HeLa cells. 
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 RESULTS 
 
Identification of an inhibitory region downstream of the ATG initiation codon of the 
hTERT gene 
 
To identify the regulatory region responsible for the repression of the hTERT gene 
expression, a series of luciferase reporter plasmids, containing various lengths of the 
promoter and structural gene were prepared and tested in transient transfection assays in 
telomerase-positive HeLa cells. As shown in figure 1, the constructs, containing only a 
fragment of the hTERT promoter, show high levels of reporter gene expression, similar to 
that of the SV40 early promoter (pGL3-control). The proximal 297 bp region is defined as 
the core promoter of the hTERT gene (Fig. 1A, pTERT-297). The 5' deletions of the 
promoter up to -811 bp weakly reduced transcriptional activity (Fig. 1, pTERT-499 and 
pTERT-811). However, transcriptional activity increased with less extended truncation 
(Fig. 1, pTERT-1821). These findings suggest the existence of a minimal promoter, 
sufficient to exhibit a high transcriptional activity and the existence of a potential negative 
regulatory region between -800 to -300 bp of the promoter. These observations are in 
agreement with recent studies that defined the function of the proximal 181 bp region as a 
minimal core promoter [20] and a negative regulatory region between -776 to -378 bp [26]. 
Interestingly, a strong decrease of luciferase activity was observed if the constructs 
tested contained a part of the structural gene (Fig. 1). The three constructs that contain the 
exon1 and intron1 exhibited a transcriptional activity 10 times less than the homologous 
constructs without the downstream region of the ATG initiation codon. Furthermore, the 
addition of part of exon2 entailed an up to a 100-fold decrease of the transcriptional 
activity of the hTERT promoter. These observations imply a potential role for the exon1, 
intron1 and exon2 in the repression of the hTERT gene expression. 
A RT-PCR analysis of transfected cells showed levels of luciferase mRNA 
expression consistent with the respective enzyme activity (Fig 1B). This result suggests 
that this strong down-regulation, due to the presence of a hTERT exon region, occurred at 
the mRNA level.  
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Fig. 1. Transcriptional activity of the hTERT promoter. (A) A schematic representation of the 
reporter plasmids. The fragments of hTERT promoter and structural gene are cloned into the 
luciferase (LUC) reporter vector pGL3-basic in the sense orientation. The 280 bp core 
promoter is shown as a black bold line. Numbers refer to the number of bases upstream (-) or 
downstream (+) of the ATG initiation codon of the hTERT gene. (B) Luciferase reporter 
plasmids containing fragments of hTERT promoter with or without structural gene were 
transfected in HeLa cells. White and gray bars indicate luciferase mRNA and protein levels, 
respectively. PGL3-basic, which lacks the enhancer/promoter, was used as a negative 
control; pGL3-control containing the SV40 enhancer/promoter was used as a positive 
control. The transcriptional activities in each reporter plasmid are indicated as relative 
luciferase activities. The values for the positive control are indicated as 100%. The level of 
RNA
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Presence of a splicing regulatory region upstream of the hTERT core promoter 
 
Due to the presence of an intronic region in the constructs, it was necessary to confirm our 
results by testing the different reading frames. To create the different reading frames, one 
or two nucleotides were inserted in the standard reporter plasmids (Fig. 2A). The splicing 
sites in the first intron are defined in literature [31]. For the first reading frame, luciferase 
activity is only detected when the first intron is spliced because, only in this condition will 
the two ATG start sites of the hTERT and luciferase genes be in phase. For the second 
reading frame, no activity should be observed because the ATG sites cannot be in phase 
(with or without splicing of hTERT intron 1). For the third reading frame, an activity must 
be detected if the first intron was not spliced, only in this condition will the two ATG sites 
be in phase. 
Figure 2B shows the results obtained with these three possible reading frames for 
the three constructs pTERT-1821/ex1, pTERT-499/ex1 and pTERT-297/ex1 (Fig. 1). As 
expected, no transcriptional activity was observed with the second reading frame (Fig. 2B, 
lanes 2). In contrast, for the first reading frame, splicing of the first intron led to a weak 
luciferase activity for the 3 different constructions (Fig. 2B, lanes 1). The results obtained 
with the third reading frame were more surprising. Some luciferase activity was observed 
with all the constructs, which indicates that splicing of the first intron did not occur 
completely. Nevertheless, for the longest construct pTERT-1821/ex1, the activity was 
significantly lower than with the first reading frame. In contrast to the construct containing 
the longest promoter sequence, the level of luciferase activity of pTERT-499/ex1 and 
pTERT-297/ex1 was higher with the third reading frame (Fig. 2B, lanes 3). Therefore, 
more efficient splicing of the first intron of the hTERT gene was obtained with increasing 
length of the hTERT promoter. 
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Fig. 2. The effect of the three reading frames on the transcritpional activity of the hTERT 
promoter. (A) A schematic representation of the reporter plasmids. Luciferase reporters 
contain a fragment of promoter and exon 1, intron 1 and the beginning of exon 2. For each 
reporter, three types of constructs were generated by the insertion of one or two nucleotides. 
(B) Reporters were transfected in HeLa cells and luciferase assays were performed. 
Numbers indicate the three possible reading frames; 1, after splicing of the first intron, the 
two ATG of hTERT and luciferase gene are in phase; 2, the two ATG are never in phase, 
with or without splicing of the first intron; 3, the two ATG are in phase if the first intron is 
not spliced. 
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The hTERT core promoter is bi-directional 
 
Promoters that lack TATA boxes and initiator elements frequently display bidirectional 
activity [32]. To determine if this is also true for the hTERT promoter, we conceived three 
reverse constructs corresponding to pTERT-811/ex1, pTERT-499/ex1 and pTERT-297/ex1 
(Fig. 3A). In the minimal construct, pTERT-297/ex1-rev, the core promoter and the exon 
region are reversed, which means that the exon region is now situated upstream of the 
promoter. This construction led to a 2-fold transcriptional activity compared to that the 
minimal hTERT promoter activity in the correct orientation (Fig. 3B). This result seems to 
indicate that the inhibitory role of the region containing the exon1 and the intron 1 is 
effective only if this region is situated downstream the promoter. For the other inverted 
constructs, pTERT-499/ex1-rev and pTERT-811/ex1-rev, a 200 and a 500 bp reversed 
fragment of the hTERT promoter were respectively inserted between the reverse core 
promoter and the luciferase reporter gene. The 200 bp fragment corresponds to the -500 to 
-300 bp of the hTERT promoter and the 500 bp fragment corresponds to the -800 to -300 
bp of the hTERT promoter. Figure 3B shows that the transcriptional activities of the 
reverse constructs pTERT -297/ex1-rev and pTERT-499/ex1-rev are respectively 86- and 
28-fold higher than activities of its homologous constructs in the correct orientation. In 
contrast, the activity of the pTERT-811/ex1-rev is not significantly different from the 
activity of its homologous construct in the correct orientation (pTERT -811/ex1). The 
difference between the two first constructs and the pTERT -811/ex1-rev is the 300 
additional bp of the hTERT promoter corresponding to the -800 to -500 bp region of this 
promoter. Our experiments show that this region, containing multiple binding motifs for 
MZF-2 [26], downregulates the hTERT promoter transcription more strongly in the reverse 
orientation than in the correct one. 
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Fig. 3. The hTERT promoter is bidirectional. (A) A schematic representation of the 
reporter plasmid. The region of the hTERT promoter was reversed in the pTERT-297/ex1, 
pTERT-499/ex1 and pTERT-811/ex1 constructs. The new constructs were named pTERT-
297/ex1-rev, pTERT-499/ex1-rev and pTERT-811/ex1-rev. (B) Relative luciferase activity 
of these three reverse constructs versus no reverse constructs: pTER-297/ex1, pTERT-
499/ex1-rev and pTERT-811/ex1-rev; and versus homologous constructs containing only 
the hTERT promoter: pTERT-297, pTERT-499 and pTERT-811. The transcritpional 
activity in each reporter plasmid was indicated as relative luciferase activities. 100% 
corresponded to the value of the pGL3-control vector activity (data not shown). 
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DISCUSSION  
 
The hTERT gene regulation is rather complex and not yet well understood. In this 
study, we addressed the potential role of the proximal part of the structural gene as a 
negative regulatory element for the hTERT promoter. To answer this question, different 
parts of the hTERT promoter, with or without a part of the structural gene, were cloned in 
luciferase reporter vectors. Four important regions, involved in the transcriptional 
regulation of the hTERT gene, have been identified from -1821 to +1071 bp of the gene 
(Fig. 4).  
The first region contains the core promoter, which gives the highest transcriptional 
activity. The result is consistent with other studies using hTERT promoter reporter vectors 
[17-19,31]. In addition, reverse constructs allowed us to conclude that this core promoter 
has the particularity of being bidirectional, and that, at least in HeLa cells, the expression 
in the reverse sense is 2-fold higher than the normal hTERT gene transcriptional level. 
The second region identified, located in the 5' flanking region of the promoter 
between -1821 to -811 bp, was involved in the regulation of the mRNA splicing processing 
(Fig. 4). Since sequences subcloned contained the first intron, the possible reading frames 
were tested. The frequency of correct splicing of the first intron was significantly more 
efficient with constructs containing the largest part of the promoter. Indeed, spliced mRNA 
was 4 times more frequent than non-spliced mRNA if the construct contains the 1821 bp 
upstream of the ATG start codon. In contrast, if the transfected constructs contained a 
shorter promoter region, the level of non-spliced mRNA became significantly higher than 
the spliced one. It is well know that regulation of the hTERT gene also implies alternative 
splicing of mRNA [12,32]. Our results indicate that the 5' flanking region of the hTERT 
promoter is involved in the splicing, at least, of the first intron of the hTERT gene. Hence, 
some regulatory factors of the RNA splicing process may be located in the 5' flanking 
region of the promoter between -1821 to –811 bp. Other studies have also suggested that 
the distant 5' flanking region of the hTERT gene is involved in the splicing regulation as 
several transcripts of hTERT mRNA could be detected. In this situation, the chromatin 
structure could be implied in this regulation; some factors could bind these sequences and 
could contribute to stabilize the spliceosome, allowing the correct splicing [29]. Moreover, 
various hTERT splicing patterns have been observed during human development 
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[29,33,34]. This observation provided evidence that alternative splicing is non-random and 
could play a role in the regulation of telomerase activity. Nevertheless, other possibilities 
could be envisioned to explain our results. Firstly, variations of the different levels of the 
three reading frames could be due to a switching of the open reading frame (ORF) during 
translation. However, the switch of the ORF had to lead to similar variation for the three 
constructs containing different part of the hTERT promoter, which was not the case in our 
experiment.  Furthermore, this event was observed in bacteria, virus and yeast, but not in 
higher eukaryote. Secondly, the ATG of luciferase could be chosen as the initiated codon. 
Indeed, under rare conditions, the first ATG is not always selected as the exclusive 
translation initiation site [35].  
The third and fourth regions were involved in repression of hTERT expression. The 
third is located within the promoter between -800 to –300 (Fig. 4). The three reverse 
constructs containing sequences situated in the intermediate promoter region (upstream to 
the core promoter) reduced hTERT transcriptional activity. With the -500 to -300 bp region 
of the promoter, the activity is decreased 2 fold. When the 300 bp of the promoter, 
corresponding to the MZF-2 binding site region [26], were added, there was almost no 
transcriptional activity detected. Therefore the inhibitory region, containing MZF-2 
binding sites, might be important to reduce significantly or even to stop the reverse 
transcriptional activity of the hTERT promoter.  
The fourth inhibitory region is located in the structural gene between the beginning 
of the exon 1 and a large part of the exon 2 (Fig.4). This sequence could play a major role 
in the repression of the hTERT promoter activity. Indeed, the transcription level of 
constructs with a part of the structural gene was decreased up to 20- to 50-fold, compared 
with the transcription level of the homologous construct lacking structural gene 
components. If a longer part of the second exon was added, the transcription was decreased 
up to 100-fold. Moreover, reverse constructs showed that this region did not inhibit the 
transcriptional activity of the hTERT gene when reversed and situated upstream of the core 
promoter. This region might be required for the binding of transcription repressor(s). It 
could explain why the hTERT core promoter, which has a transcriptional activity similar to 
that of the SV40 early promoter in vitro, induces a very low level of gene expression in 
vivo [29]. In our experiments, the luciferase mRNA expression was consistent with the 
respective enzyme activity. Nevertheless, it is important to considerate that the low level of 
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detected luciferase could be also the consequence of the mRNA instability generated by 
the fusion between hTERT and luciferase mRNA. 
In conclusion, our results show that the first two exons of the hTERT gene play an 
important role in the regulation of its expression. We furthermore found the most distal 
upstream promoter region to play a role in the regulation of hTERT mRNA splicing. How 
these sequences regulate the expression of the hTERT gene merits to be further elucidated. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGMENTS 
We wish to thank Prof. Ivan Stamenkovic for critical reading of the manuscript. This work 
was funded by a grant from the Swiss National Science Foundation (grant number: 3200-
061624.00). 
 
ATG+1
EXON 1 EXON 2
hTERT promoter
-297-811 -499-1821 +219 +324
core promoter
Bi-directional
core promoter
inhibitory region 
for the promoter 
in opposite 
direction
inhibitory region 
for the promoter 
in sense direction
regulatory region 
for splicing efficiency
MZF-2 c-Mycc-Myc
Sp1  Sp1  Sp1
MZF-2 WT1
Sp1
hTERT gene
Fig. 4. Schematic representation of the four important regions involved in the hTERT gene 
regulation. The -297 to +1 bp region corresponding to the core promoter shows a 
bidirectional activity. The -811 to -499 region contains inhibitors which contribute to repress 
reverse transcription of the core promoter. The -1821 to -811 region is involved in mRNA 
splicing processing. Finally the +1 to +1077 bp region contains inhibitor of the hTERT gene 
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ABSTRACT 
 
The expression of the catalytic subunit (hTERT) represents the limiting factor for 
telomerase activity. Previously, we detected a transcriptional repressor effect of the 
proximal exonic region (first two exons) of the hTERT gene. To better understand the 
mechanism involved and to identify a potential repressor, we further characterized this 
region. The addition of the hTERT proximal exonic region downstream of the hTERT 
minimal promoter strongly reduced promoter transcriptional activity in all cells tested 
(tumor, normal and immortalized). This exonic region also significantly inhibited the 
transcriptional activity of the CMV and CDKN2A promoters, regardless of the cell type. 
Therefore, the repressor effect of hTERT exonic region is neither cell nor promoter 
dependent. However, the distance between the promoter and the exonic region can 
modulate this repressor effect, suggesting that nucleosome positioning play a role in 
transcriptional repression. We showed by EMSA that CTCF binds to the proximal exonic 
region of hTERT. Chromatin Immunoprecipitaion (ChIP) assays confirmed the binding of 
CTCF to this region. CTCF is bound to hTERT in cells in which hTERT is not expressed, 
but not in telomerase-positive ones. Moreover, the transcriptional downregulation of CTCF 
by RNA interference derepressed hTERT gene expression in normal telomerase-negative 
cells. Our results suggest that CTCF participates in key cellular mechanisms underlying 
immortality by regulating hTERT gene expression. 
 
Keywords: Telomerase, hTERT, transient transfection, repressor, CTCF. 
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INTRODUCTION 
 
Telomeres are specific sequences composed of tandem repeats of the TTAGGG sequence 
at the end of human chromosomes (1). Possible functions of this non-coding DNA include 
prevention of chromosome degradation, end-to-end fusions, rearrangements, and 
chromosome loss (2). In normal cells, each division is associated with telomere shortening 
(3). Telomerase is a ribonucleoprotein complex in which the catalytic subunit, hTERT, 
uses a specific RNA, hTERC, as a template for the addition of telomeric repeat sequences 
to the ends of chromosomes (4-6). Telomerase activity is detectable during embryogenesis 
in a variety of fetal tissues (7), while in adult humans, telomerase activity is not detectable 
in most somatic cells (8). In contrast, highly proliferative cells, such as germ cells and stem 
cells, as well as 85-95% of cancers express telomerase (9).  
The presence of the two major subunits, hTERT and hTERC, is sufficient to reconstitute 
telomerase activity in vitro (10), but additional telomerase-associated proteins have been 
identified in vivo (11;12) . It has been shown that expression of hTERT is sufficient to 
restore telomerase activity in telomerase negative cells (13-15). Expression of the hTERT 
gene is highly regulated and correlates with telomerase activity (16;17). The genomic 
organization of the hTERT gene and features of its promoter have been described by 
several groups and a region encompassing the 283 bp upstream of the translation site, 
designated as the core promoter, is essential for transcriptional activity (18-20). Specific 
binding sites for activators and repressors of transcription have been identified in the 
hTERT promoter sequence (21-35). Additional regulatory elements have been identified 
distant from the 5' flanking region of the hTERT promoter (36) . Moreover, studies of RNA 
processing revealed complex splicing patterns in different cell types (16) which suggest 
regulation of hTERT translation by alternative splicing (37-39). 
In telomerase-positive cell lines, the transient transfection of the hTERT promoter yields a 
high level of transcriptional activity, similar to that induced by the SV40 early promoter 
(40;41). This is in stark contrast with the low endogenous-hTERT mRNA levels detected in 
telomerase-positive cell lines which are as low as 0.2 to 6 copies per cell (36;42). In 
transient transfection assays the proximal exonic region (first two exons) of the hTERT 
gene was shown to contain repressor elements (41). The regulation of hTERT expression, 
therefore, appears to be rather complex.  
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Based upon the published reports we hypothesize that the proximal exonic region of the 
hTERT gene plays an important role in the regulation of hTERT transcription. 
Conceptually, this might be due to the distance between the core promoter and the 
transcriptional start site and might involve binding of repressors, as well as histone 
acetylation. We therefore set out to explore the effect of the distance between the core 
promoter and the transcription start site on hTERT transcription in telomerase-positive and 
-negative cells. In addition, we investigated the interaction of CTCF, a ubiquitously 
expressed 11-zinc finger protein, with the first exon of the hTERT gene. 
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MATERIALS AND METHODS 
 
Cell culture 
The human tumor cell lines (HeLa, cervical adenocarcinoma; SW480, colorectal 
adenocarcinoma; NCCIT, teratocarcinoma; OVCAR-3, adenocarcinoma of the ovary and 
U2-OS, osteosarcoma) and normal human fibroblasts (BJ) were obtained from ATCC. All 
cells were grown in the medium recommended by ATCC. The GM847, HLF and 
HLF/hTERT cells were kindly provided by Dr. Joachim Lingner (ISREC, Epalinges, 
Switzerland). They were cultured in DMEM supplemented with 10% heat inactivated fetal 
bovine serum. The cell lines, HeLa, SW480, NCCIT and OVCAR-3, are telomerase-
positive, whereas the U2-OS cell line is telomerase-negative. The normal human 
fibroblasts HLF and BJ are telomerase-negative. GM847 is an SV-40 immortalized, but 
telomerase-negative cell line derived from normal fibroblasts. HLF/hTERT cells were 
obtained through stable transfection of HLF cells with hTERT cDNA construct, express 
hTERT and exhibit telomerase activity. 
 
Plasmid construction 
pTERT–297 contains the hTERT minimal promoter (41). The pTERT–297/ex1 vector 
contains the hTERT minimal promoter and 80 bp of the first exon. To construct this vector, 
an hTERT fragment was generated by PCR and cloned into the pGL3 basic vector 
(Promega, Madison, WI) previously opened with SacI and HindIII. The primers used for 
PCR amplification of the hTERT fragment also contained the SacI and the HindIII sites and 
were FW-5’-GGCTGCGAGCTCCAGGCCGGGCTCCCAGTGGAT-3’ (beginning of the 
exon1) and REV-5’-GGCAAGCTTCGAACGTGGCCAGCGGCAGCACCTC-3’ (end of 
the exon1). 
A 1804 bp fragment, containing the hygromycine resistance gene and the FRT site, was 
deleted by PvuII digestion from the pcDNA5/FRT vector (Invitrogen, Basel, Switzerland). 
The resulting 3266 bp vector was named pcDNA5. The 1983 bp firefly luciferase sequence 
was obtained through digestion of the pGL3 basic vector (Promega, Madison, WI) with 
NheI and BamHI and was subcloned into pcDNA5. This new construct contained the CMV 
promoter upstream of the firefly luciferase gene and was named pCMVluc. We further 
deleted the CMV promoter from the pCMVluc vector with BglII and NheI, and inserted 
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two other promoters, hTERT or the CDKN2A promoter amplified by PCR. These 
constructs were named pTERTluc and pCDKN2Aluc, respectively.  
After digestion of the pCMVluc, pTERTluc and pCDKN2Aluc vectors with NheI and 
HindIII, the PCR fragment containing the hTERT proximal exonic region (first exon and 
885 bp of the second exon, without the first intron) and flanking with the NheI and the 
HindIII restriction sites, was subcloned into these vectors to create the pCMVtertluc, the 
pTERTtertluc and the pCDKN2Atertluc vectors, respectively. 
Three different sequences (44, 100 and 200 bp), which did not contain motifs with 
transcriptional interest, were got from the pcDNA5 vector. These plasmid fragments were 
generated by PCR using primers containing the NheI restriction site: 5’-
GCTGGCGCTAGCTCATAGCTCACGCTGTA-3’ and 5’-
GCCTGCTAGCCCTACACCGAACTGAGATAC-3’ generated the 44 bp insert; 5’-
TAACGTGCTAGCGCGCCTTATCCGGTAACT-3’ and 5’-
GTCGCTAGCCTGCTAATCCTGTTACCAGTGGC-3’ generated the 100 bp insert; 5’-
TAACGTGCTAGCGCTTTCTCATAGCTCACGCT-3’ and 5’-
GCTGCTAGCCTGCTAATCCTGTTACCAGTGGC-3’ generated the 200 bp insert. 
Then, theses sequences were inserted into the pCMVtertluc digested with NheI, to create 
the pCMV44tertluc, pCMV100tertluc and pCMV200tertluc constructs, respectively. The 
same inserts were subcloned into the pTERTtertluc and the pCDKN2Atertluc vectors to 
create the plasmids pTERT44tertluc, pTERT100tertluc, pTERT200tertluc, 
pCDKN2A44tertluc, pCDKN2A100tertluc and pCDKN2A200tertluc.  
All these constructs have been confirmed by sequencing on an ABI Prism 3100 sequencer 
(Applied Biosystems, Foster City, CA). 
 
Transient transfection and luciferase assay 
Cells were seeded at a concentration of 300’000 / 3.8 cm2 for HeLa, NCCIT, OVCAR-3, 
U2-OS and GM847, and 100’000 cells / 3.8 cm2 for HLF, HLF/hTERT and BJ, and 
cultured overnight. Transient transfection of luciferase reporter plasmids were carried out 
using Lipofectin Plus Reagent for HeLa, or LipofectAMINE for all other cell lines 
according to the protocols recommended by the manufacturer (Invitrogen, Basel, 
Switzerland). All experiments were performed at least in triplicate. The Renilla luciferase 
reporter vector (Promega, Madison, WI) was co-transfected as an internal control for 
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transfection efficiency. Briefly, HeLa cells were exposed to a transfection mixture 
containing 0.6 µg of luciferase reporter plasmids and 0.6 µg of internal control vector mix 
with 0.75 µl of lipofectine for 3 hours at 37°C. Then, 1 ml of growth media supplemented 
with 15 % HI-FBS was added to the cells. The cells were harvested 48 hours after 
transfection. The other cell lines were exposed to a transfection mixture containing 0.8 µg 
of luciferase reporter plasmids and 0.8 µg of internal control vector with 4 µl of 
lipofectAMINE for 5 hours at 37°C. Luciferase assays were performed using the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI). To compare the results, the 
mean values of relative luciferase activity obtained in the three experiments were used. The 
transcription levels detected with the different constructs were compared to the 
transcription level of the pGL3-control vector containing the firefly luciferase gene under 
the control of the SV40 early promoter and to the transcription level of the pGL3-basic 
vector, a promoterless and enhancerless luciferase vector. 
 
siRNA transfection assay 
 Cells were seeded in 12-well plates at a concentration of 100’000 / well for HeLa and 
30’000 cells / well for BJ. The cells were then cultured overnight. Co-transfections of 
siRNA (50nM) and plasmids (1µg/well) were carried out in duplicate using the JetSI-
ENDO Cationic Transfection reagent (4 µl / well) (Polyplus-transfection, Illkirch, France) 
according to the manufacturer’s instructions. siRNA for CTCF 5’-
(UUGGUUCGGCAUCGUCGUU)dTT-3’ was synthesized by Qiagen-Xeragon 
(Germantown, MD). siRNAs for silencing-control and for luciferase pGL3 were provided 
in the jetsilencing control kit Luciferase pGL3 (Polyplus-transfection, Illkirch, France). BJ 
cells, transfected only with siRNAs, were harvested 48 hours post transfection. The hTERT 
gene expression was analyzed by RT-PCR and TRAP assay (43). HeLa cells were co-
transfected with siRNAs and either pTERT/-297 or pTERT –297/ex1, and luciferase assays 
were performed 48 hours later. 
 
RNA extraction and hTERT RT-PCR analysis 
RNAs were extracted from cells transfected with siRNA, using the TRIzol LS Reagent 
(Invitrogen, Basel, Switzerland). Platinum quantitative RT-PCR Thermoscript one-step 
system (Invitrogen) was used to amplify the hTERT mRNA using the primers LT5 5’-
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CGGAAGAGTGTCTGGAGCAA-3’ (exon3) and LT6 5’-
GGATGAAGCGGAGTCTGGA-3’ (exon4), with co-amplification of β-actin with the 
primers FW 5’-AGGCCAACCGCGAGAAGATGA-3’ and REV 5’-
GCCGTGGTGGTGAAGCTGTAG-3’. The hTERT splicing variants (α, β, α/β and FL) 
were determined by RT-PCR using the primers FW-SP 5’-
GCCTGAGCTGTACTTTGTCAA-3’ and REV-SP 5’-
CGCAAACAGCTTGTTCTCCATGTC-3’. The FL variant was obtained with the primers 
FW-FL 5’-CGCCTGAGCTGTACTTTGTCA-3’ and REV-FL 5’-
CGGCTGGAGGTCTGTCAAG-3’. RT-PCR products were analyzed on 2% agarose gel. 
The FL and the β spliced variant fragments were extracted from the gel, purified with the 
QIAquick gel extraction kit (Qiagen) and sequenced on an ABI Prism 3100 sequencer 
(Applied Biosystems, Foster City, CA). 
 
Electrophoretic mobility shift assay (EMSA) and DMS-methylation interference 
analysis 
Different fragments of the hTERT promoter and proximal exonic region were synthesized 
by PCR with the following primers: F1-FW-5’-AGCCCCTCCCCTTCCTTTC-3’ and F1-
RV-5’-CGGGTCCCCGCGCTGCACCA-3’; F2-FW-5’-GTCCGGCTGGGGTTGAG-3’ 
and F2-RV-5’-GCACGCTGGTGGTGAAGG-3’; F3-FW-5’-
GCCCGAGTGCTGCAGAGG-3’ and F3-RV-5’-GGGAGCCACCAGCACAAAGA-3’; 
F4-FW-5’-CGTGGGGGCTGCTGCTG-3’ and F4-RV-5’-ACGCCGGCCTCCCTGAC-3’. 
EMSA was performed as described earlier (44). Briefly, PCR fragments were end labeled 
using 32P-γ-ATP and T4 polynucleotide kinase (New England Biolabs). Protein–DNA 
complexes were allowed to form by incubation for 30 min at ambient temperature in PBS 
with 5mM MgCl2, 0.1mM ZnSO4, 1mM dithiothreitol, 0.1% Nonidet P-40, 10% glycerol 
and poly(dI-dC). Full-length CTCF and the Zn-Fingers DNA binding domain of CTCF 
were translated in vitro using the TnT kit (Promega, WI, USA). Protein-DNA complexes 
were resolved from unbound DNA probe in 5% native Polyacrylamide gel (PAAG) in 
0.5X TBE. 
DMS-methylation interference analysis was performed with full-length CTCF and the F1 
and F3 PCR fragments amplified by sense and antisense primers, F1-FW and F1-RW, and 
F3-FW and F3-RV, respectively. Fragments were subcloned to pCR2.1-TOPO vector 
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(Invitrogen, Carlsbad, CA) and sequence verified. Then, fragments containing the region 
F1 or F3 were amplified by PCR using 32P 5' end-labeled M13 forward or reverse primers 
in order to obtain labeling on either the sense or the antisense strand. Methylation of 
guanine residues was done by dimethyl sulfate (DMS), using conditions that modified only 
a single nucleotide per molecule fragment. After binding to high concentrations of CTCF, 
EMSA was performed. Free and bound probes were cut and extracted from the gel, cleaved 
at modified nucleotides with piperidine and then analyzed on a sequencing gel as 
previously described (45). 
The 122 bp F1wt and 103 bp F3wt fragments, containing the CTCF binding sites located 
respectively in the first and second exon of hTERT, were synthesized by PCR. Mutant 
fragments F1mut and F3mut were prepared by mutagenesis using synthetic 
oligonucleotides of 122 and 103 bp respectively, with subsequent PCR amplification with 
the same primers as for wild type fragments. Mutations were confirmed by sequencing of 
the PCR fragments. Eleven and five bases were changed in the F1 and F3 fragments, 
respectively.  
 
Chromatin immunoprecipitaion (ChIP) assay  
To cross link proteins to DNA, 12 ml of a 1% formaldehyde solution in culture medium 
was added to the cells cultured to 50% confluency, and the cells were incubated 15 minutes 
at room temperature. Then, 1.3 ml of a 1.25 M glycine solution was added to the medium 
to stop the reaction. After 5 min, the cells were centrifuged and resuspended in 10ml of 
ice-cold PBS containing protease inhibitors. One million cells were pelleted, resuspended 
in 200 µl of SDS lysis buffer (1% SDS, 10nM EDTA, 50mM Tris-HCl, pH 8.1) and 
incubated on ice for 10 minutes. The lysate was sonicated to shear DNA. The chromatin 
solution was diluted in 1800 µl of the ChIP dilution buffer (0.01% SDS; 1.1% Triton X-
100; 1.2 mM EDTA; 16.7 mM Tris-HCl, pH 8.1; 167 mM NaCl; protease inhibitors) for 
further immunoprecipitation or stored at 4°C to be directly uncrosslinked and purified 
(DNA input fraction). Magnetic beads, 80 µl, (Dynabeads M-280 Sheep anti-Rabbit IgG, 
Dynal biotech, Oslo, Norway) were washed three times with 1 ml of blocking solution (1X 
PBS; 5mg/ml BSA; 3% of a 1mg/ml sonicated herring sperm DNA solution; protease 
inhibitors). Half of the beads was suspended in 250 µl of the blocking solution either with 
2 µg of the rabbit polyclonal anti-CTCF antibody (Upstate biotechnology, Lake Placid, 
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NY) or without antibody, and rocked for 4 hours at 4°C. The beads were then washed 3 
times with 1 ml of the blocking solution, and then, added to 1 ml of the diluted chromatin 
solution and incubated overnight at 4°C. They were then washed twice with 500 µl of each 
washing solutions: low salt solution (0.1% SDS; 10% Triton X-100; 2 mM EDTA; 20 mM 
Tris-HCl, pH 8.1; 150 mM NaCl), high salt solution (0.1% SDS; 10% Triton X-100; 2 mM 
EDTA; 20 mM Tris-HCl, pH 8.1; 500 mM NaCl), LiCl solution (0.25 M LiCl; 1% NP40; 
1% deoxycholate; 1 mM EDTA; 10 mM Tris-HCl, pH 8.1) and TE (10 mM Tris-HCl; 1 
mM EDTA, pH8.0). The eluate was then resuspended in 50 µl of the elution buffer (1% 
SDS; 0.1M NaHCO3) and incubated 10 minutes at 65°C. To reverse protein-DNA 
crosslinks, eluates were incubated at 65°C for 4 hours in 120 µl of a solution containing 
1% of SDS and 0.3M NaCl. Then 180 µl of ATL buffer (Qiagen, Basel, Switzerland) and 
20 µl of proteinase K were added to samples, and incubation was performed overnight at 
55°C. Immunoprecipitated DNA was recovered by extraction with the DNeasy tissue kit 
(Qiagen, Basel, Switzerland). Purified DNA was analyzed by PCR with specific primers 
for the amplification of either the first exon of the hTERT gene to generate a 299 bp 
fragment (ChIP-ex-FW 5’-CCCTGCTGCGCAGCCACTAC-3’ and ChIP-ex-RV 5’-
TCGGGCCACCAGCTCCTTCA-3’) or the H19 gene as a control (ChIP-H19 FW 5’-
CTCCTTCGGTCTCACCGCCTGGAT-3’ and ChIP-H19-RV 5’-
CCTTAGACGGAGTCGGAGCTG-3’). PCR products were analyzed on 2% agarose gel. 
 
Western blot analysis  
Approximately 40 µg of total cell extracts prepared from transfected cells in 5X Passive 
lysis buffer (Promega) were boiled 5 minutes in loading buffer (125 mmol/L Tris-HCl, pH 
6.8, 40 g/L SDS, 200 g/L glycerol, 0.05 g/L bromphenol blue) for 5 min and then loaded 
onto a 8 % SDS-PAGE. After electrophoresis, proteins were transferred onto PVDF 
membrane. Immunodetection was performed using a rabbit polyclonal anti-CTCF antibody 
(Upstate biotechnology, Lake Placid, NY). Protein bands were visualized using ECL-Plus 
kit (Amersham Pharmacia Biotech, Switzerland) according to the manufacturer’s 
instructions. Mouse antibody against β-actin (AC-15, Sigma-Aldrich, Switzerland) in 
Western blot was used as a control for protein concentration. 
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RESULTS 
 
The inhibitory effect of the proximal exonic region of the hTERT gene is cell type 
independent 
In earlier studies on HeLa cells we found the proximal exonic region to repress hTERT 
expression (41). We further studied the effect of this regulatory region in telomerase-
positive, -negative and immortalized cells. The intronic region was omitted, to avoid 
transcript variation resulting from alternative splicing (41). As shown in Figure 1, the 
hTERT minimal promoter exhibited a high level of transcriptional activity in 4 telomerase-
positive tumor cell lines, in U2-OS and in GM847 cells (30 to 120%). In contrast, the 
promoter activity was significantly lower in the normal telomerase-negative and in the 
HLF/hTERT cells (12 to 18 %). A markedly decreased activity (7-fold in the HeLa and 
SW480, 3-fold in OVCAR-3 and NCCIT, 16-fold in U2-OS and GM847 cells) was 
observed when the first exon of the hTERT gene was included in the reporter construct 
(Figure 1). In telomerase-negative and HLF/hTERT immortalized cells, transcriptional 
activity was no longer detected. These results demonstrate that the inhibitory effect of the 
hTERT proximal exonic region is not cell type dependent. 
 
The proximal exonic region of the hTERT gene has a repressor effect on different 
promoters 
To determine if the repressor effect of the proximal exonic region is promoter specific, 
constructs containing this region but directed either by the CMV or CDKN2A promoters 
were transiently transfected into the following cell lines: HeLa, GM847, HLF/hTERT and 
BJ cells. In HeLa and GM847 cells, the CMV promoter had a 15- and 53-fold higher 
activity than the reference SV40 promoter, whereas the transcriptional activity of hTERT 
and CDKN2A promoters was significantly lower (Figure 2A). Relative to the SV40 
promoter, the activity of the CDKN2A promoter was higher in GM847 cells than in HeLa 
cells, with levels increased 1.3- and 0.4-fold respectively. In HLF/hTERT and BJ cells, the 
activity of the CMV promoter was 4.1- and 2.6-fold higher than the SV40 promoter (Figure 
2A). These results show that each promoter is more active in HeLa and GM847 than in the 
two other cell lines. We also studied the effect of the proximal exonic region of hTERT 
(first exon and 885 bp of the second exon) on the transcriptional activity of these 
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promoters (Figure 2B). In HeLa and GM847 cells, the exonic region reduced CMV 
promoter activity by 8.1- and 15.4-fold, respectively. In the same cells, CDKN2A promoter 
activity was reduced 5- and 23-fold and hTERT promoter activity was reduced 10- and 9.4-
fold. In HLF/hTERT and BJ, the activity of the CDKN2A and hTERT promoters was barely 
detectable, while the CMV promoter was 33- and a 22-fold decreased (Figure 2B). 
Therefore, the strong repressor effect of the proximal exonic region of the hTERT gene is 
both promoter- and cell type-independent.  
 
 
 
Figure 1. Transcriptional activity of the hTERT promoter in different cell lines. (A) Schematic representation 
of the luciferase reporter plasmids pTERT-297 and pTERT-297/ex1. (B) These two reporters were 
transfected into four telomerase-positive cancer cell lines (HeLa, SW480, OVCAR-3 and NCCIT), one 
telomerase-negative sarcoma line (U2-OS), and two normal telomerase-negative (BJ and HLF), and two 
immortalized (GM847 immortalized in vitro with SV40 and HLF/hTERT that exogenously expressed 
hTERT) fibroblast cell lines. For all experiments, 100% of the luciferase activity is represented by the pGL3-
control vector activity containing the SV40 enhancer/promoter. 
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Figure 2. Transcriptional activity of different promoters in HeLa, GM847, HLF/hTERT and BJ cell lines. 
(A) Activities of luciferase reporter plasmids containing the CMV, CDKN2A and hTERT promoter in these 
cell lines. (B) Activities of luciferase reporter plasmids containing the hTERT exon 1 and 885 bp of the exon 
2, without the first intron, driven by the CMV, CDKN2A and hTERT promoter in these cell lines. For all 
experiments, 100% of the luciferase activity is represented by the pGL3-control vector activity containing the 
SV40 enhancer/promoter. 
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The level of inhibition by the exonic hTERT region is dependent on the distance 
between the promoter and the exonic region 
In order to further analyze the repressive effect of the proximal exonic region of the hTERT 
gene, short plasmid sequences (44, 100 and 200 bp) were inserted between the promoter 
and the exonic region. Relative to the constructions without insert, a 2.8-fold decrease in 
promoter activity was observed after insertion of the 44 bp fragment, a 1.6-fold reduction 
with the introduction of the 100 bp fragment, while no decrease or even a slight increase in 
expression was detected when the 200 bp fragment was inserted (Table 1). The same 
pattern was observed for HeLa and GM847 cells, regardless of which promoter was used. 
In HLF/hTERT and BJ cells, similar observations were made for the CMV promoter. For 
the CDKN2A and hTERT promoters, transcriptional activity was undetectable. We 
conclude that increasing the distance between the promoter and the exonic region, by either 
44 or 100 bp, leads to significantly stronger inhibition of transcriptional activity by the 
hTERT proximal exonic region. A return to a basal level of transcriptional activity was 
observed when the 200 bp sequence was inserted, which could suggest a link with the 
nucleosome positioning. 
 
Table 1.  Relative luciferase activity after insertion of a plasmid sequence between a promoter and the 
hTERT proximal exonic region 
 Cell lines 
Transfected plasmid HeLa GM847 HLF/hTERT BJ 
 A B A B A B A B 
pTERT tertluc 8 100 12.6 100 NS - NS - 
pTERT 44 tertluc 2.5 31 9.5 75 NS - NS - 
pTERT 100 tertluc 4.7 59 6.6 52 NS - NS - 
pTERT 200 luc 10.9 136 7.6 60 NS - NS - 
         
pCDKN2A tertluc 6.7 100 5.6 100 NS - NS - 
pCDKN2A 44 tertluc 2.13 30 2.2 39 NS - NS - 
pCDKN2A 100 tertluc 4.2 60 3.1 55 NS - NS - 
pCDKN2A 200 tertluc 6.9 100 2.3 40 NS - NS - 
         
pCMV tertluc 193 100 350 100 12.5 100 7.1 100 
pCMV 44 tertluc 75 40 136 35 3.1 25 3.55 50 
pCMV 100 tertluc 150 80 277 71 5.4 43 6.67 94 
pCMV 200 tertluc 250 134 600 150 13 104 7.17 101 
A, % of luciferase activity relative to the SV40 early promoter (100%). Representative experiment of at least 
three independent transfections. 
B, % of luciferase activity relative to the plasmid without insertion (100%). 
NS, non-significant value, at the background level 
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CTCF interacts in vitro and in vivo with the hTERT proximal exonic region 
CTCF, a ubiquitously expressed 11-zinc finger nuclear phosphoprotein, binds to GC-rich 
sequences and inhibits transcription when located downstream of a transcriptional start site 
(46). Since the exonic region of the hTERT gene is GC-rich and its repressor effect is not 
cell type specific, we considered CTCF a plausible candidate for involvement in the 
inhibition of hTERT expression. (47). In vitro binding of fragments of the proximal exonic 
region to full-length CTCF protein was tested by EMSA (Figure 3B). The –100 to +133 bp 
(fragment F1, located in the exon 1) and +348 to +597 bp (fragment F3, located in the exon 
2) sequences of the hTERT gene showed retarded migration (Figures 3A and 3B). Mobility 
shifts were not observed with two other regions tested. These results demonstrate that 
CTCF binds in vitro to the first two exons of the hTERT gene. CTCF binding specificity 
was further confirmed by competition assay with F2 chicken globin insulator (48). Both F1 
and F3 fragments were successfully competed by a strong CTCF binding site and 100-fold 
excess of competitor completely abrogate CTCF binding to hTERT (Figure 3C). 
To determine if CTCF binds in vivo to this region, we performed ChIP assays. Two 
telomerase-positive cell lines (HeLa and SW480), one immortalized cell line 
(HLF/hTERT) and one telomerase-negative cell line (BJ) were tested. The experiments 
were carried out with and without CTCF-specific antibody for the immunoprecipitation. 
Then, PCR were performed at different number of cycles to amplify CTCF-hTERT exon 1 
site and H19 ICR4 site, which was used as a positive control (44). PCR reactions were 
performed at conditions in which the samples from controls without antibody always 
showed negligible levels of background amplification. Amplification of H19 ICR4 
fragment can be seen in all DNA fractions obtained with CTCF antibodies but not in 
negative controls suggesting the ChIP assay was very specific. In contrast to the H19 
ICR4, the hTERT first exon fragment was found only in immunoprecipitated-DNA from 
BJ and HLF/hTERT cells (Figure 3D). These results indicate that CTCF binds in vivo to 
the first exon of hTERT in BJ normal cells, as well as in HLF/hTERT that do not express 
endogenous hTERT, but not in telomerase-positive ones. 
A DMS-methylation interference assay was used to determine potential contact guanine 
nucleotides recognized by CTCF in the first two exons of the hTERT gene (Figures 4A and 
4B). CTCF-contacting guanines were located within the DNA sequence from positions +4 
to +39 and +422 to +440 downstream from the ATG translational start site. These CTCF 
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recognition sequences are GC-rich (83% for exon 1 and 100% for exon 2) and both contain 
CpG sites. To confirm that contact guanines were correctly identified, we performed site-
directed mutagenesis within the F1 and F3 regions. Contact guanines, marked by black 
dots on Figures 4A and 4B, were substituted by adenines. EMSA comparison of wild-type 
(F1wt and F3wt) and mutant (F1mut and F3mut) fragments showed at least 90% reduction 
of the CTCF binding upon mutation of part of the CTCF-contact guanines in F1 and F3 
(Figures 4C and 4D, respectively). The F2 fragment also contained the binding sequence 
+422 to +440, but did not exhibit retarded migration by EMSA (Figure 3B). This might be 
due to location of the CTCF binding site at the extremity of the F2 fragment. 
 
 
  
 
Figure 3. In vitro and in vivo interactions of CTCF with hTERT gene. (A) Schematic localization in the 
exons 1 and 2 of the hTERT gene of the PCR fragments used in EMSA (the ATG is considered as +1). (B) 
Electrophoretic mobility shift assay (EMSA) was carried out with either control lysate (empty), lysate 
containing the eleven zing fingers of CTCF DNA-binding domain (11ZF), or lysate containing the in vitro 
translated full-length CTCF (FLCTCF). The positions of the bound CTCF-DNA complexes, containing 
either the 11ZF domain or the FLCTCF, are indicated on the left by B-11ZF and B-FLCTCF, respectively. 
Free DNA probe (F) is also indicated. (C) Competition assay of CTCF 11ZF using radioactive probes of F1 
and F3 hTERT fragments and excess of cold F2 chicken globin insulator. L is in vitro-translated luciferase 
and was used as a negative control. Lanes covered with black triangle on top are 0-, 10-, and 100-fold molar 
excess of competitor respectively. Bound and free bands are indicated as in part B. (D) ChIP assay using 
anti-CTCF antibody on two telomerase-positive cell lines (HeLa and SW480), one immortalized cell line 
(HLF/hTERT) and one telomerase-negative cell line (BJ). PCR amplification of the test fragments (hTERT 
exon1 and H19) using as template DNA input fraction and DNA recovered from immunoprecipitated 
fractions bound (+) versus unbound (-) by the anti-CTCF antibody. 
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Figure 4. Identification of contact guanines specifically recognized by CTCF in the proximal exonic region 
of the hTERT gene. (A) DMS-methylation interference analysis was carried out with the hTERT F1 fragment. 
Top (U) and bottom (L) strands are shown respectively. Bound (B) and free (F) probes are indicated on top 
of each lane. Contact guanines are indicated in bold. Guanines substituted for adenines in site–directed 
mutagenesis are indicated by black dots (B) DMS-methylation interference analysis was carried out with the 
hTERT F3 fragment. All labels are as in part A. Guanines substituted for adenines in site–directed 
mutagenesis are indicated by black dots. Eleven and five bases were changed in the F1 and F3 fragments, 
respectively. (C) EMSA of the wt (F1wt) and mutant (F1mut) fragments F1, located in the first exon of the 
hTERT gene. (D) EMSA of the wt (F3wt) and mutant (F3mut) fragments F3, located in the second exon of 
the hTERT gene. Luciferase control (Luc) and DNA-binding domain of CTCF (11ZF) were used in the assay. 
Free (F) and bound (B) probes are indicated. 
 
 
Binding of CTCF represses hTERT transcription. 
To determine if CTCF binding to the hTERT exon 1 is responsible for the hTERT 
transcriptional inhibition, we examined the effect of CTCF depletion with small interfering 
RNA (siRNA) against CTCF. siRNA activity was examined by co-transfection of HeLa 
cells with luciferase expressing constructs pTERT-297 or pTERT–297/ex1. Western blot 
analysis of cell lysates showed a dramatic reduction of CTCF expression upon 
cotransfection of the siRNA, but not cells transfected with a control siRNA (Figure 5B). 
Consistent with our proposed role for CTCF as a negative regulator of hTERT expression, 
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cotransfection of the pTERT–297/ex1 construct (promoter and first exon of hTERT) with 
CTCF siRNA resulted in a 3-fold increase in exogenous hTERT promoter activity, when 
compared with cells cotransfected with a control siRNA (Figure 5A). 
To provide additional evidence for the role of CTCF as a repressor of hTERT gene 
expression, we transfected CTCF siRNA in BJ, a telomerase-negative human non-
immortalized fibroblast. Fortyeight hours after transfection a strong decrease of CTCF 
level was observed by western blotting (Figure 6D). The hTERT messenger was detected in 
the extract of BJ cells treated with siRNA for CTCF (Figure 6), and this with three 
different sets of primers, which amplify full-length (FL) hTERT mRNA and the α deletion, 
or the four different forms in the same time (FL, α-, β- and α/β-deletions). Each 
amplification was sequenced, confirming the presence of FL and β deletion forms of the 
hTERT mRNA. Nevertheless, no positive TRAP assay was obtained in these conditions 
(data not shown). 
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Figure 5. Depletion of CTCF by 
siRNA results in the relief of 
inhibition of hTERT promoter by the 
hTERT exonic region. (A) Luciferase 
reporter plasmids containing the 
hTERT minimal promoter, with or 
without the proximal exonic region, 
are co-transfected into HeLa cells with 
either unrelated siRNA (control 
siRNA), or CTCF siRNA or luciferase 
siRNA. In each experiment, the 
activity is calculated considering the 
activity of hTERT promoter as 100%. 
pTERT-297: minimal hTERT 
promoter; pTERT-297/ex1: minimal 
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gene. (B) Western blot showing the 
decrease of CTCF protein in cells 
treated with the specific siRNA for 
CTCF. β-actin was used as internal 
control to normalize the total protein 
amount. 
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Figure 6. Depletion of CTCF by siRNA results in transcriptional activation of hTERT in telomerase-negative 
cells. (A). RT-PCR of hTERT from extracted RNA of HeLa (telomerase-postive) and BJ (telomerase-
negative) cells treated with either control siRNA (-) or CTCF siRNA (+). RT-PCR was performed using 
primer pair LT5 and LT6 to amplify a 145 bp segment common to all hTERT transcripts. (B). Expression of 
spliced variants of hTERT mRNA. The positions of the full-length (457 bp), α-spliced (421 bp), β-spliced 
(275 bp), and α+β-spliced (239 bp) variants are indicated on the right. (C). Amplification of FL and α-spliced 
variant only. (D) Western blot showing the decrease of CTCF protein in cells treated with the specific siRNA 
for CTCF. β-actin was used as internal control to normalize the total protein amount. 
 
 
FLα
β
α+β
M
CTCF siRNA +––
BJHeLa 
300 bp
400 bp
500 bp
B
100 bp
200 bp
M
CTCF siRNA +––
BJHeLa 
FL
α
C
100 bp
200 bp
300 bp
hTERT
β-actin
M
CTCF siRNA +––
BJHeLa A
β-actin
CTCF
D
CTCF siRNA - +
Control siRNA + -
CHAPTER III 
 126
DISCUSSION 
 
In a previous study, we detected a repressor effect of the proximal exonic region (first two 
exons) of the hTERT gene on its transcription (41). To better understand the mechanism 
involved and to identify a potential repressor, we further characterized the effects of this 
region of the hTERT gene. 
Reporter gene constructs, composed of the hTERT minimal core promoter with or without 
the exonic region, were transiently transfected in normal telomerase-negative cells (BJ and 
HLF), telomerase-negative sarcoma cells (U2-OS), telomerase-positive cancer cells (HeLa, 
SW480; NCCIT and OVCAR-3) and immortalized cell lines (telomerase-negative GM847 
and telomerase-positive HLF/hTERT). The transcriptional activity of the hTERT core 
promoter was significantly higher in telomerase-postive cancer cells than in normal cells, 
very high in telomerase-negative GM847, but weak in telomerase-positive HLF/hTERT. 
Transcriptional activity of the hTERT minimal promoter was significantly up-regulated in 
GM847 cells, obtained through transfection with the SV40 large T-antigen, and 
immortalized through the Alternative Lengthening Telomere (49), in contrast to 
HLF/hTERT cell line, which was obtained by infection of primary fibroblast HLF cells 
with a MSCV-hTERT retrovirus. HLF/hTERT cells express high levels of exogenous 
hTERT, but the extension of life span does not change the phenotypic properties of the 
cells because telomerase, unlike oncogenes, does not cause growth deregulation (50). This 
could explain why, in transient transfection experiments, we did not observe transcriptional 
activation of the hTERT minimal core promoter in HLF/hTERT cells, as occurred in tumor 
and transformed cells. Thus, the presence of hTERT protein or telomerase complex does 
not itself activate hTERT gene transcription.  
The addition of the proximal exonic region of hTERT downstream of the hTERT minimal 
promoter strongly reduced promoter transcriptional activity in all cell lines tested. 
Furthermore, this exonic region significantly inhibited the transcriptional activity of the 
CMV and CDKN2A promoters, regardless of the cell type. Therefore, the repressor effect 
of the hTERT exonic region is not cell or promoter dependent. The decrease in the 
transcriptional promoter activity in presence of the hTERT exonic region was higher in 
HLF/hTERT or BJ cells than in HeLa or GM847 cells.  
Sequence insertion was used to show how structural and regulatory phenomena could 
involve nucleosome positioning (51;52). Insertion of DNA sequences of 44 or 100 bp 
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between a promoter and the hTERT exonic region resulted in reduced transcriptional 
expression, whereas a relatively constant level of transcription was observed with spacer 
DNAs of 200 bp. Thus, proper arrangement of nucleosome positioning within the hTERT 
exonic region might inoculate the activity, and perhaps accessibility, of the presumed 
repressor(s). Another explanation for this observation could be that the repressor(s) form a 
bulky complex, which physically interferes with the RNA polymerase II complex from the 
hTERT promoter. As a function of the spatial configuration of these two large complexes, 
this disturbance might be more or less pronounced. 
CCCTC binding factor (CTCF) was considered to be a good candidate for hTERT 
transcriptional inhibition: CTCF is expressed in almost all cell types, binds GC-rich 
sequences, represses transcriptional activity when it is localized downstream of a 
transcriptional start site and its activity depends on the chromatin structure (44-46;53). We 
hypothesized that CTCF might be the repressor involved. EMSA showed that CTCF binds 
to two distinct sequences in exons 1 and 2 of hTERT. The methylation interference 
experiment permitted the identification of CTCF-binding sequences within the hTERT first 
exon at +4 to +39 positions and within the hTERT second exon at +422 to +440 positions 
(relative to the ATG translational start codon). Mutations within these core sequences 
eliminated binding of CTCF, confirming the identity of the two CTCF-binding sites. 
Moreover, as one can see in Figures 4A and B, single contact guanine modification had a 
relatively low impact on CTCF binding, suggesting some evolutionary pressure to keep the 
CTCF binding sites present regardless of stochastic point mutations. In the case of the site 
F1, within the first exon of hTERT, we had to substitute 11 contact guanines in order to 
eliminate CTCF binding to the site, which is so far unprecedented. Interestingly, and 
consistent with the description of some other CTCF-binding sites (54), most of the CTCF-
contact nucleotides were located on a single DNA strand.  
Many contact guanines are part of CpG sites suggesting that CTCF binding might be 
regulated by DNA methylation. ChIP assays confirmed that CTCF binds to the first exon 
of hTERT in BJ and HLF/hTERT cells in which the endogenous hTERT gene is not 
expressed, but not in HeLa and SW480 cells which express hTERT. Moreover, in HeLa 
cells, the reduction of CTCF expression by RNA interference stimulated the transcriptional 
activity of the reporter that contained the first exon of hTERT. In BJ cells, siRNA against 
CTCF induced the transcription of hTERT mRNA. These results show that CTCF is 
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involved in the hTERT transcriptional repression. Human hTERT is the first gene 
implicated in immortality that might be controlled by CTCF. 
In addition to CTCF, several negative regulators of hTERT transcription have been 
identified, including p53, WT-1, Mad1, myeloid-specific zinc finger protein 2 (MZF-2), 
and others (55). Overexpression of wild-type p53 in MCF-7 cells can downregulate hTERT 
mRNA expression, but inhibition of p53 activity does not reactivate hTERT expression 
(56). WT-1 can inhibit hTERT transcription (30) and Mad1 can regulate the ability of c-
Myc to activate hTERT (57). Although all these factors can negatively regulate hTERT, 
none of them appear to be responsible for the down-regulation of hTERT in the majority of 
telomerase-negative cells. To our knowledge, CTCF is the only known factor that can 
negatively regulate hTERT transcription independently of the cell type. Indeed, CTCF is 
one such factor that is highly conserved, ubiquitously expressed, and possesses versatile 
regulatory functions (57). CTCF is a DNA-binding protein that uses various combinations 
of its 11 zinc fingers to recognize a variety of unrelated DNA sequences (45). It plays a 
major role in transcriptional activation of the APPB promoter (58), silencing of c-myc (45), 
insulation of -globin gene (48;59) and imprinting control of the H19 region (44). 
Concerning the hTERT gene, CTCF binds to a region located within the first two exons and 
just downstream the promoter. Silencing of hTERT could be the consequence of either 
inhibition of the transcription-initiation complex or blockage of transcription elongation.  
Our results suggest a model in which CTCF participates in key cellular mechanisms 
underlying immortality by selectively regulating hTERT gene expression. We postulate 
that, in telomerase-negative normal cells, CTCF binds to the hTERT proximal exonic 
region and thus blocks transcription. The fact that the hTERT first exon sequences are 
hypermethylated in telomerase-positive cells (60) could explain the failure of CTCF to 
bind to these sequences. 
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ABSTRACT 
 
The expression of the catalytic subunit (hTERT) represents the limiting factor for 
telomerase activity, which is inactivated in somatic cells but reactivated in about 85% of 
tumor cells. Several studies have provided important information about hTERT gene 
regulation by transcription factors, CpG methylation and histone acetylation. To date, a 
comprehensive understanding of the mechanism involved in repression of hTERT in 
telomerase-negative cells and its reactivation in the telomerase-positive cells is lacking. 
We have previously shown that CTCF represses hTERT transcription in telomerase-
negative cells by binding to its first exon. In this study, we used ChIP to prove that, in vivo, 
CTCF does not bind the hypermethylated CpG’s in the first exon of hTERT in telomerase-
positive cells. In telomerase-positive cell lines, treatment with 5-azadC led to a strong 
demethylation of hTERT, reactivation of CTCF binding to the first exon and down-
regulation of hTERT. Although full methylation of the hTERT promoter region in reporter 
vectors induced a total inactivation of the transcription, detailed mapping of CpG 
methylation showed that not all the CpG sites were methylated in telomerase-positive cells. 
By transient transfection, we show that selective demethylation within this region 
significantly increases hTERT promoter activity in a reporter plasmid. Nevertheless, this 
particular methylation profile is not sufficient to activate the hTERT transcription in ALT-
tumor cells, in which the hTERT promoter showed low activity in a luciferase reporter 
assay. This study underlines for the first time the important role of the hTERT promoter 
and exon 1 methylation for the hTERT transcription. 
 
Keywords: Telomerase, hTERT, DNA methylation, CTCF, repressor, ChIP assay 
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1. Introduction 
 
Telomeres are nucleoprotein complexes that “cap” the termini of linear 
chromosomes and stabilize them. In man telomeres are made up an average of 5 to 15 kilo-
base-pairs (kb) of the repetitive sequence TTAGGG (Moyzis et al., 1988). They are 
involved in chromosome replication, maintenance of nuclear architecture, chromosome 
stability, gene expression, aging and cell division (Blackburn, 1997;Greider, 1996). In 
normal cells, each division is associated with the loss of 50-100 base pairs at the end of the 
chromosome, which leads to the telomere shortening that acts as a mitotic counter limiting 
replicative life span. Telomerase, a RNP complex consisting of a reverse transcriptase 
bound to its own RNA template, allows the maintenance of the telomere length (Nakamura 
et al., 1997). In adult humans, telomerase activity is not detectable in most somatic cells 
(Yasumoto et al., 1996). In contrast highly proliferative cells, such as germ cells and stem 
cells, as well as 85% of cancers express telomerase (Kim et al., 1994). In vitro, two 
components are absolutely essential for the telomerase activity: the catalytic subunit, 
hTERT, containing the reverse transcriptase activity, and the RNA component, hTERC, 
containing a complementary template for the telomeric DNA sequence (TTAGGG) (Feng 
et al., 1995;Weinrich et al., 1997). It has been shown that ectopic expression of hTERT is 
sufficient to restore telomerase activity in telomerase-negative cells (Bodnar et al., 
1998;Counter et al., 1992;Weinrich et al., 1997). However, many others proteins are 
present in the telomere (Smogorzewska and De Lange 2004).  
Since the characterization of the genomic sequence of hTERT and the organization 
of the gene (Cong et al., 1999;Horikawa et al., 1999;Takakura et al., 1999;Wick et al., 
1999), many studies indicate that expression of hTERT represents the limiting factor for 
telomerase activity, and that the regulation of hTERT expression occurs primarily at the 
transcriptional level. Transient transfection experiments have allowed the characterization 
of a minimal promoter, encompassing the 283 bp region upstream of the initiation ATG 
codon (Horikawa et al., 1999;Takakura et al., 1999;Wick et al., 1999). The 5’-hTERT 
regulatory region contains numerous binding sites for transcription factors. Silencing and 
activation of gene expression can be done by the action of transcriptional repressors and 
activators. Repressors for hTERT include the tumor suppressor protein p53, Mad1, 
myeloid-specific zinc finger protein 2 (MZF-2), TGF-β and Wilms' Tumor 1 (WT1). 
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Activators of hTERT transcription have also been identified, including c-Myc, Sp1, hALP, 
Hif-1, Mbi-1, USF1/2 and estrogen response element (Yatabe et al., 2004;Valk-Lingbeek 
et al., 2004;Poole et al., 2001;Pardal et al., 2003;Nishi et al., 2004;Lv et al., 2003;Goueli 
and Janknecht, 2003;Goueli and Janknecht, 2004). Exactly how the transcription of the 
hTERT gene in normal and tumor cells, is regulated is not well understood. 
As the hTERT promoter is situated in a CpG island has led to postulate a 
transcriptional regulation by DNA methylation might be occurred. Previous studies found a 
hypermethylation of the hTERT promoter in telomerase-positive tumors and a 
hypomethylation in telomerase-negative normal tissues (Guilleret et al., 2002;Devereux et 
al., 1999;Dessain et al., 2000). These observations are in stark contrast with the general 
model of gene silencing by promoter methylation. In this model, methylation of DNA 
helps to stabilize chromatin in an inactive configuration and inhibits gene expression 
(Robertson and Jones, 2000). Although methylation of its promoter is one mechanism of 
the hTERT regulation in tumor tissues and tumor cell lines (Guilleret et al., 2002;Nomoto 
et al., 2002;Widschwendter et al., 2004), other methylation-independent mechanisms exist 
in all likelihood (Dessain et al., 2000;Devereux et al., 1999;Widschwendter et al., 
2004;Bechter et al., 2002;Lopatina et al., 2003). 
We have previously shown that the proximal exonic region of the hTERT gene 
inhibits the transcriptional activity of the minimal hTERT promoter (Renaud et al., 2003). 
Moreover, this region has a repressor effect on CMV and CDKN2A promoters, in tumor, 
normal and immortalized cell types. The CTCF 11-zinc finger factor was found to bind this 
region in vitro. In vivo, CTCF binds to the proximal exonic region in normal telomerase-
negative cells, but apparently not to the telomerase-positive one. Moreover, RNAi 
inhibition of CTCF expression in normal cells allows the transcription of hTERT (Renaud 
et al., NAR, 2005, submitted). CTCF is expressed in most cells, binds GC-rich sequences, 
represses transcriptional activity when it is localized downstream of the transcriptional 
start site and its activity is dependent on chromatin structure (Kanduri et al., 2000;Klenova 
et al., 1993;Lutz et al., 2000). These findings argue in favor of an implication of CTCF in 
the hTERT transcriptional repression in normal cells. 
In the present report, the interplay between CTCF and hTERT methylation in the 
transcriptional regulation of the hTERT gene in normal and tumor cells is described. We 
hypothesis that hTERT methylation prevents binding of CTCF alleviating its inhibitory 
CTCF and DNA methylation regulate the hTERT transcription 
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effect. As a consequences, we detailed the methylation status of the promoter and the first 
exon of hTERT, in tumor telomerase-positive as well as in tumor and normal telomerase-
negative cell lines. ChIP was used to correlate the methylation pattern of the hTERT exon 1 
to the CTCF binding. We also studied the methylation effect on the hTERT promoter on its 
transcription. All these findings highlight the role of CTCF in the repression of hTERT 
gene transcription in normal cells and the role of hTERT gene methylation in the 
upregulation of hTERT in tumor cells. 
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2. Materials and methods 
 
 
2.1. Cell culture  
 
The human tumor cell lines HeLa (cervical adenocarcinoma), SW480 (colorectal 
adenocarcinoma), U2-os (osteosarcoma) and the normal BJ fibroblasts were obtained from 
the ATCC. All these cells were grown in the medium recommended by the ATCC. The 
HLF/hTERT cells were kindly provided by Dr. Joachim Lingner (ISREC, Epalinges, 
Switzerland), and were cultured in DMEM supplemented with 10% heat inactivated fetal 
bovine serum (Invitrogen, Basel, Switzerland).  HeLa and SW480 cell lines are telomerase 
positive, whereas U2-os and BJ are telomerase negative. HLF/hTERT cells were obtained 
through stable transfection of HLF cells with an MSCV-hTERT retrovirus, constitutively 
express hTERT, and have high telomerase activity. 
 
 
2.2. Plasmid construction 
 
pTERT–297 contains the hTERT minimal promoter (-297 to -23bp) and pTERT-
1821 contains the 5’ promoter region (-1821 to -23 bp) (Renaud et al., 2003). All these 
constructs were used for the transient transfection experiments. 
For stable transfection, the pcDNA5/FRT/CMV- construct was generated by 
deletion of the CMV promoter fragment, after digestion with NruI and NheI, of the 
pcDNA5/FRT vector (Invitrogen). Then, the hTERT fragments and firefly luciferase gene 
were extracted by digestion with Asp718I and BamHI from the pTERT-297/ex2 vector, 
containing the hTERT minimal promoter and the 1071 bp downstream of the ATG (Renaud 
et al., 2003). This fragment was cloned into the pcDNA5/FTR/CMV-, to create the 
pTERT-297/ex2/FRT that is used in stable transfection experiments with or without in 
vitro methylation of all the CpG sites with the SssI methylase (Promega, Madison, USA 
WI). 
pCpG-LacZ, a CpG-free vector (InvivoGen, San Diego, USA CA), was used to 
study the effect of hTERT methylation on transcriptional activity. hTERT minimal 
promoter and exon 1 were generated by PCR, using primers containing either the SdaI or 
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the XbaI sites. These fragments were cloned into pCpG-LacZ to produce pCpG-Tm 
(hTERT promoter) and pCpG-Tmex1 (hTERT promoter and the first 80 bp of the exon). To 
eliminate the methylation effect of the hTERT promoter, the hTERT exon1 was cloned into 
pCpG-lacZ at the HindIII / XbaI site, putting the hTERT exon 1 under control of the hEF1 
CpG-free promoter. The new vectors were named pCpG-ex1. Activities of this vector was 
compared to the activity of the pCpG-lacZdel vector after deletion of the HindIII / XbaI 
fragment, to have the same promoter sequence. 
 
 
2.3. Methylation cassette assay 
 
A methylation cassette assay was used to determine the hypomethylation effect of a 
specific regulatory region on hTERT activity. Two restriction sites were introduced by site-
directed mutagenesis using the QuickChange XL Site-Directed Mutagenesis Kit 
(Stratagene, USA CA) in pCpG constructs. The mut1 primers set (FW-mut1 5’-
ACCTTCCAGCTCCGGATCCTCCGCGCGGAC-3’ and REV-mut1 5’-
GTCCGCGCGGAGGATCCGGAGCTGGAAGGT-3’) created the upstream site BamHI 
(in bold) and the mut2 primers set (FW-mut2 5’-
CCGCCCTCTCCTCGACGGCGCGAGTTTCAGG-3’ and REV-mut2 5’-
CCTGAAACTCGCGCCGTCGAGGAGAGGGCGG-3’) created the downstream site TaqI 
(in bold). The generated plasmids, pCpG-Tm ∆ (containing the hTERT minimal promoter) 
and pCpG-Tmex1 ∆ (containing the hTERT minimal promoter and the first 80 bp of exon 
1), were in vitro methylated with the SssI methylase following the manufacturers 
instructions (Promega). The methylated and unmethylated cassette BamHI-TaqI 110 bp 
fragment (-183 to –74 bp of the hTERT sequence) were extracted through enzymatic 
digestion and ligated back into the methylated or unmethylated vector, using the Ligafast 
Rapid Ligation System (Promega). The efficiency of the ligation reaction was assessed by 
analysis of an aliquot of the ligation reaction mixture on a 1% agarose gel. The remainder 
of the ligation reaction mixtures were then transfected into HeLa and U2-os cells. β-
galactosidase activities were measured as described. 
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2.4. Transfection, luciferase and β-galactosidase assays 
 
Stable transfection experiments were performed with the Flp-In system (Invitrogen) 
that allows the integration, always at the same site, of the gene of interest in the genome of 
a mammalian cell. A HeLa Flp-In host cell line was created with this system. Positive 
clones had integrated the Zeocin-β-galactosidase fusion gene and were selected with 500 
µg/ml of Zeocin antibiotic. We selected a clone that contained a single insertion of the 
FRT site and showed an average β-galactosidase activity. The vector containing the gene 
of interest was integrated into the genome via Flp recombinase-mediated DNA 
recombination at the FRT site. Integration allows transcription of the gene of interest and 
confers hygromycin resistance and Zeocin sensitivity. 
After conditions optimization, transient transfection assays were performed with 
cells seeded at a concentration of either 200’000 / 3.8 cm2 for HeLa and SW480, or 50’000 
cells / 3.8 cm2 for BJ. Cells are then cultured overnight. Transient transfections of reporter 
plasmids (0.75 µg / well) were carried out in triplicate using JetPEI Cationic Polymer 
Transfection reagent (4 µl / well) (Polyplus-transfection, Illkirch, France). All experiments 
were performed at least twice and in triplicate. The pRL-tk vector (0.25 µg / well) 
(Promega) was co-transfected as an internal control for transfection efficiency. Luciferase 
assays were performed using the Dual-Luciferase Reporter Assay System (Promega). 
Luciferase activity of the different constructs was compared to that of the pGL3-control 
vector containing the firefly luciferase gene under the control of the SV40 early promoter 
and to that of the pGL3-basic vector, a promoterless and enhancerless luciferase vector. 
Analysis of LacZ reporter plasmids was performed with a β-galactosidase assay. 
Briefly, protein was extracted from cells using 500 µl of the 5X passive lysis buffer 
(Promega). In a 96 wells-plate, 50 µl of cell lysate was analysed with 100 µl of the β-
galactosidase substrate buffer (NaH2PO4 0,2M pH 8, β -mercaptoethanol 0.1M, MgCl2 
2mM, ONPG 1.33 mg/ml). The kinetics of the β-galactosidase activity was followed with a 
colorimeter at 414 nm during 15 minutes. The kinetics defined a linear curve and the mean 
was calculated with values take at a fixed time point. β-galactosidase activity of the 
different constructs was compared to the level of the pCpG-LacZ vector containing the 
synthetic LacZ∆CpG gene under the control of a mammalian promoter (combination of the 
CMV enhancer, the human elongation factor 1 alpha core promoter and 5’UTR containing 
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a synthetic intron) and to the level of the pCpG-basic vector, corresponding to that of the 
pCpG-LacZ vector deleted of the promoting region. 
Statistical comparisons were made using the Student t-test. 
 
2.5. 5-azadC treatment 
 
Treatment with the demethylating agent, 5’-aza-2’-deoxycytidine (5-azadC), was 
performed on HeLa, SW480, and U2-os cell lines. Cells were treated 24h after seeding, 
with 3 µM of 5-azadC (Flucka, Buchs, Switzerland) every 48h and for 4 passages. Cells 
were then collected and treated for ChIP or used for DNA and RNA extractions (as 
described below). 
 
 
2.6. RNA extraction and RT-PCR 
 
RNA was extracted from cells before and after 5-azadC treatment, using the TRIzol 
LS Reagent (Invitrogen). Platinum quantitative RT-PCR Thermoscript one-step system 
(Invitrogen) was used to amplify the hTERT mRNA using the primers LT5 5’-
CGGAAGAGTGTCTGGAGCAA-3’ (exon3) and LT6 5’-
GGATGAAGCGGAGTCTGGA-3’ (exon4), with coamplification of β-actin with the 
primers actin-FW 5’-AGGCCAACCGCGAGAAGATGA-3’ and actin-REV 5’-
GCCGTGGTGGTGAAGCTGTAG-3’. 
 
 
2.7. Chromatin immunoprecipitation (ChIP) 
 
To crosslink proteins to DNA, 12 ml of a 1% formaldehyde solution in culture 
medium was added to the cells cultured to 50% of confluency, and the cells were incubated 
15 minutes at room temperature. Then, 1.3 ml of a 1.25 M glycine solution was added to 
the medium to stop the reaction. After 5 min, the cells were centrifuged and resuspended in 
10ml of ice-cold PBS containing protease inhibitors. One million cells were pelleted, 
resuspended in 200 µl of SDS lysis buffer (1% SDS, 10nM EDTA, 50mM Tris-HCl, pH 
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8.1) and incubated on ice for 10 minutes. The lysate was sonicated to shear DNA. The 
chromatin solution was diluted in 1800 µl of the ChIP dilution buffer (0.01% SDS; 1.1% 
Triton X-100; 1.2 mM EDTA; 16.7 mM Tris-HCl, pH 8.1; 167 mM NaCl; protease 
inhibitors) for further immunoprecipitation or stored at 4°C to be directly uncrosslinked 
and purified (DNA input fraction). Magnetic beads, 80 µl, (Dynabeads M-280 Sheep anti-
Rabbit IgG, Dynal biotech, Oslo, Norway) were washed three times with 1 ml of blocking 
solution (1X PBS; 5mg/ml BSA; 3% of a 1mg/ml sonicated herring sperm DNA solution; 
protease inhibitors). Half of the beads was suspended in 250 µl of the blocking solution 
either with 2 µg of the rabbit polyclonal anti-CTCF antibody (Upstate biotechnology, Lake 
Placid, NY) or without antibody, and rocked for 4 hours at 4°C. The beads were then 
washed 3 times with 1 ml of the blocking solution, and then, added to 1 ml of the diluted 
chromatin solution and incubated overnight at 4°C. They were then washed twice with 500 
µl of each washing solutions: low salt solution (0.1% SDS; 10% Triton X-100; 2 mM 
EDTA; 20 mM Tris-HCl, pH 8.1; 150 mM NaCl), high salt solution (0.1% SDS; 10% 
Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.1; 500 mM NaCl), LiCl solution (0.25 
M LiCl; 1% NP40; 1% deoxycholate; 1 mM EDTA; 10 mM Tris-HCl, pH 8.1) and TE (10 
mM Tris-HCl; 1 mM EDTA, pH8.0). The eluate was then resuspended in 50 µl of the 
elution buffer (1% SDS; 0.1M NaHCO3) and incubated 10 minutes at 65°C. To reverse 
protein-DNA crosslinks, eluates were incubated at 65°C for 4 hours in 120 µl of a solution 
containing 1% of SDS and 0.3M NaCl. Then 180 µl of ATL buffer (Qiagen, Basel, 
Switzerland) and 20 µl of proteinase K were added to samples, and incubation was 
performed overnight at 55°C. Immunoprecipitated DNA was recovered by extraction with 
the DNeasy tissue kit (Qiagen, Basel, Switzerland). Purified DNA was analyzed by PCR 
with specific primers for the co-amplification of the first exon of the hTERT gene to 
generate a 171 bp fragment (TERT-FW 5’-CTGCTGCGCACGTGGGAAGCC-3’ and 
TERT-REV 5’-GTCCCCGCGCTGCACCAGCC-3’) or the H19 gene as a 149 bp control 
(H19-FW 5’-CACCGCCTGGATGGCACGGAATTG-3’ and H19-REV 5’-
TGCGACGCGTGGCTTGGGTGAC-3’). Amplification was performed with the following 
PCR conditions: 94°C for 30 sec, 62°C for 45 sec and 72°C for 60 sec. The cycle number 
and the amount of templates were varied to ensure that results were within the linear range 
of the PCR. PCR products were analyzed on 2% agarose gel. 
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2.8. DNA methylation analysis 
 
DNA was extracted from culture cells using the DNeasy tissue kit (Qiagen). Two 
µg of DNA were modified in 40 µl of water with sodium bisulfite as previously described 
(Benhattar and Clement, 2004). After bisulfite modification, amplification of the promoter 
and first exon regions was performed with the primers 5’-CTACCCCTTCACCTTCCAA-
3’ and 5’-GTTAGTTTTGGGGTTTTAGG-3’. Amplification was performed using the 
master mix (Promega), with the following PCR conditions: 40 cycles of 94°C for 30 sec, 
57°C for 45 sec and 72°C for 50 sec. Triplicate PCR products were cloned into the pGEM-
T vector using the pGEM-T vector system II (Promega). After transformation of JM109 
E.Coli competent cells (Promega), plasmid DNA was extracted from bacterial clones with 
the QIAprep Spin Miniprep Kit (Qiagen). Each clone was analyzed by sequencing with the 
M13 forward primer (5’-GTAAAACGACGGCCAG-3’), using a Big Dye Terminator 
Cycle Sequencing Kit, and an ABI Prism 3100 sequencer (Applied Biosystems, Foster 
City, CA). 
To verify the methylation status of the hTERT stable transfectant, DNA from cells 
were extracted with the DNeasy extraction kit (Qiagen) and analyzed by MS-SSCA 
(Benhattar and Clement, 2004). The forward Primer used was specific to the plasmid 
sequence (5’-TGTATGAAGAATTTGTTTAGGGTTA-3’) and the reverse primer was 
located within the second exon of hTERT  (5’-AACCACCAACTCCTTCAAA-3’). 
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3. Results 
 
3.1. CTCF interaction with the first exon of hTERT is methylation dependent 
 
To evaluate binding of CTCF, ChIP assay was performed on two telomerase-
positive tumor cell lines (HeLa and SW480), normal telomerase-negative cells (BJ) and 
telomerase-positive immortalized cells (HLF/hTERT). CTCF binding to the H19 gene was 
used as a positive control for the efficiency of the experimental protocol. hTERT exon 1 
was coamplified with H19, as positive control. PCR reactions were performed at 
conditions in which the samples from no-antibody control always showed low levels of 
background amplification (Data not shown). Figure 1 shows that CTCF bound to the first 
exon of hTERT only in the two endogenous telomerase-negative BJ and HLF/hTERT cell 
lines. These experiments demonstrate that CTCF bound in vivo to the first exon of the 
hTERT gene in the normal but not in the tumor cell types tested (Fig. 1). 
 
 
 
Figure 1. In vivo interaction of CTCF with the hTERT gene. Binding of CTCF to the first exon of hTERT in 
telomerase-positive and negative cell lines was analyzed by ChIP assay using anti-CTCF antibody. PCR co-
amplified the tested fragments (hTERT exon1 and H19) using as template DNA input fraction and DNA 
recovered from immunoprecipitated fractions bound by the anti-CTCF antibody. 
 
 
As methylation status of CpG dinucleotides within the CTCF recognition sequence 
can influence its binding (Kanduri et al., 2000), examined the methylation status of CpG 
sites within the hTERT minimal promoter and first exon region (-200 to +100bp). 
Methylation profiles of HeLa, SW480, U2-os, BJ and HLF/hTERT were defined after 
bisulfite modification and cloning of the PCR products. Twelve clones from HeLa, SW480 
and U2-os, and 4 clones from BJ and HLF/hTERT were sequenced (Figure 2). In HeLa, 
SW480 and U2-os, a global hypermethylation was observed in the promoter and the exonic 
region. Especially the recognition sequence of CTCF in the hTERT first exon (Renaud et 
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al, NAR 2005, submitted) was found highly methylated in the majority of the analyzed 
clones (Figure 2, region B). In contrast, only few CpG sites were found methylated in BJ 
and HLF/hTERT. 
 
 
Figure 2. Genomic bisulfite sequencing of hTERT promoter and proximal exonic region (–200 to +100 
nucleotide bases around the ATG transcriptional start site). After PCR amplification and cloning, 12 clones 
of HeLa, SW480 and U2-os, as well as 4 clones of BJ and HLF/hTERT cells were analyzed. Each square 
represents one CpG site. Methylated CpG sites are indicated in black and unmethylated one in white. Region 
A: in this region (–80 to –165 bp), multiple CpG sites were found to be unmethylated in HeLa, SW480 and 
U2-os cells. Region B: location where CTCF binds to the first exon of the hTERT gene. 
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This raised the possibility that low CTCF binding to its target sequences might be 
due to CpG methylation. To test this hypothesis, HeLa cells were stably transfected with an 
hTERT construct, pTERT –297/ex2/FRT (Figure 3A) and this vector was methylated in 
vitro before transfection. Genomic DNA of stable transfectants were extracted after 30 
population doublings (PD) and the methylation status was analyzed by MS-SSCA 
(Benhattar and Clement, 2004). To differentiate endogenous hTERT gene sequences from 
the transfected sequence, we used a specific forward primer located in the reporter vector 
(Figure 3A). The transfected hTERT sequence remained methylated even after 30 PDs, 
whereas the unmethylated control transfectants stayed unmethylated (Figure 3B). ChIP 
assay was performed on methylated and unmethylated stable transfectants. CTCF bound to 
the hTERT exonic region of the vector sequences only when this region was unmethylated 
(Figure 3C). These results indicate that methylation of the first exon of hTERT prevents 
binding of CTCF. Hypermethylation of the hTERT exonic region therefore might be 
responsible for the release of CTCF as a repressor, allowing transcription of the hTERT 
gene. 
 
 
 
3.2. CTCF binding is restored after 5-azadC treatment 
 
As was shown in previous studies (Guilleret and Benhattar, 2003;Kumakura et al., 2005), 
5-azadC treatment of telomerase-positive cells inhibits hTERT transcription and reduces 
telomerase activity. We hypothesis that hTERT first exon demethylation restores CTCF 
binding. To test this hypothesis we treated HeLa, SW480 and U2-os with 5-azadC during 3 
weeks. Demethylation of hTERT was confirmed by sequencing (Figure 4A). ChIP revealed 
significant CTCF binding (Figure 4B). Moreover, downregulation of hTERT expression 
after treatment of the two telomerase-positive cell lines, HeLa and SW480, was found by 
RT-PCR (Figure 4C), but also of the U2-os telomerase-negative tumor cells. In this latter, 
demethylation led to reexpression of hTERT (Figure 4C). 
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Figure 3. hTERT methylation and CTCF binding. (A) Representation of the hTERT sequence cloned into the 
pTERT-297/ex2/FRT. Arrows represent the localization of the primers used for the verification of the 
methylation status of stable transfectant. (B) SSCP gel to verify the methylation status of the stable 
transfectant. Unmethylated and fully methylated controls were obtained from plasmids used for stable 
transfection. UT and MT represent, respectively, the unmethylated and the methylated plasmids stably 
transfected into HeLa cells after 30 PDs. (C) Binding of CTCF to the first exon of hTERT in stable 
transfected cell line was analyzed by ChIP assay using anti-CTCF antibody. PCR co-amplified the tested 
fragments (hTERT exon1 and H19) using as template DNA input fraction and DNA recovered from 
immunoprecipitated fractions bound by the anti-CTCF antibody. 
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Figure 4. CTCF binding to the exogenous hTERT sequence after 5-azadC treatment. (A) Genomic bisulfite 
sequencing of hTERT promoter and proximal exonic region (–200 to +100 nucleotide bases around the ATG 
transcriptional start site). After PCR amplification and cloning, 4 clones of HeLa, SW480 and U2-os were 
analyzed. Each square represents one CpG site. Methylated CpG sites are indicated in black and 
unmethylated one in white. Region A and region B were represented for an easy comparison with the figure 
2. (B) Binding of CTCF to the first exon of hTERT in 5aza-dC cell lines was analyzed by ChIP assay using 
anti-CTCF antibody. PCR co-amplified the tested fragments (hTERT exon1 and H19) using as template DNA 
input fraction and DNA recovered from immunoprecipitated fractions bound by the anti-CTCF antibody. (C) 
RT-PCR analyses of hTERT expression in cells before and after 5-azadC treatment. β-actine was used as 
internal control of the RNA quality. 
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3.3. hTERT methylation inhibits transcriptional activity 
 
To evaluate the importance of hTERT methylation in hTERT activation, transient 
transfection of HeLa cells was performed with CpG-free plasmids previously methylated 
or not in vitro. The hTERT minimal promoter did not show any activity if all the CpG sites 
were methylated (Figure 5). In the same manner, no transcriptional activity was observed 
with methylated plasmids containing the promoter and the first exon of hTERT. Since the 
hTERT promoter was inhibited by methylation, a construct containing the hEF1 CpG-free 
promoter upstream of the first exon of hTERT was also tested after in vitro methylation. 
The activity of the hEF1 promoter alone was not affected by DNA methylation, whereas 
addition of the hTERT exonic region induced a decrease of the hEF1 promoter activity 
(Figure 5). Nevertheless, methylation of the first exon was not sufficient to overcome the 
transcriptional inhibitory effect of this region, but did not lead to a complete inhibition of 
the transcriptional activity, as observed with methylation of the hTERT promoter. 
Therefore, methylation could have a potential inhibitory role on the hEF1 promoter 
activity. These results show that the complete methylation of the hTERT promoter induce 
the inhibition of the transcriptional activity.  
 
Figure 5. Effect of the hTERT promoter methylation on the transcriptional activity. Transcriptional activity 
of the hTERT minimal promoter or the hEF1 CpG free promoter, with or without the presence of the hTERT 
exon 1 in a methylated CpG free plasmid. Methylated and unmethylated constructs were transiently 
transfected in HeLa cells. The 100% activity is represented by the activity of ummethylated promoters. 
Empty circle represent unmethylated CpG site and solid circle represent methylated CpG site. * represents 
the significance (student t-test p<0.05). 
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3.4. A region of the hTERT minimal promoter must be hypomethylated to 
allow its transcriptional activity 
Sequencing of bisulfite-modified DNA from tumor cell lines showed a partial 
demethylation of the promoter, between –80 to –160 bp (Figure 2, region A). A recent 
study has also observed a partial methylation of the promoter region in telomerase-positive 
cell lines (Kumakura et al., 2005). This hypomethylation, just upstream of the 
transcriptional start sites, could permit the low transcriptional activity of the hTERT 
promoter observed in vivo in tumor cells (Ducrest et al., 2001;Yi et al., 2001). 
To prove the importance of the region A (Figure 2) in the hTERT transcriptional 
activity, we performed a methylation cassette assay (Robertson and Ambinder, 1997). 
Recombinant plasmids were created, containing a cassette from -183 to -73 (12 CpG sites) 
in a β-galactosidase reporter plasmid,. The methylated or unmethylated cassette was 
excised, ligated back into the methylated or unmethylated vector, and the ligated mixture 
was transfected into the HeLa and U2-os cell lines. Methylation of the cassette fragment 
reduced the activity of the hTERT promoter to background (Figure 6), a result similar to 
that obtained with the fully methylated promoter. In contrast, the unmethylated cassette 
ligated to the methylated vectors, led to a 3 to 5-fold reduction of the transcriptional 
activity, compared to the activity obtained with the unmethylated reporters, in the U2-os 
and HeLa cells, respectively. 
 
Figure 6. Cassette methylation assay in three independent transfection experiments. Transcriptional activity 
of the partial demethylation of the hTERT minimal promoter in a methylated CpG free plasmid. The different 
constructs were transiently transfected in HeLa and U2-os cells. The 100% activity is represented by the 
activity of ummethylated plasmid. Empty circle represent unmethylated CpG site and solid circle represent 
methylated CpG site. 
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Thus, in a context of hypermethylation of the 5’-region of the hTERT gene,  
hypomethylation of the region A (Figure 2), where 3 of the 4 Sp1 binding sites are 
localized, is sufficient to obtain a certain level of hTERT expression, as it was observed in 
vivo (Ducrest et al., 2001;Yi et al., 2001). 
 
3.5. Regulation of hTERT transcription might be cell specific 
 
Telomerase-negative U2-os cells show the same methylation profile as telomerase-
positive HeLa and SW480 cells, but do not express hTERT. Regulation of the hTERT 
transcription might be different between ALT and telomerase-positive cells. To explore 
this possibility HeLa and U2-os were transfected with the pTERT-297 and pTERT-1821 
vectors containing respectively the minimal and the distal (approximately 1.8 kb of 
sequences upstream of the hTERT ATG) hTERT promoter. Taking the activity of the SV40 
promoter as an internal standard, the minimal hTERT promoter was 4-fold more active in 
HeLa than in U2-os. The activity of the minimal and the ‘long’ hTERT promoter were 
equivalent in HeLa, whereas in U2-os the long promoter was significantly less active than 
the minimal promoter (Figure 7). These results suggest a differential regulation of the 
hTERT transcription in HeLa and U2-os cells, and an important role of the 5’ flanking 
region to differentiate the transcriptional potential of hTERT methylated telomerase-
positive and telomerase-negative cells. 
 
Figure 7. Transcriptional activity of the 
hTERT promoter in HeLa and U2-os. The 
100% activity is represented by the activity 
of SV40 early promoter. The hTERT 
promoter activities were calculated 
relatively to the activity of the SV40 
promoter considering as 100% of the 
luciferase activity. ** represent the 
statistical significance (Student t-test 
p<0.01). 
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4. Discussion 
 
A major mechanism to regulate telomerase activity is the transcriptional control of 
hTERT, the catalytic subunit of the human telomerase. The regulation of the hTERT gene 
has been extensively studied, since it may be the key to understand the reactivation of 
telomerase in cancer cells, and the mechanism of cell immortalisation. However regulation 
of the hTERT gene appears to be rather complex and remains insufficiently understood. A 
~4kb CpG island with a GC content up to 70% was identified in the 5’-region of the 
hTERT gene. Several groups have noticed that promoter methylation might be involved in 
hTERT regulation. Our previous studies suggested that methylation of the hTERT promoter 
and proximal exonic region might be involved in the regulation of the expression of the 
gene (Guilleret and Benhattar, 2003). This is counter-intuitive as in the general model of 
regulation by DNA methylation, in which promoter hypermethylation goes along with 
repression of transcription (Robertson and Jones, 2000). Some reports suggest that the 
hTERT promoter and ALT-associated gene(s) or promoter(s) are in juxtaposition and that 
activation of either telomerase or ALT pathway is regulated by a common repressor in a 
manner dependent on the methylation status of either promoters or genes (Kumakura et al., 
2005;Perrem et al., 1999). We observed that CTCF, a ubiquitously expressed 11-zinc 
finger protein, binds to a region located in the first two exons of the hTERT gene in cells in 
which hTERT is not expressed but not in telomerase-positive ones (Renaud et al, NAR, 
2005, submitted). Inhibition of CTCF binding in telomerase-negative cells induced hTERT 
transcription, which supports the notion that CTCF is involved in the transcriptional 
repression of hTERT. The aim of the present study was to define more precisely the role of 
CTCF and DNA methylation in the regulation of hTERT expression. 
CTCF binds preferentially to GC-rich DNA regions, exerts an inhibitory effect 
when placed downstream of the transcriptional start site and is released when its binding 
site is methylated (Kanduri et al., 2000). In a previous study, we have shown that CTCF 
binds to GC-rich regions within the exons 1 and 2 of the hTERT gene and its repressor 
effect is general, neither cell type specific nor promoter dependent. In the hTERT CpG 
island, binding of CTCF might be influenced by the methylation status of the CTCF sites. 
In vivo, when hTERT is not methylated, either the endogenous (in BJ cells) or the 
exogenous gene (in HLF/hTERT and with the unmethylated hTERT plasmid in HeLa 
cells), the ChIP assay revealed that CTCF binds to the first exon of hTERT. On the 
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contrary, when hTERT is methylated (HeLa, SW480, U2-os or methylated hTERT plasmid 
in HeLa cells), CTCF does not bind any more to its recognition site. Therefore, CTCF, 
which acts as a repressor, does not bind to hTERT when the sequence is hypermethylated. 
In the hTERT-methylated cell lines, a treatment with the 5-azadC demethylating agent led 
to a strong demethylation of hTERT, and, as a consequence, to a reactivation of the CTCF 
binding on the proximal exonic region. As previously observed, transcription of hTERT 
was strongly repressed during drug exposure (Guilleret and Benhattar, 2003;Kumakura et 
al., 2005). Therefore, the main role of DNA methylation is probably to prevent binding of 
the CTCF repressor and, as a consequence, to allow transcription of the hTERT gene. 
Nevertheless, in telomerase-negative tumor cells U2-os, the drug exposure lead to a partial 
reactivation of the hTERT expression, as well as the CTCF binding. These opposite effects 
could be due to a dual effect of the 5-azadC. In the one hand it leads to demethylation of 
gene(s) that could be necessary to the hTERT transcription, in the other hand, the 
demethylation of the first exon of hTERT allows the binding of CTCF. As the analysis 
concerns the global cell population, some cells could express hTERT and others could 
restore the CTCF binding to hTERT. 
DNA methylation is an epigenetic process known as a general inhibiting 
mechanism. In this model, methylation of DNA helps to stabilize chromatin in an inactive 
configuration and inhibits gene expression (Robertson and Jones, 2000). The hTERT 
promoter is located in a large CpG island comprising a very high number of CpG sites. 
Several groups have shown that the hTERT promoter is hypermethylated in a majority of 
telomerase-positive tissues and cell lines (Dessain et al., 2000;Devereux et al., 
1999;Guilleret et al., 2002). In this context, it is very difficult to understand how hTERT 
can be transcribed and why hTERT is an exception to the general rule, in which the 
promoters located in hypermethylated CpG islands should not be transcribed. According to 
our data, the hTERT promoter does not make exception to this rule. Our results show 
clearly that a complete methylation of the hTERT promoter lead to a complete inhibition of 
its activity. Thus, even if the CTCF repressor cannot bind any more on the hTERT gene, 
complete methylation of all the CpG sites contained in this region will also lead to a total 
inhibition of the transcription.  
A detailed mapping of CpG methylation within the 5'-region of the hTERT gene 
showed that not all the CpG sites were methylated in telomerase-positive cells (Guilleret 
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and benhattar, 2004). In the present study, a region between –165 to –80 bp upstream of 
the transcription start site was found hypomethylated in tumor cell lines. A cassette 
methylation assay was used to demonstrate the importance of this region for the 
transcriptional activity of the hTERT promoter. Our data clearly indicate that selective 
demethylation of 12 CpGs limited to a small region upstream the transcription start site 
significantly activates hTERT promoter activity in a reporter plasmid. This region contains 
3 of the 4 Sp1 sites present in the hTERT core promoter. Interestingly, unmethylation of 
these Sp1 sites is in accordance to the hypothetic protective role of SP1 against CpG 
islands methylation (Caiafa and Zampieri, 2005). A recent study also showed that the 
hTERT transcription required a partial methylation of its promoter (Kumakura et al., 2005). 
In summary, there is transcription of the hTERT promoter when a large region downstream 
of the transcription start is highly methylated and when a small part of the promoter region 
is unmethylated, probably in order to allow the transcription complex to be formed.  
Some hTERT-methylated telomerase-negative tumor cell lines, as the U2-os ALT 
cells, revealed a methylation pattern similar to that observed for the telomerase-positive 
cells. This result would indicate that a partial demethylation of the hTERT promoter is 
apparently not sufficient to lead to its expression. We observed that one of the additional 
conditions for an hTERT expression is the high potential transcriptional level of the 
promoter region. Indeed, in transient transfection assays, the level of expression of the 
hTERT promoter, either the minimal (-297 to –21) or the long one (-1821 to -21) was 
significantly lower in U2-os than in HeLa cells. Moreover, in U2-os the level of 
transcription with the long promoter is much lower than with the minimal one, which is not 
the case for HeLa. These findings suggest that for U2-os some transcriptional activators are 
probably missing and some repressors could bind to the upstream part of the promoter. The 
cumulated effects could be sufficient to reduce significantly or even to stop the 
transcriptional activity of the hTERT promoter.  
In summary, an upregulation of hTERT can be obtained only if several conditions 
are met. Firstly, the main required event for the hTERT transcriptional activation is the 
absence of CTCF binding on the first exon of hTERT. In this way, hypermethylation of the 
hTERT CpG island, which was observed in a majority of telomerase-positive tumors cells, 
could be one of the most important mechanism necessary to prevent CTCF binding. 
Secondly, although the hTERT CpG island must be hypermethylated, at least to prevent the 
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binding of CTCF, methylation of the promoter itself must be partial to allow a certain level 
of hTERT transcription. The third required condition for the hTERT transcription is the 
potential activation of the hTERT promoter, without considering the inhibitory effect of the 
proximal exonic region. All these findings allow a better understanding of the hTERT 
regulation. In this study, we demonstrate that the transcriptional activation of hTERT is 
complex and requires precise conditions. This could have important implications for the 
proposed of hTERT inhibition as anticancer therapies. 
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ABSTRACT 
 
Telomerase is an RNA-dependent DNA polymerase that synthesizes telomeric DNA. It is 
not active in most somatic cells, but is reactivated during tumorigenesis. The catalytic 
subunit hTERT is an essential element of the telomerase complex but the regulation of its 
expression has not been elucidated completely. In a preceding study, we showed that the 
ubiquitous highly conserved CCCTC binding factor (CTCF) inhibits hTERT transcription 
through binding to its first exon in normal cells. Although several studies have shown that 
the hypermethylation of hTERT goes along with telomerase activation, the mechanisms 
involved remain unclear. We postulate that methylation of hTERT might inhibit the 
binding of CTCF, which then no longer bocks hTERT transcription. Hypermethylation of 
hTERT, however, is not invariably associated with telomerase activity. In this study we 
show that hTERT is unmethylated in most testicular and ovarian cancers, as well as cancer 
cell lines derived from these tumors. BORIS, the paralogue of CTCF, is expressed in 
spermatocytes and we investigated its role in the regulation of the hTERT transcription in a 
testicular teratocarcinoma (NCCIT) and ovarian carcinoma cell line (OVCAR-3). In the 
adult, BORIS is exclusively expressed in male germ cell lineage only when CTCF is not 
expressed and vice versa. We show that BORIS and CTCF occur in the same nucleus in 
NCCIT and OVCAR-3 cells. We show that CTCF and BORIS bind to the first exon of 
hTERT in vivo in these cell lines. Moreover, transfection of BORIS into normal cells 
activates the hTERT transcription. Thus, in testicular and ovary tumor cells BORIS plays 
the role of CTCF antagonist, and as such allows the transcription of hTERT. 
 
Keywords: Telomerase, hTERT, CTCF, BORIS. 
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1. Introduction 
 
The telomerase complex plays a role in a variety of physiological and pathological 
processes, including cell proliferation, cell differentiation, carcinogenesis and aging 
(Blackburn, 1997;Greider, 1996). The enzyme stabilize telomere length by adding 
hexameric repeats to telomeric ends (TTAGGG) of the chromosomes, which compensate 
for the continuous telomere erosion due to the end replication problem (Nakamura et al., 
1997). Maintenance of telomeres is required for cells to escape from replicative senescence 
and sustained proliferative capacity. In adult humans, telomerase activity is not detectable 
in most somatic cells (Yasumoto et al., 1996). In contrast, continuously cycling cells such 
as germ cells and stem cells, as well as 85-95% of cancers express telomerase (Kim et al., 
1994). Of the components that make up telomerase, the RNA component, hTERC, and the 
reverse transcriptase, hTERT, are essential for the reconstitution of telomerase activity in 
vitro (Feng et al., 1995;Smogorzewska and De Lange, 2004;Weinrich et al., 1997). 
Moreover ectopic expression of hTERT is sufficient to restore telomerase activity in 
telomerase-negative cells (Bodnar et al., 1998;Counter et al., 1998;Weinrich et al., 1997). 
Therefore, hTERT expression is considered as a rate-limiting factor in regulating the 
telomerase activity (Liu et al., 2000). Many studies suggest that the regulation of hTERT 
expression occurs primarily at the transcriptional level. 
Subsequent to the elucidation of the sequence and the organization of the hTERT 
gene, a minimal promoter encompassing the 283 bp region upstream of the initiation ATG 
codon and numerous binding sites for transcription factors, have been identified (Cong et 
al., 1999;Horikawa et al., 1999;Takakura et al., 1999;Wick et al., 1999). Several activators 
of hTERT transcription were identified, including c-Myc, Sp1, hALP, Hif-1, Mbi-1, 
USF1/2 and estrogen response element (Dimri et al., 2002;Goueli and Janknecht, 
2003;Goueli and Janknecht, 2004;Lv et al., 2003;Nishi et al., 2004;Poole et al., 2001;Valk-
Lingbeek et al., 2004;Yatabe et al., 2004). A Few repressors, including p53, Mad1, 
myeloid-specific zinc finger protein 2 (MZF-2), TGF-β and Wilms' Tumor 1 (WT1), have 
been identified. Clearly, a variety of factors is involved in the regulation of hTERT 
transcription, but exactly how hTERT is reactivated in cancer cells and how telomerase 
activity is suppressed in most somatic cells remain elusive. It has been suggested that a 
repressor downregulates the transcriptional activity of hTERT, which inactivates 
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telomerase. We found the proximal exonic region of hTERT to play an important role in 
the transcriptional regulation of the gene (Renaud et al., 2003). Furthermore, CTCF, which 
binds to the first exon, was capable to repress hTERT transcription in normal cells (Renaud 
et al, 2005, submitted). Thus, it becomes important to identify the mechanism(s) that 
regulate exon 1 binding of CTCF in the context of modulation of hTERT transcription. 
The hTERT promoter being situated in a CpG island suggests transcription 
regulation by DNA methylation. On this subject contradictory results have been published 
(Dessain et al., 2000;Devereux et al., 1999;Guilleret et al., 2002;Lopatina et al., 
2003;Nomoto et al., 2002;Shin et al., 2003). Our recent studies show that hTERT promoter 
hypermethylation does not exclude hTERT expression (Guilleret et al., 2002;Guilleret and 
Benhattar, 2003). Along with promoter methylation, however, other methylation-
independent mechanisms must be implicated (Bechter et al., 2002;Dessain et al., 
2000;Devereux et al., 1999;Lopatina et al., 2003;Widschwendter et al., 2004) as for 
example in testicular and ovarian cancer. 
Some telomerase-positive cells, including germ cells, express BORIS, a paralogue 
of CTCF. BORIS was found to be present mainly in primary spermatocytes of the testis, 
and expressed in a pattern mutually exclusive with CTCF during male germ cell 
development (Loukinov et al., 2002). BORIS is also involved in epigenetic 
reprogramming, both in normal development and in tumorigenesis (Klenova et al., 
2002;Loukinov et al., 2002;Klenova et al., 2002;Loukinov et al., 2002). Moreover, BORIS 
and CTCF bind to the same recognition sequence. Based upon these observations, we 
postulate that BORIS plays a role in the regulation of hTERT expression in normal and 
tumor testicular germ cells, through competition with CTCF. 
In this study, we analyzed the methylation pattern of hTERT in testicular and ovarian 
tumors, as well as in the NCCIT and OVCAR-3 cell lines. We also investigated the role of 
BORIS in the regulation of hTERT expression. Our data indicate that when BORIS is 
expressed in tumor cells, transcription of hTERT takes place despite the presence of the 
CTCF. 
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2. Materials and methods 
 
2.1. Tissue samples and cell lines 
Tissues samples from 10 germ cell tumors (five testicular and five ovarian) were 
analyzed. The use of human tissue samples for this study was according to the guidelines 
of the ethical committee of the Medical Faculty of Lausanne. The human tumor cell lines 
(HeLa, cervical adenocarcinoma; NCCIT, testis teratocarcinoma, OVCAR-3, ovarian 
carcinoma) and the normal  fibroblasts (BJ) were obtained from the ATCC. The cells were 
grown in the medium recommended by the ATCC. HeLa, NCCIT and OVCAR-3 cell lines 
are telomerase-positive, whereas BJ are telomerase-negative. All cells were tested to be 
mycoplasma free. 
 
2.2. DNA methylation analysis 
DNA was extracted from cultured cells using the DNeasy tissue kit (Qiagen, 
Hilden, Germany). Two µg of DNA were modified in 40 µl of water with sodium bisulfite 
as previously described (Benhattar and Clement, 2004). After bisulfite modification, 
methylation analysis of hTERT promoter was done by amplification with the primer 
TRTmet-FW 5’-GGGTTATTTTATAGTTTAGGT-3’ and the TRTmet-REV 5’-
AATCCCCAATCCCTC-3’. PCR conditions are the following: 35 cycles of 94°C for 30 
sec, 54°C for 45 sec and 72°C for 50 sec. A semi-nested PCR was necessary to obtain 
optimal amplification and this was performed with the reverse primer TRTmetN-REV 5’-
AATCCACTAAAAACCC-3’. Semi-nested PCR conditions were 20 cycles of 94°C for 30 
sec, 48°C for 45 sec and 72°C for 50 sec. Amplification of the promoter and first exon of 
hTERT was performed with the primers 5’-CTACCCCTTCACCTTCCAA-3’ and 5’-
GTTAGTTTTGGGGTTTTAGG-3’. Amplification was done, using the master mix 
(Promega), with the following PCR conditions: 40 cycles of 94°C for 30 sec, 57°C for 45 
sec and 72°C for 50 sec. Experiments were performed in triplicate. PCR products were 
cloned into the pGEM-T vector using the pGEM-T vector system II (Promega). After 
transformation of E. Coli JM109 competent cells (Promega), plasmid DNAs were 
extracted from bacterial clones with the QIAprep Spin Miniprep Kit (Qiagen). Each clone 
was analyzed by sequencing, using the M13 forward primer (5’-
CHAPTER V 
 168
GTAAAACGACGGCCAG-3’), on an ABI Prism 3100 sequencer (Applied Biosystems, 
Foster City, CA). 
 
 
2.3. Plasmid construction 
(i) hTERT reporters. pTERT–297 contain the hTERT minimal promoter (Renaud 
et al., 2003). The pTERT–297/ex1 vector contains the hTERT minimal promoter and 80 bp 
of the first exon. To generate this vector, an hTERT fragment was generated by PCR and 
cloned into the pGL3 basic vector (Promega) previously opened with SacI and HindIII. 
The primers used for PCR amplificatoion of the hTERT fragment contained also the SacI 
and the HindIII sites and were FW-5’-
GGCTGCGAGCTCCAGGCCGGGCTCCCAGTGGAT-3’ and REV-5’-
GGCAAGCTTCGAACGTGGCCAGCGGCAGCACCTC-3’. All these constructs were 
used for the transient transfection experiments. 
(ii) BORIS expression vector. The BORIS cDNA was cloned in pCMV6-XL4 by 
ORIGENE Technologies (Rockville, MD, USA). 
 
 
2.4. Transient transfection and luciferase assays 
After optimization of the transfection conditions, cells were seeded at a 
concentration of 200’000 / 3.8 cm2 for HeLa, NCCIT and OVCAR-3, and 50’000 cells / 
3.8 cm2 for BJ. Cells are then cultured overnight. Transient transfections of reporter 
plasmids (0.75 µg / well) and expression vector (1 µg / well) were carried out in triplicate 
using JetPEI Cationic Polymer Transfection reagent (8 µl / well) (Polyplus-transfection, 
Illkirch, France). All experiments were performed at least twice. The pRL-tk vector (0.25 
µg / well) (Promega, Madison, WI) was co-transfected as an internal control for 
transfection efficiency. Luciferase assays were performed using the Dual-Luciferase 
Reporter Assay System (Promega, Madison, WI). The levels of the different constructs 
were compared to the level of the pGL3-control vector containing the firefly luciferase 
gene under the control of the SV40 early promoter and to the level of the pGL3-basic 
vector, a promoterless and enhancerless luciferase vector. 
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2.5. Immunfluorescence 
HeLa, NCCIT and OVCAR-3 cells were grown 24 hours in 4-well tissue culture 
chamber slides. Cells were washed in 1X PBS and fixed 10 minutes in 4% 
paraformaldehyde/1X PBS solution, freshly prepared. After 2 washes with 1X PBS, cells 
were permeabilized 15 minutes in 1X PBS / 0.2% Triton solution, freshly prepared. Cell 
slides were washed in 1X PBS and then, cells were bocked in a 1X PBS/10% goat serum 
during 90 minutes. Rabbit anti-BORIS and mouse anti-CTCF antibodies (product by 
Lobanenkov’s lab) were diluted at 1/200 and 1/400, respectively, in antibody diluent 
solution (DakoCytomation, Carpinteria, CA) added with 0.5M NaCl. Slides were placed at 
4°C overnight. The next day, cells were washed 3 times in 1X PBS/1% milk/0.5% 
TritonX-100. Secondary antibodies FITC-anti-rabbit and Cy3-anti-mouse (Sigma-Aldrich, 
St. Louis, MO) were added at 1/100 in 1X PBS and incubated for 1 hour at RT in dark. 
Cells were then washed 3 times in 1X PBS/1% milk/0.5% TritonX-100, followed by 3 
washes in 1X PBS. Slides were mounted in 1X PBS/20% glycerol. Image were analyzed 
on a fluorescence microscope (Nikon, Confocal microscope C1, Chiyoda-ku, Tokyo). 
 
 
2.6. RNA extraction and RT-PCR  
RNA was extracted from cells transfected with siRNA, using the TRIzol LS 
Reagent (Invitrogen, Basel, Switzerland). Platinum quantitative RT-PCR Thermoscript 
one-step system (Invitrogen) was used to amplify the hTERT mRNA using the primers 
LT5 5’-CGGAAGAGTGTCTGGAGCAA-3’ (exon3) and LT6 5’-
GGATGAAGCGGAGTCTGGA-3’ (exon4), with coamplification of β-actin with the 
primers actin-FW 5’-AGGCCAACCGCGAGAAGATGA-3’ and actin-REV 5’-
GCCGTGGTGGTGAAGCTGTAG-3’. The hTERT splicing variants (α, β, α/β and FL) 
were determined by RT-PCR using the primers FW-SP 5’-
GCCTGAGCTGTACTTTGTCAA-3’ and REV-SP 5’-
CGCAAACAGCTTGTTCTCCATGTC-3’. The FL (full-length) variant was obtained with 
the primers FW-FL 5’-CGCCTGAGCTGTACTTTGTCA-3’ and REV-FL 5’-
CGGCTGGAGGTCTGTCAAG-3’. RT-PCR products were analyzed on 2% agarose gel. 
The FL and the β spliced variant fragments were extracted from the gel, purified with the 
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QIAquick gel extraction kit (Qiagen) and sequenced on an ABI Prism 3100 sequencer 
(Applied Biosystems, Foster City, CA). 
BORIS expression was screened with the primers RT-BORIS-FW 5’-
AAGCCGCGAACGGAGACGAAG-3’ and RT-BORIS-REV 5’-
ACGCCTTCATCCACTTCCTCTTT-3’. CTCF expression was screened with the primers 
RT-CTCF-FW 5’-GTGGCGCGGAGAATGATTAC-3’ and RT-CTCF-REV 5’-
TCCACAATGGCTTCGACTGC-3’. RT-PCR products were analyzed on 2% agarose gel. 
 
2.7. Chromatin immunoprecipitaion (ChIP) assay 
To crosslink proteins to DNA, 12 ml of a 1% formaldehyde solution in culture 
medium was added to the cells cultured to 50% of confluency, and the cells were incubated 
15 minutes at room temperature. Then, 1.3 ml of a 1.25 M glycine solution was added to 
the medium to stop the reaction. After 5 min, the cells were centrifuged and resuspended in 
10ml of ice-cold PBS containing protease inhibitors. One million cells were pelleted, 
resuspended in 200 µl of SDS lysis buffer (1% SDS, 10nM EDTA, 50mM Tris-HCl, pH 
8.1) and incubated on ice for 10 minutes. The lysate was sonicated to shear DNA. The 
chromatin solution was diluted in 1800 µl of the ChIP dilution buffer (0.01% SDS; 1.1% 
Triton X-100; 1.2 mM EDTA; 16.7 mM Tris-HCl, pH 8.1; 167 mM NaCl; protease 
inhibitors) for further immunoprecipitation or stored at 4°C to be directly uncrosslinked 
and purified (DNA input fraction). Magnetic beads, 80 µl, (Dynabeads M-280 Sheep anti-
Rabbit IgG, Dynal biotech, Oslo, Norway) were washed three times with 1 ml of blocking 
solution (1X PBS; 5mg/ml BSA; 3% of a 1mg/ml sonicated herring sperm DNA solution; 
protease inhibitors). Half of the beads was suspended in 250 µl of the blocking solution 
either with 2 µg of the rabbit polyclonal anti-BORIS antibody or without antibody, and 
rocked for 4 hours at 4°C. The beads were then washed 3 times with 1 ml of the blocking 
solution, and then added to 1 ml of the diluted chromatin solution and incubated overnight 
at 4°C. They were then washed twice with 500 µl of the following washing solutions: low 
salt solution (0.1% SDS; 10% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.1; 150 
mM NaCl), high salt solution (0.1% SDS; 10% Triton X-100; 2 mM EDTA; 20 mM Tris-
HCl, pH 8.1; 500 mM NaCl), LiCl solution (0.25 M LiCl; 1% NP40; 1% deoxycholate; 1 
mM EDTA; 10 mM Tris-HCl, pH 8.1) and TE (10 mM Tris-HCl; 1 mM EDTA, pH8.0). 
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The eluate was then resuspended in 50 µl of the elution buffer (1% SDS; 0.1M NaHCO3) 
and incubated 10 minutes at 65°C. To reverse protein-DNA crosslinks, eluates were 
incubated at 65°C for 4 hours in 120 µl of a solution containing 1% of SDS and 0.3M 
NaCl. Then 180 µl of ATL buffer (Qiagen, Basel, Switzerland) and 20 µl of proteinase K 
were added to samples, and incubation was performed overnight at 55°C. 
Immunoprecipitated DNA was recovered by extraction with the DNeasy tissue kit (Qiagen, 
Basel, Switzerland). Purified DNA was analyzed by PCR with specific primers for the co-
amplification of the first exon of the hTERT gene to generate a 171 bp fragment (TERT-
FW 5’-CTGCTGCGCACGTGGGAAGCC-3’ and TERT-REV 5’-
GTCCCCGCGCTGCACCAGCC-3’) or the H19 gene as a 149 bp control (H19-FW 5’-
CACCGCCTGGATGGCACGGAATTG-3’ and H19-REV 5’-
TGCGACGCGTGGCTTGGGTGAC-3’). Amplification was performed with the following 
PCR conditions: 94°C for 30 sec, 62°C for 45 sec and 72°C for 60 sec. The cycle number 
and the amount of template were varied to ensure that results were within the linear range 
of the PCR. PCR products were analyzed on a 2% agarose gel. 
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3. Results 
 
 
3.1. In testicular and ovarian cancer cells, the hTERT promoter is not methylated 
Methylation analysis of five testicular and five ovarian cancers showed the hTERT 
promoter to be unmethylated, except for one ovarian cancer that was hypermethylated 
(Figure 1A). Methylation analysis of the tesicular (NCCIT) and the ovarian (OVCAR-3) 
cancer cell lines showed the hTERT promoter to be unmtehylated, in contrast with the 
telomerase-positive cervical cancer cell line, HeLa, which was hypermethylated (Figure 
1A). RT-PCR showed hTERT to be expressed in all of these tissues and cell lines 
regardless of the methylation status (Figure 1B). We next analyzed the methylation status 
of the hTERT CpG island in NCCIT, OVCAR-3 and HeLa cell lines. In HeLa, 
hypermethylation of the promoter and of the first exon was found, whereas 
hypomethylation of this region was found in NCCIT and OVCAR-3 (Figure 1C). 
According to these results, the loss of CTCF binding on the first exon of hTERT is not a 
consequence of DNA methylation. 
 
 
3.2. The repressor effect of the proximal exonic region of the hTERT gene is less 
efficient in testicular and ovarian tumor cell lines than in HeLa 
The inhibitory effect of the first exon of hTERT was tested in NCCIT and OVCAR-
3, and compared to that in HeLa. These three cell lines were transiently transfected with 
the pTERT-297 and the pTERT-297/ex1 reporter vectors, containing respectively the 
hTERT minimal promoter only or with the hTERT exon 1 (Figure 2A). The transcriptional 
activity of the hTERT minimal promoter was considered as a reference value. A 2- and 3-
fold increase of the pTERT-297/ex1 activity was observed in the NCCIT and OVCAR-3 
cells, respectively, in comparison to the activity noticed in the HeLa cells (Figure 2B). The 
inhibitory effect of CTCF in the hTERT transcription is lower in NCCIT and OVCAR-3 
cells than in HeLa cells, and it does not involve DNA methylation. Therefore, we 
investigated the role of BORIS, paralogue of CTCF, in the hTERT regulation. 
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Figure 1. Expression and methylation patterns of hTERT in human tumors and cell lines. (A) hTERT 
promoter methylation analysis was performed by MS-SSCA. Controls obtained from plasmids containing 
hTERT sequences which are either unmethylated (0%), from a equal mixture of unmethylated and fully 
methylated (50%), and fully methylated (100%). The cell lines are: HeLa, cervical adenocarcinoma; NCCIT, 
testicular teratocarcinoma; and OVCAR-3, ovarian carcinoma. (B) hTERT mRNA was detected by RT-PCR, 
with β-actin as internal control. (C) Genomic bisulfite sequencing of hTERT promoter and proximal exonic 
region (–200 to +100 nucleotide bases around the ATG transcriptional start site). After PCR amplification 
and cloning, 5 clones of NCCIT, OVCAR-3 and HeLa were analyzed. Each square represents one CpG site. 
Methylated CpG sites are indicated in black and those unmethylated in white. 
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Figure 2. Transcriptional activity of the hTERT minimal promoter with or without the proximal exonic 
region. (A) Schematic representation of the luciferase reporter plasmids pTERT-297 and pTERT-297/ex1. 
(B) Luciferase reporter plasmids containing the hTERT minimal promoter, with (pTERT-297/ex1) or without 
(pTERT-297) the proximal exonic region, are transfected into HeLa, NCCIT and OVCAR-3 cell lines. In 
each experiment, the activity is calculated considering the activity of hTERT promoter as 100%. 
 
 
 
3.3. CTCF and BORIS are co-expressed in testicular and ovarian cancer cell lines 
As BORIS is expressed in male germ cells, we investigated the expression of 
BORIS and CTCF in NCCIT and OVCAR-3. RT-PCR experiments showed that these two 
factors are expressed in both cell lines, but not in HeLa, in which BORIS expression was 
detected at a very low level (Figure 3A). 
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Figure 3. Expression and localization of CTCF and BORIS in NCCIT, OVCAR-3 and HeLa cells. (A) RT-
PCR of CTCF and BORIS in RNA extracted from NCCIT, OVCAR-3 and HeLa cells. (B) 
Immunofluorescence staining of CTCF and BORIS in NCCIT (a, b, c), OVCAR-3 (d, e, f) and HeLa (g, h, i) 
cells. Images a, d and g: CTCF immunostaining with a mouse monoclonal CTCF antibody, followed by 
incubation with an anti-mouse-Cy3 antibody. Images b, e and h: BORIS immunostaining with a rabbit 
polyclonal BORIS antibody, followed by incubation with an anti-rabbit-FITC antibody. Images c, f and I: 
merge of BORIS and CTCF staining revealed a co-localization within the nucleus. 
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In normal cells, BORIS and CTCF were found to be expressed in an mutually 
exclusive pattern (Loukinov et al., 2002). By immunocytofluorescence in NCCIT, 
OVCAR-3 and HeLa, we found BORIS and CTCF to be co-localized in the nucleus of 
NCCIT and OVCAR-3 (figure 3B, a-f). In HeLa cells, CTCF was localized in the nucleus, 
but BORIS staining was weak (Figure 3B, g-i). We can note that in NCCIT, the BORIS 
staining is likely more important in the nucleolus than in the nucleus. 
 
 
3.4. BORIS and CTCF bind in vivo to the same region of the hTERT gene 
We showed that CTCF and BORIS are co-expressed in NCCIT and OVCAR-3 
cells. As BORIS shares the 11 zinc finger DNA binding domain of CTCF (Klenova et al., 
2002;Loukinov et al., 2002), we investigated in vivo binding of CTCF and BORIS to 
hTERT. CTCF bound to the first exon of hTERT in NCCIT and OVCAR-3 but not in HeLa 
cells (Figure 4A). Likewise, BORIS bound to the first exon of hTERT in NCCIT and 
OVCAR-3 but not in HeLa (Figure 4B). 
 
 
 
 
  
 
Figure 5. In vivo binding of CTCF and BORIS to the first exon of hTERT in the telomerase-positive NCCIT, 
OVCAR-3 and HeLa cells. ChIP assay using either anti-CTCF antibody (A) or anti-BORIS antibody (B) 
PCR co-amplified the tested fragments (hTERT exon1 and H19) using as template DNA input fraction and 
DNA recovered from immunoprecipitated fractions bound by antibodies. 
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3.5. BORIS expression induced transcription of the hTERT gene 
Co-transfection of the BORIS gene, under the control of the CMV promoter, and 
hTERT reporter constructs was carried out in HeLa cells. The pTERT-297 reporter activity 
was considered as the reference level (100%), because it contained only the hTERT 
minimal promoter. The activity of the pTERT-297/ex1 vector was 1.5-fold higher in HeLa 
cells cotransfected with BORIS (Figure 5A), giving an activity close to this observed in 
NCCIT (Figure 2B). Expression of BORIS in HeLa cells prevented the binding of CTCF, 
reducing its repressor effect and inducing  higher transcriptional activity of the hTERT 
reporter. To confirm the stimulating effect of BORIS on hTERT transcription, the BORIS 
expression vector was transfected into BJ fibroblasts. These do not expressed BORIS and 
hTERT. After transfection with the pCMV-BORIS vector, BORIS and hTERT transcripts 
were detected by RT-PCR (figure 5B). RT-PCR detection of full-length and the α-spliced 
variant of hTERT showed the presence of full-length hTERT transcript. 
 
 
 
 
 
Figure 5. Transient transfection of a BORIS expression vector in HeLa and BJ cells. (A) Luciferase activities 
of pTERT-297 or pTERT-297/ex1 co-transfected with or without pCMV-BORIS in HeLa cells. In each 
experiment, the activity was calculated relative to the activity of hTERT promoter as 100%. pTERT-297: 
minimal hTERT promoter; pTERT-297/ex1: minimal promoter and first exon of the hTERT gene. (B) RT-
PCR of BORIS and hTERT from total RNA of BJ cells transfected with the pCMV-BORIS vector. 
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4. Discussion 
 
Telomerase activity is detected in highly proliferative cells such as germ cells and 
stem cells, as well as in 85% of cancers. Numerous studies have attempted to identify 
looked a specific hTERT activator in cancer cells or a specific repressor in normal cells. To 
date, numerous factors have been identified (Poole et al., 2001), most are particular to just 
a few or a single cell line. CTCF might be a ubiquitous repressor of hTERT. As the hTERT 
promoter line is situated in a CpG island, the regulation of hTERT by DNA methylation 
seemed to be a reasonable mechanism to explore. As methylation of the CTCF-binding site 
inhibits binding of the CTCF protein (Kanduri et al., 2000), we hypothesized that 
methylation of the hTERT gene, which occurs in many cancer cells, might prevent the 
repressor effect of CTCF. However, hTERT hypermethylation is always seen in cancer 
cells, which indicates that other methylation-independent mechanisms exist. We found, the 
hTERT hypomethylation to occur predominantly in testicular and ovarian cancers. For 
ovarian cancers, this has been reported before (Widschwendter et al., 2004). The question 
arises how cancer cells that have a methylation profile similar to normal somatic cells 
manage to express hTERT.  
BORIS, a paralogue of CTCF, is expressed at a high level only in male germ cells 
(Loukinov et al., 2002). We therefore investigated the role of BORIS in the regulation of 
hTERT in the testicular and ovarian cancer cell lines, NCCIT and OVCAR-3, which are 
telomerase-positive. Both express a high level of BORIS, whereas telomerase-positive 
HeLa cells do not express detectable levels of BORIS. In NCCIT and OVCAR-3 cells, the 
hTERT promoter and the proximal exonic region were found unmethylated in contrast to 
HeLa cells. In transient transfection of hTERT reporters, the presence of the hTERT exon 1 
led to an inhibition of transcription 2- to 3-fold lower in NCCIT and OVCAR-3 than in 
HeLa. Therefore, the repressor effect of the hTERT exon 1 in reporter assay could be less 
efficient in BORIS-positive cells than in BORIS-negative ones. 
Although male germ cells express CTCF and BORIS in a mutually exclusive 
pattern, they co-localized in the nucleus of NCCIT and OVCAR-3. In addition, ChIP 
experiments revealed that CTCF and BORIS bind in vivo to the first exon of hTERT. Thus, 
CTCF and BORIS seem to act as antagonists, in their binding to the hTERT exon 1. 
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In HeLa cells, co-transfection of the BORIS and the hTERT reporter reduced the 
repressor effect of hTERT exon1 on its promoter activity. Transient expression of BORIS 
in HeLa cells with the hTERT exon1 reporter showed promoter activity close to that in the 
BORIS-positive NCCIT cells. Thus, BORIS could, at least partially, prevent the repression 
of hTERT transcription by the CTCF protein. We furthermore showed that the transfection 
of the BORIS in telomerase-negative BJ cells induces transcription of the hTERT gene. 
These results demonstrate that BORIS and CTCF have an opposite effects on the 
transcriptional activity of the hTERT gene.  
Taken together, our results underline the role of BORIS in the transcriptional 
activation of hTERT in testicular and ovarian cancers. In these cells, BORIS is required to 
counteract the negative effect of CTCF on the hTERT transcription. In male germ-cells, 
CTCF and BORIS are expressed in a mutually exclusive pattern, thus, in cells lacking 
CTCF, BORIS is probably not directly required for the activation of hTERT. The co-
expression of CTCF and BORIS was only observed in cancer cells (Klenova et al., 2002). 
The implication of BORIS in the hTERT activation might be an essential factor in the 
immortalization process of testicular and ovarian cancer cells. In addition, in these tumors 
co-expression of both CTCF and BORIS might be at the origin of epigenetic deregulation 
leading to carcinogenesis. These findings open a way in the carcinogenesis understanding 
for potential anti-cancer therapies in testicular and ovarian cancer. 
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ABSTRACT 
 
BORIS, which is a paralogue of CTCF, is a male germ-line-specific protein associated 
with epigenetic reprogramming events. BORIS transcripts have been detected at a high 
level in normal testis and in testicular, ovarian and endometrial cancers, at a medium level 
in ovaries of young women, at a very low level in tumor tissues and cell lines, but not at all 
in most normal tissues (colon, breast, kidney, prostate, brain, lung, lymph node, heart…). 
Using RLM-RACE PCR, we identified two transcription start sites, about 900 and 1450 
bases upstream the ATG transcription start site. Transcription from promoter A (the most 
upstream promoter), which shows 14 potential binding sites for the CCAAT displacement 
protein (CDP/cut) factor, seems to occur in all BORIS-positive cells. Promoter B (proximal 
promoter), which is situated in a CpG island, appeared to be hypomethylated in normal 
testicular tissues and germ cell tumors, and this corresponded with high expression. In 
contrast, promoter B is fully methylated in normal BORIS-negative normal and tumor 
cells. Treatment with 5-azadC of two BORIS-negative cell lines resulted in BORIS 
reactivation by demethylation of promoter B. Multiple transcript variants were identified 
and they seem to be promoter dependent. One specific splice variant, lacking the exon 6, 
was strongly expressed when the promoter was hypomethylated and thus activated. In 
conclusion, we have identified two BORIS promoter regions that regulate expression of 
alternatively spliced forms of the gene. The resulting proteins probably have different 
functions. 
 
Keywords: BORIS; CTCF-like; promoter regulation; alternative splicing; DNA 
methylation 
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1. Introduction 
 
CTCF is a ubiquitously expressed, highly conserved nuclear protein (Lobanenkov et 
al 1990) which has been implicated in tumour suppression and appears to be involved in 
several aspects of gene regulation including activation, repression, imprinting of genetic 
information and insulator function (Bell et al 1999; Filippova et al 1996; Hark et al 2000; 
Vostrov et al 2002; Vostrov and Quitschke 1997). 
The CTCF parologue known as ‘Brother of the Regulator of Imprinted sites’ 
(BORIS), recognizes the same DNA binding sites as CTCF, but in normal cells it is 
expressed exclusively in the testis (Loukinov et al 2002). The BORIS protein shares the 11 
zinc finger DNA binding domain of CTCF but contains distinct N- and C-termini (Klenova 
et al 2002; Loukinov et al 2002). The nucleoprotein complexes generated by BORIS and 
CTCF bound to the same DNA sites are likely to have distinct functions. BORIS is only 
present in primary spermatocytes of the testis, and expressed in a mutually exclusive 
manner with CTCF during male germ cell development (Loukinov et al, 2002). Switching 
to BORIS may allow these cells to perform specific functions that otherwise are inhibited 
in the presence of CTCF. It is interesting to note that demethylation of the entire genome 
occurs during the time that BORIS is expressed. Moreover, the erasure of methylation 
marks during male-germ line development is associated with dramatic up-regulation of 
BORIS and down-regulation of CTCF expression. It is also possible that BORIS-CTCF 
switching is intimately linked with initiating (or regional targeting) de novo DNA 
methylation. In this case, reactivation of CTCF would serve to target de novo methylation 
to the paternal imprinting marks. 
The characterization of BORIS genes in human and mouse provide a new means to 
understand the molecular mechanisms involved in epigenetic reprogramming both in 
normal development and in tumorigenesis (Klenova, Morse, III, Ohlsson, and Lobanenkov 
2002). 
The human chromosome 20q13.2 region that encompasses the BORIS gene is 
commonly amplified or exhibits moderate gains of material in many human cancers. The 
localization of human BORIS to this locus, as well as frequent LOI (Loss Of Imprinting) in 
cancer involving abnormal methylation of CTCF target sites (Klenova, Morse, III, 
Ohlsson, and Lobanenkov 2002) raised the possibility that aberrant activation of BORIS 
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expression in tissues other than testis could be associated with tumour development 
(Pembrey 2002). BORIS transcription is indeed abnormally activated in varying 
proportions of a wide variety of cancers (Klenova, Morse, III, Ohlsson, and Lobanenkov 
2002). In addition, BORIS is defined as a novel member of the cancer testis (CT) gene 
family. An interplay of DNA-methylation and CTCF silencing in BORIS-positive cells that 
express other CT genes may indicate a common mechanism for transcriptional regulation 
of both BORIS and CT genes (Klenova, Morse, III, Ohlsson, and Lobanenkov 2002). 
Therefore, CTCF and BORIS may act successively to govern epigenetic states in normal 
male germ cell development, while the rivalry caused by aberrant activation of BORIS in 
soma is associated with cancer. 
Deregulation of BORIS/CTCF regulatory pathways observed in many cancers is 
associated with two events on two different chromosomes: a copy-gain/amplification at 
20q13 linked with activation of BORIS, and LOH at 16q22 linked with a decrease in 
CTCF dosage. These two events converge in deregulating the same pathway that involved 
CTCF targets recognized by the same 11 ZF domain shared by CTCF and BORIS 
(Klenova, Morse, III, Ohlsson, and Lobanenkov 2002). 
 
In this study, we investigated the expression of BORIS in normal and tumoral cell 
lines and tissues. Moreover, two transcriptional start sites were identified in the 5’ flanking 
region of this gene and two promoters were characterized in transient transfection reporters 
assays. In addition, we highlight the presence of an important alternative splicing of the 
mRNA of BORIS occurring strongly in normal testis. Results of this study provide the 
basis for a better understanding of the regulatory mechanisms of the BORIS factor in 
normal and tumor cells. 
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2. Materials and methods 
 
2.1. Cell lines and tissue samples 
 
The normal BJ fibroblast cell line and seventeen tumor cell lines were investigated in 
this study (osteosarcoma: U2-OS; Lung: HS520, SW2; colon: SW480, Co115, Co112; 
Blood: HL-60; breast: MCF-7, T47D; cervix: HeLa, A431; prostate: PC3; testis: NCCIT; 
ovary: OVCAR-3, OVMZ37, SK-OV-3, OVCA32). All these cell lines were grown in the 
medium recommended by ATCC (all products from Invitrogen, Basel, Switzerland). 
Normal and tumor tissues were obtained from the Tissue Bank of the Institute of Pathology 
of Lausanne. Twenty-four human normal tissue samples (bone marrow, bladder, heart, 
kidney, skin, colon, testis and ovary) and 26 tumor tissue samples (bladder, breast, colon, 
kidney, lung, testis, ovary and endometrium) were analyzed. The use of human tissue 
samples for this study was according to the guidelines of the ethical committee of the 
Medical Faculty of Lausanne. 
 
2.2. RT-PCR analysis for BORIS expression 
 
RNAs were extracted from frozen tissue or culture cells using the TRIzol LS Reagent 
(Invitrogen, Basel, Switzerland). One-step RT-PCR was performed with 200 ng of total 
RNA in 20 µl solution. BORIS expression was screened using the set of primers: RT-A3 
5’-AAGCCGCGAACGGAGACGAAG-3’ and RT-B3 5’-
ACGCCTTCATCCACTTCCTCTTT-3’. 
 
2.3. Identification of transcription initiation sites using RNA ligase-mediated 
rapid amplification of 5' cDNA ends (5' RLM-RACE)  
 
GeneRacer system (Invitrogen, Basel, Switzerland), based on RNA ligase-mediated 
and oligo-capping rapid amplification of cDNA, was carried out based on the 
manufacturer’s instruction. The kit ensures the amplification of only full-length transcripts 
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via elimination of truncated messages from the amplification process. Total RNA was 
dephosphorylated using calf intestinal phosphatase then decapped to target full-length 
messenger RNAs. An RNA oligonucleotide was then ligated to the full-length decapped 
mRNAs. Ligated mRNA was reverse-transcribed with a BORIS specific primer situated in 
the first exon (RACE-EX1 5’-CAGAGGTACGCTCGGCCTCCAAC-3’, -159 to -138). 
Then 5’ cDNA end was amplified by nested PCR using the GC-Rich PCR system (Roche) 
and with BORIS specific reversed primers (RACE-EX1N 5’-
GGCCTTTTTCCGGCATCAACT-3’, -79 to -59; RACE-N 5’-
TTGGGGTTGAAGTGGATGAGGAAG -3’, +1294 to +1271). Amplified products were 
separated by electrophoresis on 1% agarose gel and purified on SNAP column 
(Invitrogen). Purified PCR fragments were cloned in a PCR-TOPO vector (Invitrogen), 
sequenced and analyzed. 
 
2.4. Construction of luciferase reporter vectors and transfection assays 
 
Different fragments from the 5’-flanking region of the BORIS gene were prepared by 
PCR amplification. The amplification process introduced HindIII and Asp718 I sites in the 
5’ and 3’ ends respectively. All fragments were inserted into the pGL3-basic vector 
(Promega, Madison, WI) open with HindIII and Asp718I. HeLa, NCCIT and OVCAR-3 
cells were seeded in 12-well dishes at a concentration of 300’000 cells / well, one day 
before the transfection. Then, they were transiently transfected with the different constructs 
(0.75 µg / well) with the jetPEI Cationic Polymer Transfection reagent (4 µl / well) 
(PolyPlus-transfection, Illkirch, France) according to the manufacturer’s instructions. All 
experiments were performed at least three times. The pRL-tk vector (0.25 µg / well) 
(Promega, Madison, WI) was co-transfected as an internal control for transfection 
efficiency. Luciferase assays were performed using the Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI). To compare the results the mean values of relative 
luciferase activity was used. The levels of the different constructs were compared to the 
level of the pGL3-control vector containing the firefly luciferase gene under the control of 
the SV40 early promoter and to the level of the pGL3-basic vector, a promoterless and 
enhancerless luciferase vector. 
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2.5. DNA methylation analysis 
 
DNA was extracted from frozen tissue or culture cells using the DNeasy tissue kit 
(Qiagen, Hilden, Germany). Two µg of DNA were modified in 40 µl of water with sodium 
bisulfite as previously described (Benhattar and Clement 2004; Clement and Benhattar 
2005). After bisulfite modification, PCR on BORIS promoter B was performed with the 
primers 5’-CCTCCCCCAACCCTACCTAA-3’ and 5’-
GTTTTTGGTTTGTGGGTTTTGTT-3’ using the master mix (Promega) with a final 
concentration of 5% DMSO, under the following PCR conditions: 35 cycles of 94°C for 30 
sec, 54°C for 45 sec and 72°C for50 sec. The first PCR product diluted on 1/50 was 
amplified by semi-nested-PCR with the primers 5’-CACTACCACCCTCCACTCTC-3’ 
(+931 to 1950) and 5’-GTTTTTGGTTTGTGGGTTTTGTT-3’ (+964 to +980). Each PCR 
product was analyzed by MS-SSCA and MS-DBA (Benhattar and Clement 2004; Clement 
and Benhattar 2005) as previously described. In the MS-DBA approach Two 3’-end DIG-
labeled probes, 5’-AACCCGACGACGACCGAC-3’ and 5’-
CCAACCCAACAACAACCAAC-3’, were used to recognize the methylated and the 
unmethylated DNA, respectively.  
 
2.6. Splicing analysis 
 
Splicing analysis of the intron 0 was performed with 2 sets of primers: RT-A1 5’-
GCCCTCGTGCCCTCCTTACT-3’ (-1357 to -1337, downstream the transcriptional start 
site of promoter A) and RT-A2 5’-CAGAGCCCACAAGCCAAAGAC-3’ (-878 to -858, 
downstream the transcriptional start site of promoter B) for the upper strand, and RT-B1 
5’-GGCCTTTTTCCGGCATCAACT-3’ (+59 to +79,within the first exon) for the lower 
strand. Splicing analysis within the structural gene was performed by RT-PCR with the 
following primers: SPLI-A 5’-GGTGGCCAGTGAAGACAGTAAG-3’ (end of the exon1) 
and SPLI-B 5’-CAGGCGACAGGAAACATCTCT-3’ (beginning of the exon 10). 
Analysis of splicing of the exon 6 was done on tissues and cell lines with the RT-EX5 5’-
CGCCATGTCCGATCCCACACT-3’ (exon5) and RT-EX7 5’-
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GGGCATAGCGTTCATGGAAGAC-3’ (exon7) primers. Sequencing of all PCR products 
was done on an ABI Prism 3100 sequencer (Applied Biosystems, Foster City, CA). 
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3. Results 
 
3.1. BORIS expression in normal and tumor cells 
 
Various cell lines, normal and tumor tissue samples were tested by RT-PCR for 
BORIS expression. In normal tissues, only testis and ovaries of young women were found 
positive for BORIS. In tumor tissues, only those from testis, ovary, endometrium and 
breast (2/7) were found positive for BORIS. In cell lines, the normal fibroblast BJ was 
BORIS negative, 6 tumor cell lines had a strong BORIS expression (U2-OS, osteosarcoma; 
HS520, lung cancer; NCCIT, testicular cancer; and OVCAR-3, OVMZ37, OVCA32, ovary 
cancers), and a background expression of BORIS was seen in the other cell lines (Table 1). 
 
3.2. Identification of transcription initiation sites 
 
To identify transcription initiation sites, 5’ RLM-RACE was performed. This method 
has a major advantage over other methods of mapping transcription start sites, such as 
primer extension, nuclease protection assays, or traditional 5' RACE, in that only authentic 
capped 5' ends of mRNAs are detected. The technique was based on RNA ligase-mediated 
(RLM-RACE) and oligo-capping rapid amplification of cDNA ends methods, and results 
in the selective ligation of an RNA oligonucleotide to the 5’ ends of decapped mRNA. This 
method allowed the amplification of only full-length transcripts via elimination of 
truncated messages. The 5’ RLM-RACE assays were performed on total RNA extracted 
from a normal testis tissue, and from NCCIT and OVCAR-3 tumor cell lines. An estimated 
150bp PCR product was obtained and, after cloning and sequencing, the first start site was 
identified at +899 bp from the ATG translational start site (Fig. 1). Using the GC-Rich 
PCR system and nested-primer upstream of the first transcription start site, an estimated 
200bp PCR product was generated. No amplification was observed with NCCIT. This new 
site was mapped to +1447 nucleotides upstream of the ATG translation start codon (Fig. 
1).  
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Table 1. BORIS expression in normal and tumor cell lines and tissues. 
 Name Tissue origin BORIS mRNA 
expression 
Methylation of 
promoter B 
Normal cell line BJ fibroblast - + 
 
 
Tumor cell lines 
with background 
level of BORIS 
expression 
SW2 
SW480 
Co115 
Co112 
HL-60 
MCF-7 
T47D 
HeLa 
A431 
PC 3 
SK-OV-3 
 
lung 
colon 
colon 
colon 
blood 
breast 
breast 
cervix 
cervix 
prostate 
ovary 
+/- 
+/- 
+/- 
+/- 
+/- 
+/- 
+/- 
+/- 
+/- 
+/- 
+/- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
Tumor cell lines 
with high level of 
BORIS expression 
U2-os 
HS-520 
NCCIT 
OVCAR-3 
OVMZ37 
OVCA32 
 
osteosarcoma 
lung 
testis 
ovary 
ovary 
ovary 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
Normal tissues 
 bone marrow 
bladder 
heart 
kidney 
skin 
colon 
testis 
ovary (young 
woman) 
 
- 
- 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
 
Tumor tissues 
 bladder 
lung 
colon 
kidney 
breast 
testis 
ovary 
endometrium 
 
- 
- 
- 
- 
+ (1/6) 
+ 
+ 
+ (1/3) 
+ 
+ 
+ 
+ 
- (1/6) 
- 
- (1/3) 
+ 
* -: no detectable expression; +: medium to high expression; +/-: expression at the background level 
** +: methylation; -: partial demethylation (at least 10%) 
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Figure 1. Nucleotide sequence of the 5′-upstream region of the human BORIS gene is shown together with a 
portion of the coding region. Potential binding sites of transcriptional regulatory proteins predicted by the 
MatInspector program are shown in boxes. The ATG translational start site is in bold and is designated as 
nucleotide +1. The main start sites for transcription, as determined by 5’-RACE, are indicated by arrows. The 
transcribed sequences are underlined. Nucleotides of the CpG island are shaded in gray.  
 
 
 
CTGTCCAGCCCACCCCAACCCATCTCCTGGAACCCTTGTAAGGTCTCTCCCCGCCCAGTCCCTGCTGCGTCCATTTCCCACCCAAGTCTCTAAGCACCCC
ATTCCCCATCCTCTCCCATTGCCCCTCCTTATCCTCCCCCCGACCCCAGGTCTCCCAGCGCCCCCTGCAAGGCCCTTCTTCCCTCCTTACCCATTCCCCA
CCCCTGCCCCGCCTAGGTCTCCCAGCGCCCCCTGCAGGCCCTCCTCCCCTTCTTATCCAAGCCCCCCAGGTTCCCCAGCGCCCCCTGCAGGCCCTCCTCC
CTCCTTATCCATTCCCCACCAGGTCTCAGTGCCCCCTGCAGGCCCTTCTCCCCTCCTTATCCATTCCCTCCACCCCCGCCCAAGTCTCCCAGCGCCCTCT
CCAGGCCCTCCTCCCTCCTTATCCTTTCCCCTCCAGGTCTCCCAGCGCCCCTTGCAGGCCCCCCTCCACTCCTTATCCATTCCCCGCCAGCGTCTCCCAG
TGCCCCTTGCGGCCATCCTCCCCTCCTTATCCATTTCCCCCCCAGGTCTCCCAGCGCCCCCTGAGGGCCCTCTTCCCCTCCTTATCCATTCCCCCCAAGG
TCTCCCAGCGCCCCCTACAGGGCTCTCCTCCCCTCCTCATTCCACCCCTCCCCCCAGTATCTCAGTGCCTCCTGCGGGCCCTCCTCCCACCCTTATCCAT
TCCCCTCCCCTAGGTCTCCCAGCGCCCCCTGCAGGACCCCCTCCCCTCCTTATCCATTCCCCCACAAGGTATCCCAGCGCCCCCTGCAGGGCTCTCCTCC
CCTCCTCATTCCACCCCTCCCCCCAGTCTCTCAGTGCCTCCTGCGGGCCCTCCTCCTCTCCTTATCCATTCCCCTCCCCCAGGTCTCCCAGCACCCCTTG
CAGGCCCTCCTCCCCTCCTTATCCATTCCCCTCCCCCAAGTCTCCCAGCACCCCTTGCAGGCCCTCCTCCCCTCCTTATCCATTCCCCCACCCCTCGCCC
CCCGCAGGGCTCCCAGGGCCCCCTGCAGACCCTCCTCCCCTTGTCCTCTCCTATTCATCCCCCAGGTCTCCCAAGAACCCCTGCAGACCCTCCTCCCCTC
CTTATCCATTACCCTCACCTCAGGTCTCCCCGCCCCCCTGCAGGGCTCTCCCCTCCTCATTCCACCCCTCCCCCTGGTATCTCAGTGCCTCCTGTTGGCC
CTCCTACCCTCCTTATCCATTCCCCTCCCCTAGGTGTCACAGGCCCCCTGCAGGCCCCCCTCCCCTCCTTATCCATTACCCACCACCCCCCTCAGGTCTC
CCAGCCCCCCTGCAGGGCTATCCTCCCCGCCTCATTCCACCCCTCCCCCCCTCATTCCACCCCTCCCCCCAGTATCTCAGTGCCTCCTGTGGGCCCTCCT
CCCCTCCTTATCCATTCCCCCTCAGATCTCCCAGGCCCCCTGCAGGCCCTCGTGCCCTCCTTACTTCCCCCCCGGGTCTCCCAGCGCCCCCTGCGGGGCC
CTCCTCCCTTCCTCATCCACTTCAACCCCAAGGTATTTCCGTGCCCCTGCAGGACCCTCCTCCCCTCCTTAGGCGCTCCCCCACTACCCAGTCTTCCAGT
GCCCTGCAGGCTCTCCTCCTCTCCTTATCCACCCCCACCCCAGGTCTCCCAGTGCCCTGTATGGGACCCTCCTCCCCTCCTCATCCACCCCCCCAGGTCC
ACCAGTGCCCCCTCTGGGGTCCTCCTCATCCGTGCTCCCCCTCCCCCTCCCTACTCCCCTTCCCCCCTGCCCCCACAGTACATCACCCCCTCCCCCAACC
CTGCCTGGCTCCGCCCCCTTCACGCCCCCTCTTTTCCGCTCCGCGCCTGCGCACTGCCACCCTCCACTCTCGCGCCAGCCCGGCGGCGGCCGGCTGTGGG
CTGCAGCACGCGGTGCACGAGGCAGAGCCCACAAGCCAAAGACGGAGTGGGCCGAGCATTCCGGCCACGCCTTCCGCGGTGAGGGGCCAGTCCCGGTCAA
GCCCACCTGCTCTCCTCCAAGAGCATGGGCTGTTCTGGGCGTGGGCGGAGGGAGGGGCTGGCCGGAAAGGCCCAAGGGCGGGCGGCAGACGCTGAGGGGC
TGCCTGGGAGGGTCGGGTCGGGGCGGGGCGTGGGGGGCAGGGTAAAGCAGGGGCCCTGCCAGGCCTCCGAGGGAGTGTGCTTGGTCTGGCCGAGGGCTGC
TTGGCCAAGTCTGGGTGGGCTCGAGGCCACTAGGCCCAAAGCCTGCCTGGCTCTGAGGGTGCTAGGTCTAGAACCGTGCACGAGGGGAATGCCTGCTCGG
GCCCGAACCTCGCTGGGCGCCGGGTGTGCACTGGCCCGGGGCCTGCTTGGACCTGAAACTTGCTAGGCCCAGGATATGCACTGGCCGAGAGCCTGCTGGG
CCCAAACCTTACTAGGCCCAGGATGTTCACTGACTGAACCGGCTCAGGCCTAACCTTGCTAGGCCCAGGATATGCACTGGGCCAGAGTGTGCTCAGGCGG
AACCTTGCCAGGCGCAGGATGTGTGCTGGCCCTAAGCCTGCTGAGGCCCAAACCTGTTCGTTCTAGGGTTTTGTACAAAATCCTGCTTTAGCCTAAATCC
TGCTTAGCCTTGACCCCCTCCTAGACCCAAGCCAGATCAGCATTGTTCTGACCCTACTAAGTCCAAAACCTTTTGAGGCCAGACCTTGTTTCAACTCCAA
AGCCTGCTAGGTTCCAGCACCCCCCGCATCCCTCCTCATACCACCCCCTTCTCCCCCCTATGGAAACCGCTTGCTTATTTTTCAAACAGGCCAAGTCATT
ATGGCAGCCACTGAGATCTCTGTCCTTTCTGAGCAATTCACCAAGATCAAAGAACTCGAGTTGATGCCGGAAAAAGGCCTGAAGGAGGAGGAAAAAGACG
GAGTGTGCAGAGAGAAAGACCATCGGAGCCCTAGTGAGTTGGAGGCCGAGCGTACCTCTGGGGCCTTCCAGGACAGCGTCCTGGAGGAAGAAGTGGAGCT
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3.3. Characterization and transcriptional activity of BORIS promoters  
 
To functionally characterize the two putative promoters, different fragments of the 
regions upstream the 2 transcriptional start sites were cloned into a firefly luciferase-
expressing vector (Fig. 2). Transfections with pGL3 (SV40 promoter) vector were carried 
out as a control. Transfection assays were carried out into two BORIS-positive cell lines 
(NCCIT and OVCAR-3) and a very weakly positive one (HeLa). As shown in Figure 2, 
transfection of these cell lines with a construct containing 510 bp of the upstream 
sequences –1370 to –861, produced substantial levels of activity (23 to 40% of that of 
pGL3). To better define the cis-acting sequences, smaller promoter constructs were 
generated. A strongest luciferase activity (38 to 50% of that of pGL3) was obtained with 
the construct containing 246 bp of BORIS sequences (–1106 to –861), while significantly 
reduced activity was produced by a construct containing only 136 bp of BORIS sequences 
(-996 to –861). These results indicate that the sequences responsible for BORIS promoter 
B regulation are contained within a core region of 111 bp, situated 996 to 1106 bp 
upstream of the ATG translational start site. To study transcriptional regulation by 
promoter A, two further reporter constructs were investigated (Fig. 2). The larger construct 
(-2071 to –1276) showed a transcriptional activity in the three cell lines, while only 
background levels of luciferase activity was observed with the construct containing 138 bp 
of BORIS sequences (-1413 to -1276). Nevertheless, activity of promoter A was 
significantly higher in NCCIT than in OVCAR-3 and HeLa. These results suggest that the 
level of transcriptional activity of the promoter could be cell specific. Sequence analysis, 
using MatInspector, revealed that the BORIS promoter regions contain putative binding 
sites for several transcription factors (Fig. 1). The promoter A contains binding sites for 
SP1, AP-2, CREB and a huge number of CDP/cut (CCAAT displacement protein). 
Notably 14 potential binding sites for the CDP/cut factor are present in the highly 
repetitive promoter A region. The promoter B is situated in a GC-rich region and contains 
binding sites for Sp1, AP-2, NF-κB, N-Myc and p53.  
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Figure 2. Determination of BORIS promoters A and B activities. The assay was performed by transient 
expression of luciferase reporter constructs in HeLa, NCCIT and OVCAR-3 cell lines. Left: schematic 
representation of BORIS promoter luciferase reporter constructs. Numbers indicate positions of nucleotides 
of the 5’-flanking region of the BORIS gene, as shown in fig. 2. Right: relative luciferase activities compared 
with the pGL3 control vector activity, which was considered to have 100% activity. 
 
 
3.4. Regulation of promoter B by DNA methylation 
 
The GC-rich promoter B is localized in a CpG island (Fig. 1), suggesting that 
methylation may be involved in regulation of BORIS expression. DNA from 18 cell lines, 
24 human normal tissue samples and 26 tumor tissue samples were extracted and analyzed 
by methylation-sensitive single-strand conformation analysis (MS-SSCA) and 
methylation-sensitive dot blot assay (MS-DBA) after sodium bisulfite modification 
(Benhattar and Clement 2004; Clement and Benhattar 2005). Hypomethylation of 
promoter B was observed in normal testis and testis tumors, and in one ovary and one 
breast tumor (Fig. 3A). In all the cell lines and other tissues investigated, the promoter B 
region was found totally methylated. To confirm the regulation of promoter B by DNA 
methylation, a treatment with 5-azadC of two negative or only weakly BORIS-positive cell 
lines (HeLa and Co115) was performed. The result showed a partial demethylation of the 
promoter B and a strong activation of BORIS expression in both cells (Fig. 3B). 
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Figure 3. A: BORIS expression and methylation patterns of BORIS promoter B in human tissues and cell 
lines. Lanes 1-2: MS-SSCA and MS-DBA unmethylated and fully methylated controls respectively, obtained 
from plasmids containing BORIS promoter B sequences; lanes 3-4: NCCIT and OVCAR-3 cell lines; lanes 
5-8: normal tissues, respectively colon, skin, and two testis; lanes 9-13: tumor tissues, respectively bladder, 
testis, ovary, breast, colon. BORIS mRNA was detected by RT-PCR, with β-actin as internal control. B: 
BORIS expression and methylation patterns of BORIS promoter B in two BORIS-negative cell lines treated 
with 5-azadC. Lanes 1-2: MS-SSCA unmethylated and fully methylated controls respectively; lane 3: HeLa 
cells; lane 4: HeLa cells after 5-azadC treatment; lane 5: Co115 cells; lane 6: Co115 cells after 5-azadC 
treatment. BORIS mRNA was detected by RT-PCR, with β-actin as an internal control. 
 
 
3.5. Analysis of splicing variant transcripts 
 
By RT-PCR, we observed that transcription by promoters A and B lead always to the 
same splicing of intron 0 (data not shown). To look whether the different promoters can 
lead to different alternative splicing forms, BORIS mRNA was amplified from the end of 
the first exon to the beginning of the last exon with the primers SPLI-A and SPLI-B. In 
addition to the full-length transcript, an alternatively spliced form of the BORIS gene 
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lacking exon 6 was observed in a normal testicular tissue. Then, to determine the 
occurrence of this alternative splicing, we tested BORIS-positive cells and tissues with a 
specific set of primers (RT-EX5 and RT-EX7). Full-length transcripts were detected in all 
these samples (Fig. 4A). An alternatively spliced form lacking exon 6 was observed in 
normal testis and testis tumors and in the endometrial carcinoma, while only a background 
of expression was detected in the other tumors and in all cell lines (NCCIT, OVCAR-3, 
OVMZ37, HS520 and U2-OS) investigated (Fig. 4A). Interestingly, a positive correlation 
was observed between hypomethylation of the promoter B and presence of this truncated 
transcript.  
To determine if a link between alternative promoters and alternative transcripts might 
exist, additionnal RT-PCR experiments were performed. Amplification was done with 
upstream primers situated in the 5'-UTR regions and specific for either promoter A or B. A 
semi-nested PCR was performed to visualize the alternative transcripts. Full-length 
transcripts were observed in the analyzed samples (NCCIT, OVCAR-3, normal testis) with 
both promoters, A and B (Fig. 4B). A similar observation was done with the alternatively 
spliced transcript, but the expression level of this spliced form was high in the testis, where 
promoter B is not methylated and only at a background level in OVCAR-3 and NCCIT, 
where this promoter is methylated (Fig. 4B). This suggest that the spliced form lacking 
exon 6 is expressed at a significant level only when promoter B is not methylated, and 
active. 
 
 
Figure 4. A: study of the exon 6 deletion by RT-PCR in BORIS-positive human tissues and cell lines. Lanes 
1-4: four BORIS-positive cell lines, respectively NCCIT, OVMZ37, U2-os, HS520; lanes 5-6 : normal testis 
samples; lane 7 : control RT-PCR; lanes 8-10 : testis tumor samples; lanes 11-13 : ovary tumor samples; lane 
14: endometrium tumor sample. B: study of the link between the alternative promoters and the exon 6-
deleted transcript. Lane 1: NCCIT cell lines; lane 2: OVCAR-3 cell lines; and lane 3: normal testis sample. 
FL = Full-Length transcript; Del-ex6 = exon 6–deleted transcript; M: 100bp ladder marker. 
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4. Discussion 
 
BORIS is specifically expressed in male germ cells and is involved in the epigenetic 
reprogramming (Loukinov et al 2002). In this study, the expression of BORIS mRNA was 
examined in human tissues and cell lines. BORIS transcripts were detected not only in the 
normal testis, but also in the ovary of young woman and in numerous tumor tissues and 
cell lines. BORIS mRNA expression was high in testicular and ovarian tumors, as well as 
in some breast and endometrial tumors. Likewise, high BORIS expression was detected in 
tumor cell lines of testicular or ovarian origin, while low expression was noticed in other 
tumor cell lines. 
This selective expression of BORIS led us to study the transcriptional regulation of 
this gene. RLM-RACE PCR identified two transcriptional start sites at 899 bp and 1447 bp 
upstream of the ATG. Cloning of sequences upstream of these transcriptional start sites 
indicated the presence of two promoters. The proximal promoter B appears regulated by 
methylation and contains putative binding sites for Sp1, p53 and AP-2. AP-2 participates 
in gene regulatory mechanisms during development and cellular differentiation (Huang and 
Domann 1998). Sp1 is a ubiquitous transcription factor which normally leads to 
constitutive gene activation (McKnight and Tjian 1986). Hypomethylation of promoter B 
correlated with BORIS mRNA expression in normal testis and testis tumors. However, this 
promoter was methylated, and thus inactive, in the majority of tumor tissues and cell lines 
that expressed BORIS. This promoter B therefore seems to modulate BORIS expression in 
normal tissue. 
Distal promoter A showed transcriptional activity in transiently transfected cells. 
However, the transcriptional level depended on the cell type. Activity of this promoter was 
higher in teratocarcinoma testis cell line NCCIT, than in the cervix- or the ovary- 
adenocarcinoma cell lines (respectively HeLa and OVCAR-3). Moreover, the promoter A 
sequences contained SP-1 and CDP/cut factor binding sites. The CDP/cut family 
constitutes a highly conserved group of homeoproteins that are involved in cell growth, 
differentiation and development (Nepveu 2001). CDP/cut proteins function as 
transcriptional repressors for a large number of genes including p21 and c-myc (Coqueret 
et al 1998; Dufort and Nepveu 1994). Many genes regulated by CDP/cut are expressed in 
highly differentiated cells (Zhu et al 2004). In tumor cell lines the BORIS promoter B was 
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always fully methylated, leaving promoter A could for BORIS to be transcripted from. 
These observations suggest that activation of the promoter A only is characterizes a 
pathological situation such as neoplasia. The level of BORIS mRNA was found to differ 
significantly between tumor cell lines from germ-cell  and non-germ-cell. We speculate 
that tumors derived from BORIS-positive tissue such as the testis contain undifferentiated 
cells in which lack the CDP/cut factor. In that case, promoter A is functional, because 
promoter B is fully methylated. This might be the case in tumors derived from germinal 
tissues (testis, ovary), or from frequently regenerative tissues (endometrium), that contain 
high levels of BORIS mRNA. We detected two transcripts of BORIS mRNA: in addition 
to the full-length transcript, an exon 6-deleted transcript was identified. The proteins differ 
only in the absence of the exon 6 encoded polypeptide sequence as the splice variant 
remain in frame. Expression of exon 6-deleted transcript was expressed only when 
promoter B was active. An active promoter A resulted in full-length with only traces of the 
spliced variant detectable. How the balance between transcription from promoter A and 
promoter B is kept is presently unknown. 
In summary, we show that the BORIS gene has two promoters that govern 
transcription of two mRNA spliced variants that produce proteins which might have 
different functions. Promoter B is involved in the regulation of the BORIS gene in normal 
tissues and promoter A might be implicated in BORIS activation during the 
carcinogenesis. BORIS might play a significant role in the epigenetic reprogramming, 
during normal development and in the development of cancer. 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
This work was supported by a grant from the Swiss National Science Foundation (Grant 
number: 3100AO-101732). The authors thank Patricia Martin, Sabrina Streuli and Melanie 
Kohler for skillful technical assistance. 
CHAPTER VI 
 200
5. References 
 
Bell,A.C., West,A.G., Felsenfeld,G., 1999. The protein CTCF is required for the enhancer 
blocking activity of vertebrate insulators. Cell 98, 387-396. 
Benhattar,J., Clement,G., 2004. Methylation-sensitive single-strand conformation analysis: 
a rapid method to screen for and analyze DNA methylation. Methods Mol. Biol. 
287, 181-193. 
Clement,G., Benhattar,J., 2005. A methylation sensitive dot blot assay (MS-DBA) for the 
quantitative analysis of DNA methylation in clinical samples. J. Clin. Pathol. 58, 
155-158. 
Coqueret,O., Berube,G., Nepveu,A., 1998. The mammalian Cut homeodomain protein 
functions as a cell-cycle-dependent transcriptional repressor which downmodulates 
p21WAF1/CIP1/SDI1 in S phase. EMBO J. 17, 4680-4694. 
Dufort,D., Nepveu,A., 1994. The human cut homeodomain protein represses transcription 
from the c-myc promoter. Mol. Cell Biol. 14, 4251-4257. 
Filippova,G.N., Fagerlie,S., Klenova,E.M., Myers,C., Dehner,Y., Goodwin,G., 
Neiman,P.E., Collins,S.J., Lobanenkov,V.V., 1996. An exceptionally conserved 
transcriptional repressor, CTCF, employs different combinations of zinc fingers to 
bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol. 
Cell Biol. 16, 2802-2813. 
Hark,A.T., Schoenherr,C.J., Katz,D.J., Ingram,R.S., Levorse,J.M., Tilghman,S.M., 2000. 
CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 
locus. Nature 405, 486-489. 
Huang,Y., Domann,F.E., 1998. Redox modulation of AP-2 DNA binding activity in vitro. 
Biochem. Biophys. Res. Commun. 249, 307-312. 
Klenova,E.M., Morse,H.C., III, Ohlsson,R., Lobanenkov,V.V., 2002. The novel BORIS + 
CTCF gene family is uniquely involved in the epigenetics of normal biology and 
cancer. Semin. Cancer Biol. 12, 399-414. 
Lobanenkov,V.V., Nicolas,R.H., Adler,V.V., Paterson,H., Klenova,E.M., Polotskaja,A.V., 
Goodwin,G.H., 1990. A novel sequence-specific DNA binding protein which 
interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5'-
flanking sequence of the chicken c-myc gene. Oncogene 5, 1743-1753. 
Loukinov,D.I., Pugacheva,E., Vatolin,S., Pack,S.D., Moon,H., Chernukhin,I., Mannan,P., 
Larsson,E., Kanduri,C., Vostrov,A.A., Cui,H., Niemitz,E.L., Rasko,J.E., 
Docquier,F.M., Kistler,M., Breen,J.J., Zhuang,Z., Quitschke,W.W., Renkawitz,R., 
Klenova,E.M., Feinberg,A.P., Ohlsson,R., Morse,H.C., III, Lobanenkov,V.V., 
2002. BORIS, a novel male germ-line-specific protein associated with epigenetic 
BORIS expression and promoters characterization 
 201
reprogramming events, shares the same 11-zinc-finger domain with CTCF, the 
insulator protein involved in reading imprinting marks in the soma. Proc. Natl. 
Acad. Sci. U. S. A 99, 6806-6811. 
McKnight,S., Tjian,R., 1986. Transcriptional selectivity of viral genes in mammalian cells. 
Cell 46, 795-805. 
Nepveu,A., 2001. Role of the multifunctional CDP/Cut/Cux homeodomain transcription 
factor in regulating differentiation, cell growth and development. Gene 270, 1-15. 
Pembrey,M.E., 2002. Time to take epigenetic inheritance seriously. Eur. J. Hum. Genet. 
10, 669-671. 
Vostrov,A.A., Quitschke,W.W., 1997. The zinc finger protein CTCF binds to the APBbeta 
domain of the amyloid beta-protein precursor promoter. Evidence for a role in 
transcriptional activation. J. Biol. Chem. 272, 33353-33359. 
Vostrov,A.A., Taheny,M.J., Quitschke,W.W., 2002. A region to the N-terminal side of the 
CTCF zinc finger domain is essential for activating transcription from the amyloid 
precursor protein promoter. J. Biol. Chem. 277, 1619-1627. 
Zhu,Q., Maitra,U., Johnston,D., Lozano,M., Dudley,J.P., 2004. The homeodomain protein 
CDP regulates mammary-specific gene transcription and tumorigenesis. Mol. Cell 
Biol. 24, 4810-4823. 
 
 
 203
 
 
 
 
CHAPTER VII 
 
 
 
 
 
CONCLUSION AND PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VII 
 204
Reactivation of telomerase is mechanism used by most cancer cells to achieve 
indefinite growth and this generally occurs early in tumorigenesis. The catalytic subunit of 
telomerase, hTERT, is the limiting factor for its activation (Bodnar et al., 1998;Counter et 
al., 1998). Numerous reports have presented a wide range of mechanisms potentially 
involved in the transcriptional control of hTERT. Between, on the one hand, the 
identification of activators and repressors that bind to the hTERT 5’ regulatory region, and 
on the other the role of CpG methylation and histone acetylation, an abundance of 
regulatory models have been suggested (Cong and Bacchetti, 2000;Dessain et al., 
2000;Devereux et al., 1999;Ducrest et al., 2002;Goueli and Janknecht, 2003;Goueli and 
Janknecht, 2004;Guilleret et al., 2002;Lv et al., 2003;Nishi et al., 2004;Pardal et al., 
2003;Poole et al., 2001;Takakura et al., 2001;Yatabe et al., 2004). Regulation of hTERT 
transcription, of its transport to the nucleus, the assembly of the telomerase holoenzyme, its 
recruitment to the telomere, and the role of post-translational modification of hTERT 
protein are areas of intense investigation. No single mechanism can explain the silence of 
telomerase in most somatic cells and its reactivation in tumor cells. The study presented in 
the thesis illustrates the complexity of the hTERT transcriptional regulation in normal and 
tumor cells. 
 
 
We first addressed the characteristics of the hTERT regulatory sequences. We used 
promoter sequences of different length with or without the first and the second exons in 
transient transfection experiments. We distinguished two new regions involved in the 
regulation of hTERT expression: the most distal upstream promoter region that plays a role 
in the regulation of hTERT mRNA splicing, and the first two exons of the hTERT gene that 
play an important role in the transcriptional regulation of its expression. Of interest is in 
this context the inhibitory region encompassing the hTERT gene itself. We then 
characterized the region that might be involved in the repression of hTERT in normal and 
its activation in cancer cells. We demonstrated that hTERT repression by the exonic region 
is independent of the promoter or cell-type, and hypothesize that the nucleosome structure 
plays a role. Further analysis showed that CTCF binds hTERT exon 1 and 2, and inhibits 
hTERT transcription in normal telomerase-negative cells. As yet, CTCF is the only factor 
that can repress hTERT transcription independent of the cell type, in normal and tumor 
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cells. As hTERT regulatory sequences are located in a CpG island, and binding of CTCF is 
influenced by methylation of the CpG sites (Kanduri et al., 2000), we examined the 
methylation status of hTERT regulatory sequences in different cell types and its 
implications on CTCF binding. We found that CTCF does not bind to the methylated first 
exon of hTERT. Moreover, we found that only telomerase-positive tumor cells were 
methylated, whereas normal cells were unmethylated. These results confirmed previously 
published data (Dessain et al., 2000;Devereux et al., 1999;Guilleret et al., 2002;Nomoto et 
al., 2002). In transient transfection assays, the full methylation of the hTERT promoter 
totally inhibits its activity. Detailed mapping of methylated sites in the 5'-region of the 
hTERT promoter showed that not all CpG sites are methylated in telomerase-positive cells. 
A region between –165 to –80 bp upstream of the translation start site was found 
hypomethylated in cancer cell lines and might allow some transcriptional activity of the 
promoter. Methylation of the first exon of hTERT interferes with CTCF binding, and 
partial demethylation of the promoter allows a low transcriptional activity, similar to what 
we observed in vivo. Although the hTERT CpG island methylation is an important factor 
required for the hTERT activation, it is not sufficient by itself. ALT-telomerase-negative 
osteosarcoma cells have a methylation profile similar to that of telomerase-positive cancer 
cells, but they do not express hTERT. In these cells, transient transfection of the 5’-
flanking region of the hTERT promoter decreases its transcriptional activity, since this 
effect is not observed in telomerase-positive tumor cells. Factor(s) activating the hTERT 
promoter seem to be necessary for its activation, but not present in all cell types. 
A role for CTCF in the regulation of hTERT expression seems not to be linked only 
to the methylation status of hTERT. Methylation analysis of ovarian and testis cancer 
tissues and cell lines showed the hTERT promoter and first exon region not to be 
methylated. As CTCF and its paralogue BORIS are expressed only in an exclusive manner 
in normal spermatocytes (Loukinov et al., 2002), we studied the BORIS effect on hTERT 
transcription in ovarian and testis cancer cell lines. We found that BORIS and CTCF are 
co-expressed, and probably compete for binding to the hTERT exon 1. Moreover, transient 
expression of BORIS in normal cells induces the expression of full-length hTERT mRNA. 
This indicates that BORIS is directly involved in the activation of hTERT transcription and 
in competing with CTCF binding and thus alleviating the CTCF block.  
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It has been suggested that abnormal co-expression of BORIS and CTCF might 
disrupt the CTCF-mediated gene silencing during development and tumorigenesis 
(Klenova et al., 2002). As BORIS and CTCF are both involved in hTERT regulation and as 
BORIS seems to be involved in deregulation of epigenetic in cancer cells, we investigated 
BORIS expression in normal and cancer cells. We found that BORIS transcripts are 
present at a high level in normal testis and in testicular, ovarian and endometrial cancers, at 
an intermediate level in ovaries of young women, at a very low level in most cancers and 
cancer cell lines, but not at all in most normal tissues (colon, breast, kidney, prostate, brain, 
lung, lymph node, heart…). We then characterized the promoter region of BORIS and 
found two distinct promoters. Promoter A (the most upstream promoter), shows 14 
potential binding sites for the CCAAT displacement protein (CDP) factor. Promoter B 
(proximal promoter) is situated in a CpG island and is regulated by DNA methylation. 
Transcription from promoter A was found in most BORIS-positive cells. Promoter B was 
mostly hypomethylated in normal testicular tissues and germ cell tumors, in line with 
BORIS expression. Multiple transcripts were found promoter dependent. One splice 
variant, lacking exon 6, was strongly expressed only when promoter B was 
hypomethylated. Exon 6 encodes a zinc finger, which might be involved in the DNA 
binding of BORIS.  
 
In summary, we have investigated the implication of CTCF, BORIS and DNA 
methylation, in the regulation of hTERT transcription in normal and most cancer cells. Our 
model for the regulation of hTERT expression is elaborated in Figure 14. In our model, 
CTCF is a central player in the hTERT regulation. In telomerase-negative somatic cells, 
CTCF inhibits hTERT transcription, preventing telomerase activation. In telomerase-
positive tumor cells, the inhibition by CTCF is counteracted either by DNA methylation of 
its binding sites, or by competition with other factors, such as BORIS in ovary and testis 
cancer cells. Telomerase-positive lymphoma tumor cell lines were found to have 
unmethylated hTERT regulatory sequences and not to express BORIS (unpublished 
results). The inhibition of hTERT by CTCF in these cells might be disrupted by another 
factor or mechanism that remains to be identified. 
Although this model explains the hTERT regulation in almost tumor cell types, 
several points remain to be further clarified. 
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Figure 16: Hypothetic model of hTERT regulation in normal and cancer cells. In normal cells, hTERT 
promoter and gene are not methylated, CTCF can inhibit the transcription. In most tumor cells, hTERT 
promoter and gene are hypermethylated, except in a region upstream of the transcription start site. The 
methylation releas CTCF and some transcritpion of hTERT occurs. In ovary and testis cancer cells, hTERT is 
not methylated, but the BORIS factor prevent the binding of CTCF, allowing transcritpion of hTERT. Green 
arrows represent the transcriptional start sites; empty circles represent unmethylated CpG sites and solid 
circles the methylated ones. 
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To go further in the hTERT regulation model, it would be interesting to study the 
distal upstream promoter region as a regulator of hTERT splicing and the ALT-pathway. At 
least 7 alternatively spliced mRNA variants of hTERT (4 insertions and 3 deletions [α, β 
and α/β]) can co-exist. Furthermore, the presence of these alternative forms is regulated 
during development, depending on the tissue type (Ulaner et al., 1998;Ulaner et al., 
2000;Wick et al., 1999). These differences could be due to specific factor(s) that bind the 
distal upstream promoter region of hTERT. A recent study suggests that cells activate ALT 
pathway because they lack some factors that enable the activation of hTERT transcription 
(Stewart, 2005). This hypothesis is in agreement with our observations. Indeed, a heat 
shock in a telomerase-negative oseosarcoma cell line induced an increase of the hTERT 
promoter activity in luciferase reporter assays (unpublished results). It would be interesting 
to study hTERT expression in telomerase-negative cancer cells after a heat shock. 
Identification of such factors will lead to a better understanding as to how ALT-cells 
immortalize during cell transformation. Furthermore, as the distal region of the hTERT 
promoter is involved in the regulation of hTERT splicing such factors might have similar 
effect. 
In this study, we detailed the binding effect of CTCF on the first exon of hTERT. 
Likewise, the CTCF binding site in the second exon of hTERT might be involved in the 
activation of the hTERT promoter and further experiments are needed to clarify this issue. 
To better understand the mechanism of this model, exactly how CTCF inhibits 
hTERT transcription needs to be further investigated. The association of CTCF with 
histone deacetylase activity suggests that the transcriptional repression might occur 
through chromatin condensation (Lutz et al., 2000). This hypothesis is in agreement with 
our observation that the inhibitory effect of CTCF on hTERT transcription is dependent on 
the nucleosome structure. CTCF might interact with the transcriptional machinery or with 
histone deacetylases to allow inhibition of the hTERT promoter.  
How the pattern of methylation of hTERT CpG island is established during 
tumorigenesis must also be further studied. The establishment and maintenance of DNA 
methylation are tightly regulated and vary in time and space. A small but significant 
proportion of all CpG islands become methylated during development and when this 
happens the associated promoters are permanently silent (e.g. developmentally 
programmed CpG-island methylation is involved in genomic imprinting (Bird, 2002). 
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Hypo- or hyper-methylation occurs in adult somatic cells, during aging, or in cancer (Issa, 
2000). The extent of methylation can change dynamically from one cell to another. 
Sequencing of the hTERT promoter and of exon 1 in cells at different stages of 
immortalization showed a progressive methylation of the hTERT promoter as well as of the 
CTCF binding region in the hTERT first exon (unpublished results). CTCF might be 
involved in this process by recruitment of protein(s) necessary for DNA methylation. 
BORIS is involved in establishing methylation patterns during development, potentially in 
interacting with specific proteins involved in DNA methylation. Such proteins might also 
be involved in hTERT methylation during carcinogenesis. 
The study of BORIS regulation is a subject of intense investigation. Gel shift 
experiments showed that exon 6 deleted BORIS binds the p19arf promoter, but not other 
binding sites, including imprinting control region sites, c-myc insulator and Xist promoter 
(unpublished results). This splice-variant also stimulated hTERT transcription in 
transfection experiments in normal telomerase-negative cells (unpublished result). These 
preliminary results indicate that the exon 6 of BORIS is not necessary for the hTERT DNA 
binding and for its transcriptional activation. It would be important to study the role of 
BORIS splice variants during normal and tumor development in order to better understand 
their role in the regulation of hTERT transcription. 
 
Based upon our results and our knowledge, we suggested that a relation ship exist 
between BORIS and CTCF, the pattern of gene promoter methylation, and hTERT 
regulation during tumorigenesis. It is clear that for most cancer cells telomerase is required 
for continuous tumor cell proliferation and malignant progression, but it is not yet clear 
whether telomerase is active as a consequence of selection of preexisting telomerase-
positive cells during carcinogenesis or through induction of hTERT expression in cells that 
lack telomerase activity. Relatively low levels of telomerase activity have been detected in 
proliferative cells of self-renewing tissues (Forsyth et al., 2002;Masutomi et al., 2003). 
These cells might be the cancer precursors cells, which fit with a cancer stem cell 
hypothesis. In this study, we found BORIS transcripts in most tumor types, but at a very 
low level. BORIS might be expressed at a basal level in most cells or at a high level in only 
few cells. It is tempting to speculate that the latter cells might be tumor stem cells. A 
“cancer stem cell” has been defined as a cancer cell that has the ability for self-renewal, 
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giving rise to another malignant stem cell as well as daughter cell that undergoes 
differentiation. To date, a tumor is regarded as a clone of cells that has arisen from a single 
transformed cell, through continuous accumulation of genetic errors and epigenetic 
changes. Recent evidence suggests that stem cells may be the source of the mutant cells 
that give rise to cancer and maintain their growth (Keith, 2004). Although both cancer stem 
cells and non-clonogenic tumor cells harbor the genetic abnormalities that result in cancer, 
the latter population would lack the ability to self-renew (Kopper and Hajdu, 2004;Radtke 
and Raj, 2003;Taipale and Beachy, 2001;Willert et al., 2003). This lack of self-renewal 
could be due to the loss of telomerase activity during later cell divisions. As BORIS and 
CTCF are involved in epigenetic reprogramming (Klenova et al., 2002), hTERT 
methylation might be modified during tumor cell proliferation, inhibiting hTERT 
expression. It has been suggested that BORIS marks the methylation specific sites during 
development. Later in somatic cells, CTCF might be responsible for maintaining the 
methylation pattern (Feinberg et al., 2002). We postulate that co-expression of BORIS and 
CTCF contributes to tumorigenesis through deregulation of methylation.  
In Germ cells, telomerase is expressed at a high level, allowing a constant 
maintenance of telomeres at a constant length. BORIS is present in spermatocytes 
(Loukinov et al., 2002) and in oocytes (unpublished data). These germ cells might be the 
precursors of ovarian and testicular cancer cells, in which hTERT transcription is regulated 
through BORIS expression. 
In the same manner, telomerase is highly expressed in hematopoietic stem cells. 
These cells might be the precursors of lymphoma or other tumors link to hematopoietic cell 
lineage. The factor(s) involved in the hTERT regulation in these cells is not BORIS 
(unpublished data) and they remain to be identified. A recent study showed that the arrest 
of PAX-5 in precursor B-cells induced shortening of their telomeres (Schaniel et al., 2002). 
Preliminary results showed that PAX-5 binds the first exon of hTERT in vitro (unpublished 
data). Further experiments are necessary to prove the real implication of PAX-5 in the 
hTERT regulation. 
Immunohistochemical studies of BORIS, CTCF and hTERT expression and of 
hTERT methylation must be performed in different normal and tumor tissues, to establish 
whether the methylation pattern of hTERT and the expression of these genes are correlated. 
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Likewise, mechanisms that regulate the hTERT expression in normal germ and stem 
cells must also be the center of new investigations. These two cell types probably have 
different mechanisms for hTERT regulation, because it has been shown that the telomere 
length progressively decreases in stem cells, whereas it stays constant in germ cells. 
Implications of CTCF and BORIS in the hTERT regulation in germ and stem cells is not 
exclude and must be investigated in the future. 
 
The hTERT regulatory model proposed here is the only one that takes into account 
the epigenetic status of the gene and involved transcription factors. Transcriptional gene 
regulation study requires not only the one-by-one analysis of transcriptional factors, but 
also a general overview of epigenetic events. This work underlines the fact that genetic and 
epigenetic regulations can never be dissociated. Our results allow a better understanding of 
the hTERT inactivation in normal somatic cells and its activation in tumor cells, and can 
open the way to the elaboration of new anti-telomerase strategies in cancer. 
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